Institutes
Refine
Year of publication
Document Type
- Article (1594)
- Preprint (157)
- Doctoral Thesis (61)
- Conference Proceeding (57)
- Book (1)
- Review (1)
Language
- English (1871) (remove)
Has Fulltext
- yes (1871)
Is part of the Bibliography
- no (1871) (remove)
Keywords
- COVID-19 (39)
- SARS-CoV-2 (36)
- inflammation (30)
- Video (18)
- prostate cancer (17)
- Inflammation (15)
- Epilepsy (14)
- ADHD (13)
- Cancer (12)
- autophagy (12)
- bladder cancer (12)
- Capsule endoscopy (11)
- cancer (11)
- radical prostatectomy (11)
- Genetics (10)
- data science (10)
- tumor microenvironment (10)
- Small bowel (9)
- apoptosis (9)
- glioblastoma (9)
- macrophage (9)
- stroke (9)
- Apoptosis (8)
- Endoscopy (8)
- Mortality (8)
- Quality of life (8)
- Surgery (8)
- breast cancer (8)
- epilepsy (8)
- hypoxia (8)
- immunotherapy (8)
- survival (8)
- Angiogenesis (7)
- EEG (7)
- Immunology (7)
- Radiotherapy (7)
- Seizure (7)
- Treatment (7)
- aging (7)
- chemotherapy (7)
- children (7)
- endothelial cells (7)
- fMRI (7)
- mortality (7)
- oxidative stress (7)
- Balloon enteroscopy (6)
- Depression (6)
- Enteroscopy (6)
- Heart failure (6)
- MRI (6)
- Magnetic resonance imaging (6)
- Medical research (6)
- Outcome (6)
- Prostate cancer (6)
- TAVI (6)
- angiogenesis (6)
- artificial intelligence (6)
- glioma (6)
- machine learning (6)
- microRNA (6)
- osteoarthritis (6)
- proliferation (6)
- risk factors (6)
- targeted therapy (6)
- thrombosis (6)
- vaccination (6)
- Biomarker (5)
- Bipolar disorder (5)
- Breast cancer (5)
- Calliphoridae (5)
- Comorbidity (5)
- Epidemiology (5)
- Forensic entomology (5)
- Herb induced liver injury (5)
- Hypoxia (5)
- Immunotherapy (5)
- Machine learning (5)
- Macrophages (5)
- NADPH oxidase (5)
- Omicron (5)
- Postural control (5)
- Risk factors (5)
- biomarker (5)
- colorectal cancer (5)
- coronavirus (5)
- digital medicine (5)
- gene therapy (5)
- hippocampus (5)
- integrins (5)
- iron deficiency (5)
- lung cancer (5)
- mTOR (5)
- machine-learning (5)
- miRNA (5)
- outcome (5)
- pain (5)
- prevalence (5)
- reactive oxygen species (5)
- 177Lu-PSMA-617 (4)
- Adenocarcinoma (4)
- Alcohol (4)
- Animal models (4)
- Antiviral therapy (4)
- Aortic stenosis (4)
- Cochlear implant (4)
- Critical care (4)
- Drug induced liver injury (4)
- Elderly (4)
- Endoscopic retrograde cholangiopancreatography (4)
- Endothelial cells (4)
- Glioma (4)
- Hepatotoxicity (4)
- Herbal hepatotoxicity (4)
- IntelliCage (4)
- Melanoma (4)
- Neurology (4)
- Oncology (4)
- PCR (4)
- PSMA (4)
- Pain (4)
- Physical activity (4)
- Prevalence (4)
- Proteomics (4)
- ROS (4)
- Rare diseases (4)
- Stroke (4)
- acute myeloid leukemia (4)
- antiviral therapy (4)
- bibliometrics (4)
- child (4)
- diabetes (4)
- drug resistance (4)
- elderly (4)
- epidemiology (4)
- external beam radiotherapy (4)
- extracellular matrix (4)
- growth (4)
- haemophilia treatment (4)
- hepatocellular carcinoma (4)
- infection (4)
- influenza (4)
- iron (4)
- liver (4)
- macrophage polarization (4)
- macrophages (4)
- metastasis (4)
- metastatic prostate cancer (4)
- microglia (4)
- mitochondria (4)
- neuropathic pain (4)
- patients (4)
- phosphorylation (4)
- polypharmacy (4)
- quality of life (4)
- synaptic plasticity (4)
- systematic review (4)
- thrombolysis (4)
- tooth loss (4)
- treatment (4)
- treatment centres (4)
- 3D printing (3)
- ACLF (3)
- AML (3)
- ARDS (3)
- Acute kidney injury (3)
- Acute lymphoblastic leukemia (3)
- Acute myeloid leukemia (3)
- Adhesion (3)
- Angiography (3)
- Artificial intelligence (3)
- Ataxia telangiectasia (3)
- Autism spectrum disorder (3)
- Autopsy (3)
- Biochemistry (3)
- Brain (3)
- Burden of illness (3)
- COMP (3)
- Cardiovascular diseases (3)
- Cell biology (3)
- Chronic hepatitis C (3)
- Cirrhosis (3)
- Classification (3)
- Clinical decision support systems (3)
- Collagen (3)
- Colorectal cancer (3)
- Complications (3)
- Computer-assisted diagnosis (3)
- Data science (3)
- Dental implant (3)
- Dental students (3)
- Diagnosis (3)
- Diagnostic markers (3)
- ER stress (3)
- Edema (3)
- Endocrinology (3)
- Epigenetics (3)
- Extracellular vesicles (3)
- Fasting (3)
- Gene regulation (3)
- Glioblastoma (3)
- HBV (3)
- Health care (3)
- Healthcare costs (3)
- Healthy adults (3)
- HoLEP (3)
- Human behaviour (3)
- Hypertension (3)
- Immunohistochemistry (3)
- Incidence (3)
- Induction chemotherapy (3)
- Interleukin (3)
- Lung failure (3)
- Major depressive disorder (3)
- Metabolomics (3)
- Microbiology (3)
- Microwave ablation (3)
- Molecular biology (3)
- Multianalyte detection (3)
- NK cells (3)
- NSCLC (3)
- Neuroscience (3)
- Non-coding RNA (3)
- Pandemic (3)
- Parkinson’s disease (3)
- Patient blood management (3)
- Patient safety (3)
- Peri-implantitis (3)
- Platelet-rich fibrin (3)
- Pneumonia (3)
- Polypharmacy (3)
- Pre-analytics (3)
- Pulmonary embolism (3)
- RNA (3)
- Rectal cancer (3)
- Registry (3)
- Rhabdomyosarcoma (3)
- Rheumatoid arthritis (3)
- Safety (3)
- Sex (3)
- Sport (3)
- Status epilepticus (3)
- Suicide (3)
- Survival (3)
- Systematic review (3)
- TIPS (3)
- Transfusion (3)
- Translational research (3)
- Trauma (3)
- Tumor microenvironment (3)
- Ultrasound (3)
- VEGF (3)
- Vaccination (3)
- adhesion (3)
- adverse events (3)
- anemia (3)
- animal model (3)
- aortic stenosis (3)
- bleeding (3)
- brain metastases (3)
- cancer specific survival (3)
- cartilage (3)
- cervical cancer (3)
- chronic kidney disease (3)
- cirrhosis (3)
- cognition (3)
- colon cancer (3)
- critical care (3)
- curcumin (3)
- dentate gyrus (3)
- depression (3)
- diagnosis (3)
- electrophysiology (3)
- epigenetics (3)
- ergonomics (3)
- exercise (3)
- exosomes (3)
- extracellular vesicles (3)
- fibrosis (3)
- flow cytometry (3)
- functional outcome (3)
- gene expression (3)
- haemophilia care (3)
- heart (3)
- heart failure (3)
- hematopoietic stem cell transplantation (3)
- hemorrhage (3)
- hepatitis C virus (3)
- immune cells (3)
- immunity (3)
- immunohistochemistry (3)
- innate immunity (3)
- liver cirrhosis (3)
- liver transplantation (3)
- lncRNA (3)
- long non-coding RNA (3)
- magnetic resonance imaging (3)
- mesenchymal stromal/stem cells (3)
- metabolomics (3)
- multimorbidity (3)
- multiple sclerosis (3)
- neurodegeneration (3)
- nociception (3)
- obesity (3)
- outcomes (3)
- overall survival (3)
- oxidative phosphorylation (3)
- p53 (3)
- pediatric (3)
- periodontitis (3)
- platelets (3)
- polytrauma (3)
- portal hypertension (3)
- primary care (3)
- proteomics (3)
- psoriasis (3)
- public health (3)
- quantitative MRI (3)
- radiotherapy (3)
- seizure (3)
- sphingolipids (3)
- sphingosine 1-phosphate (3)
- sphingosine-1-phosphate (3)
- stress (3)
- sulforaphane (3)
- supportive periodontal therapy (3)
- tissue engineering (3)
- toll-like receptor (3)
- trauma (3)
- traumatic brain injury (3)
- tyrosine kinase inhibitor (3)
- yeast (3)
- 3D rapid prototyping (2)
- ADAM15 (2)
- ALK (2)
- ATM (2)
- Abort (2)
- Accidental reaction (2)
- Acinetobacter baumannii (2)
- Acuris (2)
- Addiction (2)
- Age estimation (2)
- Aging (2)
- Allergen avoidance (2)
- Alzheimer’s disease (2)
- Anandamide (2)
- Anemia (2)
- Animal model (2)
- Anti-IgE (2)
- Antibiotics (2)
- Aspergillus (2)
- Ataxia-telangiectasia (2)
- Attention-deficit/hyperactivity disorder (2)
- Attitude (2)
- Autologous biomaterial (2)
- Autophagy (2)
- BA.1 (2)
- BAG3 (2)
- BCOR (2)
- BMI (2)
- BMNC (2)
- BNT162b2 (2)
- BPH (2)
- Bacterial infection (2)
- Behavior (2)
- Bibliometrics (2)
- Bile duct stone (2)
- Biomedical informatics (2)
- Biopsy (2)
- Biorecognition strategies (2)
- Bladder cancer (2)
- Bleeding (2)
- Blood (2)
- Blood loss estimation (2)
- Blow flies (2)
- Body modification (2)
- Bone density (2)
- Bone marrow (2)
- C-reactive protein (2)
- CD14 (2)
- COVID 19 (2)
- COVID-19 surveillance (2)
- CRM (2)
- CSM (2)
- CT (2)
- Calpain (2)
- Cancer therapy (2)
- Cancer-specific mortality (2)
- Cardiovascular magnetic resonance (2)
- Case report (2)
- Cell culture (2)
- Cell death (2)
- Cell death and immune response (2)
- Cerebellum (2)
- Cesarean section (2)
- Chemoradiotherapy (2)
- Child (2)
- Cholangiography (2)
- Cholangiopancreatography (2)
- Chronic kidney disease (2)
- Clinical Trials and Observations (2)
- Cochlear implantation (2)
- Cognition (2)
- Colonoscopy (2)
- Comparative analysis (2)
- Computational models (2)
- Computer software (2)
- Corona (2)
- Covid-19 (2)
- Cryoelectron microscopy (2)
- DMEK (2)
- DNA methylation (2)
- Deep brain stimulation (2)
- Degradation (2)
- Development (2)
- Diagnostic algorithm (2)
- Differential diagnosis (2)
- Directly acting antiviral agent (2)
- Dopamine (2)
- Double-balloon enteroscopy (2)
- Dravet syndrome (2)
- Drug hepatotoxicity (2)
- Drugs (2)
- Dynamic MRI (2)
- EET (2)
- EGFR (2)
- EWSR1 (2)
- Education (2)
- Emotion regulation (2)
- Encephalopathy (2)
- Endocannabinoid (2)
- Endocannabinoids (2)
- Endoscopic retrograde (2)
- Endothelium (2)
- Enterscopy (2)
- Entscheidungsassistenz (2)
- Environmental support (2)
- EphB4 (2)
- Epicutaneous immunotherapy (2)
- Epidemiology and End Results (2)
- Epileptische Anfälle (2)
- Evidence-based medicine (2)
- Exercise (2)
- Exosomes (2)
- Extracellular matrix (2)
- FFLU (2)
- FHIR (2)
- Feedback (2)
- Fibronectin (2)
- Forensic medicine (2)
- Function (2)
- GEMs (2)
- GPCR (2)
- Gene Regulation (2)
- Gene expression (2)
- Gene fusion (2)
- Genetics research (2)
- Geographic variation (2)
- Geriatric patients (2)
- Germany (2)
- Gleason score (2)
- Glucose (2)
- HCV (2)
- HIV (2)
- HL7 FHIR (2)
- HNSCC (2)
- Healthcare resource utilization (2)
- Healthcare worker (2)
- Heart (2)
- Hepatitis C (2)
- Hepatitis C virus (2)
- Hepatocellular carcinoma (2)
- High oblique sagittal osteotomy (2)
- Hippocampus (2)
- ISR (2)
- Identification (2)
- Immune cells (2)
- Immunogenicity (2)
- Infection (2)
- Infections (2)
- Innate Immunity (2)
- Insulin signalling (2)
- Intensive care treatment (2)
- Intensive care units (2)
- Interferon (2)
- Interleukin-1 (2)
- Interleukin-6 (2)
- Iron (2)
- Ketogenic diet (2)
- L-DOPA (2)
- Labor and delivery (2)
- Legs (2)
- Leptin (2)
- Lipidomics (2)
- LncRNA (2)
- Local therapy (2)
- Long-term potentiation (2)
- Low-molecular-weight heparin (2)
- Lucilia sericata (2)
- Lymphectasia (2)
- Machine-learning (2)
- Macrophage polarization (2)
- Medical consultation (2)
- Medical diagnostics (2)
- Medical risk factors (2)
- Medizinstudenten (2)
- Memory (2)
- Mental health (2)
- Metabolic diseases (2)
- Migration (2)
- Mitochondria (2)
- Mitochondrial dysfunction (2)
- Model (2)
- Molecular autopsy (2)
- Molecular neuroscience (2)
- Monocytes (2)
- Morphology (2)
- Multidetector computed tomography (2)
- Multimorbidity (2)
- Musculoskeletal system (2)
- Myeloid Neoplasia (2)
- Myocardial infarction (2)
- Myocarditis (2)
- NADH dehydrogenase (2)
- NAFLD (2)
- NASH (2)
- NCCN (2)
- NCoR1 (2)
- NF-κB (2)
- NS5A (2)
- Neurodegeneration (2)
- Neuron (2)
- Neurotransmitter (2)
- Next-generation sequencing (2)
- Nrf2 (2)
- Nucleic acid biomarkers (2)
- OXA-48 (2)
- Obesity (2)
- Oral immunotherapy (2)
- Orthognathic surgery (2)
- Osteoarthritis (2)
- Osteoporosis (2)
- Outcomes (2)
- PD-L1 (2)
- Pathogenesis (2)
- Pathologic complete response (2)
- Patient needs (2)
- Patientenbedürfnisse (2)
- Patterns of care (2)
- Pediatric (2)
- Pelargonium sidoides (2)
- Penile cancer (2)
- Penile carcinomas (2)
- Periodontal treatment (2)
- Person-Umwelt-Passung (2)
- Person-environment fit (2)
- Phagocytosis (2)
- Pharmacology (2)
- Physiology (2)
- Plasticity (2)
- Point-of-care testing (2)
- Polytrauma (2)
- Portal hypertension (2)
- Post-mortem interval (2)
- Preclinical research (2)
- Predictive coding (2)
- Predictive markers (2)
- Pregnancy (2)
- Preterm birth (2)
- Prevention (2)
- Primary health care (2)
- Prognostic tool (2)
- Prophylaxis (2)
- Protein biomarkers (2)
- Pseudomonas aeruginosa (2)
- Psoriasis (2)
- Psychedelics (2)
- Psychology (2)
- Questionnaire (2)
- RCT (2)
- RNA therapeutics (2)
- RNAseq (2)
- Radiation (2)
- Radical prostatectomy (2)
- Radiomics (2)
- Reactive oxygen species (2)
- Redoxin (2)
- Rehabilitation (2)
- Reliability (2)
- Rescue medication (2)
- Research Article (2)
- Respiratory distress syndrome (2)
- Reward (2)
- Ribavirin (2)
- S1P receptors (2)
- SARS-CoV-2 monitoring (2)
- SARS-CoV-2 testing (2)
- SCC (2)
- SPM (2)
- SUMO (2)
- SV2A (2)
- Schizophrenia (2)
- Sensitivity (2)
- Signaling (2)
- Specificity (2)
- Spine (2)
- Squamous cell carcinoma (2)
- Standard endoscopy (2)
- Standard value (2)
- Standardization (2)
- Stem cell (2)
- Sudden death (2)
- Superficial vein thrombosis (2)
- Supported decision making (2)
- Surveillance (2)
- Synaptic transmission (2)
- Systemic inflammation (2)
- Systemic therapy (2)
- T-cell (2)
- TGF-β (2)
- TSC (2)
- Teaching (2)
- Telemedicine (2)
- Temozolomide (2)
- Tight junctions (2)
- Tomography (x-ray computed) (2)
- Tooth loss (2)
- Training (2)
- Treatment outcome (2)
- Type 2 diabetes (2)
- Undergraduate medical education (2)
- Unterstützung der Umwelt (2)
- Upper body posture (2)
- Usability (2)
- Uteroglobin (2)
- Vaccine uptake rate (2)
- Validity (2)
- Variant histology (2)
- Vascular endothelial growth factor (VEGF) (2)
- Visual estimation (2)
- Volume therapy (2)
- Wearable cardioverter-defibrillator (2)
- Women (2)
- Wound healing (2)
- Wounds (2)
- acute coronary syndromes (2)
- adaptation (2)
- adipose-derived stromal/stem cells (2)
- adult (2)
- age (2)
- alcohol use disorder (2)
- algorithm (2)
- alpha power (2)
- animal experiments (2)
- antibiotic resistance (2)
- antiseizure medication (2)
- atherosclerosis (2)
- attention (2)
- bacteria (2)
- biliary stricture (2)
- bioenergetics (2)
- biomarkers (2)
- biopsy cores (2)
- blood pressure (2)
- blood transfusion (2)
- bone (2)
- bone regeneration (2)
- bortezomib (2)
- brain cancer (2)
- brain metastasis (2)
- cabozantinib (2)
- campesterol (2)
- cancer treatment (2)
- cancer-specific mortality (2)
- cardiolipin (2)
- cardiovascular disease (2)
- caregivers (2)
- cell cycle (2)
- cell migration (2)
- ceramides (2)
- cerebral hemorrhage (2)
- cerebral venous thrombosis (2)
- cerebrospinal fluid (2)
- cesarean section (2)
- chemoradiotherapy (2)
- childhood acute myeloid leukemia (2)
- cholestanol (2)
- cholesterol absorption (2)
- cholesterol synthesis (2)
- clinical isolates (2)
- clinical trial (2)
- clinical trials (2)
- co-infection (2)
- coagulopathy (2)
- complementary medicine (2)
- complexome profiling (2)
- complication (2)
- computed tomography (2)
- confinement (2)
- constipation (2)
- contemporary (2)
- cytokines (2)
- dance (2)
- dental implant (2)
- deubiquitinase (DUB) (2)
- development (2)
- dexamethasone (2)
- diabetes mellitus (2)
- diabetic nephropathy (2)
- diagnostic algorithm (2)
- disease burden (2)
- dopamine (2)
- dysphagia (2)
- efficacy (2)
- endovascular treatment (2)
- ephrinB2 (2)
- epidermal growth factor receptor (2)
- epithelial to mesenchymal transition (2)
- everolimus (2)
- executive function (2)
- fall (2)
- fibroblasts (2)
- follow-up (2)
- furcation involvement class III (2)
- fusion biopsy (2)
- general practice (2)
- glycolysis (2)
- guided bone regeneration (2)
- healthcare worker (2)
- histology (2)
- homeostatic plasticity (2)
- hyperglycemia (2)
- immune checkpoint inhibitors (2)
- immune response (2)
- in vitro (2)
- infections (2)
- inflammatory bowel disease (2)
- insulin (2)
- integrative medicine (2)
- intermediate risk (2)
- invasion (2)
- iron metabolism (2)
- kidney (2)
- kidney cancer (2)
- kinematic analysis (2)
- lathosterol (2)
- leptin (2)
- levetiracetam (2)
- lifestyle intervention (2)
- lipids (2)
- lipocalin-2 (2)
- lipoxygenase (2)
- liver fibrosis (2)
- localized prostate cancer (2)
- lockdown (2)
- long-term success (2)
- long-term tooth survival (2)
- low molecular weight heparin (2)
- low-glycaemic meal replacement (2)
- lymph node dissection (2)
- mRNA (2)
- mast cells (2)
- medical students (2)
- melanoma (2)
- metabolism (2)
- metastatic castration-resistant prostate cancer (2)
- mice (2)
- monitoring (2)
- monocytes (2)
- motility (2)
- multicentre study (2)
- multidetector computed tomography (2)
- multiple myeloma (2)
- musculoskeletal disorders (2)
- ncRNA (2)
- neural oscillations (2)
- neurocognitive (2)
- neutralization (2)
- neutralizing antibodies (2)
- next-generation sequencing (2)
- niche (2)
- nitric oxide (2)
- nivolumab (2)
- occupational infections (2)
- olfaction (2)
- oligomerisation (2)
- other-cause mortality (2)
- out-patient paediatrics (2)
- pandemic (2)
- patient blood management (2)
- pediatric patients (2)
- pediatric surgery (2)
- penile cancer (2)
- pentose phosphate pathway (2)
- perception (2)
- peri-implant diseases (2)
- peri-implantitis (2)
- periodontitis stage III and IV (2)
- pertussis (2)
- phagocytosis (2)
- pharmacokinetics (2)
- physical activity (2)
- pneumonia (2)
- post-translational modifications (2)
- postoperative pain (2)
- prediction (2)
- predictive (2)
- predictive coding (2)
- predictor (2)
- preeclampsia (2)
- pregnancy (2)
- prevention (2)
- primary cilium (2)
- primary prostate cancer (2)
- process evaluation (2)
- prognosis (2)
- prognostic (2)
- prostaglandin E (2)
- prostaglandins (2)
- prostate carcinoma cells (2)
- proteasome (2)
- protein-protein interaction (2)
- protein-rich (2)
- pulmonary embolism (2)
- qualitative research (2)
- questionnaire (2)
- radiation (2)
- radical cystectomy (2)
- radical prostatecomy (2)
- receptor (2)
- refractory (2)
- regenerative medicine (2)
- relapse (2)
- renal cell carcinoma (2)
- residual myometrial thickness (2)
- resistance mutation (2)
- resistant cell lines (2)
- resolution of inflammation (2)
- respiratory chain (2)
- respiratory tract infection (2)
- resting-state (2)
- rheumatoid arthritis (2)
- risk group (2)
- salvage radical prostatectomy (2)
- salvage therapy (2)
- scaffold (2)
- schizophrenia (2)
- second-line (2)
- serine protease (NS3-4A) (2)
- serum (2)
- simulation training (2)
- sitosterol (2)
- smooth muscle cells (2)
- soft tissue (2)
- speech perception (2)
- spinal dural leaks (2)
- spine head (2)
- status epilepticus (2)
- stereotactic radiosurgery (2)
- strength training (2)
- stress granules (2)
- sub-lineage (2)
- subchondral bone (2)
- superficial siderosis (2)
- surgery (2)
- synaptopodin (2)
- systematic biopsy (2)
- systemic antibiotics (2)
- temozolomide (2)
- temporal lobe epilepsy (2)
- therapeutics (2)
- therapy (2)
- thymus (2)
- total hip replacement (2)
- transcription factor (2)
- triple-negative breast cancer (2)
- tumor necrosis factor (2)
- tumor-associated macrophages (2)
- tyrosine kinase inhibitors (2)
- ubiquitin (2)
- ubiquitination (2)
- upgrading (2)
- urinary incontinence (2)
- urological cancer (2)
- vaccine (2)
- vascular biology (2)
- very high risk (2)
- viruses (2)
- waiting time (2)
- walking (2)
- weight reduction (2)
- white matter hyperintensity (2)
- working memory (2)
- Ärztliche Aufklärung (2)
- (lyso)phospholipids (1)
- (sub-) luxation (1)
- 1-propanol (1)
- 1H NMR; Conformational Properties (1)
- 2-AG (1)
- 2-Arachidonoyl glycerol (1)
- 2-deoxy-d-glucose (1)
- 223Radium-dichloride (1)
- 26 LncRNA (1)
- 2′,3′-cGAMP (1)
- 3 mm RAS instruments (1)
- 3 mm instruments (1)
- 3-hydroxyisovaleryl carnitine (1)
- 3-year survival (1)
- 3D culture (1)
- 3D gait analysis (1)
- 3D laparoscopy (1)
- 3D printing using composite resin (1)
- 3D printing using zirconia (1)
- 3D-models (1)
- 3D-printing (1)
- 3T3-L1 mouse fibroblasts (1)
- 4-fluoroamphetamine (1)
- 5-lipoxygenase (1)
- 9-aminoacridine (1)
- A498 cells (1)
- AAA+ disaggregase (1)
- ABC transporter (1)
- ABCB5 (1)
- ACE inhibitor (1)
- ACKR (1)
- ACL (1)
- ACT-777991 (1)
- ACTH (1)
- ADAMTS13 (1)
- ADCC (1)
- ADGRE1 (1)
- ADHS (1)
- AGMO (1)
- AIDS (1)
- AKT (1)
- AKT signaling (1)
- AKT-mTOR pathway (1)
- ALD (1)
- ALDH2 (1)
- AMP-activated kinase (AMPK) (1)
- AO-PCCF (1)
- APT-CEST (1)
- ASPECTS (1)
- AT1 receptor antagonist (1)
- ATG3 (1)
- ATG4 (1)
- ATG8 (1)
- ATP (1)
- AU-rich element (1)
- Abductor pollicis longus (1)
- Ablation (1)
- Ablation Techniques (1)
- Abrasion (1)
- Abusive head trauma (AHT) (1)
- Accidents (1)
- Accumulated degree days (1)
- Acidic Amino Acids (1)
- Acquired resistance (1)
- Actaea cimicifuga (1)
- Activated partial thromboplastin time (1)
- Active middle ear implants (1)
- Activities of daily living (1)
- Acute (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute appendicitis (1)
- Acute decompensation (1)
- Acute elbow dislocation (1)
- Acute inflammation (1)
- Acute kidney failure (1)
- Acute myeloid leukaemia (1)
- Acute respiratory distress syndrom (1)
- Acute-on-chronic liver failure (1)
- Acute-on-chronic subdural hematoma (1)
- Adeno associated virus (1)
- Adherence (1)
- Adhesins (1)
- Adiposity (1)
- Administrative claims data (1)
- Adult neurogenesis (1)
- Adult-onset ADHD (1)
- Adults (1)
- Advanced stage (1)
- Adverse drug reaction (1)
- Adverse effects (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Aeroplysinin-1 (1)
- Affect (1)
- Affective Misattribution Procedure (1)
- Affinity Chromatography (1)
- Affinity Labeling (1)
- Ag-RDT (1)
- Aganglionosis (1)
- Age determination (1)
- Ageing (1)
- Aggression (1)
- Airport-related emissions (1)
- Akt-mTOR pathway (1)
- Akt-mTOR signaling (1)
- Aktivierte partielle Thromboplastinzeit (1)
- Albumin (1)
- Albumin ratio (1)
- Algorithms (1)
- All-oral therapy (1)
- Allogeneic (1)
- Allosteric inhibition (1)
- Alpha power (1)
- Alpha-fetoprotein (AFP) (1)
- Alzheimer's disease (1)
- Ambient air (1)
- Amblyopia (1)
- Ambulatory Assessment (1)
- Amino acids (1)
- Amisulpride (1)
- Amitriptyline (1)
- Amniotic fluid (1)
- Amphetamine (1)
- Anaemia (1)
- Anakinra (1)
- Anal cancer (1)
- Analgesia (1)
- Analogue modelling (1)
- Analysis tool (1)
- Anatomy (1)
- Anderson–Fabry (1)
- Anemia management (1)
- Angiectasia (1)
- Angiodysplasia (1)
- Angiomyolipoma (1)
- Angststörungen (1)
- Animal disease models (1)
- Animal experiment (1)
- Anion and Zwitterion Transport (1)
- Anomalous venous atrial connections (1)
- Anorexia Nervosa (1)
- Anschlussheilbehandlung (1)
- Anti-inflammatory (1)
- Anti-rheumatic agents (1)
- Anti-seizure medication (1)
- Antibiotic steward-ship (1)
- Antibodies (1)
- Antibody avidity (1)
- Antibody therapy (1)
- Anticholinergic (1)
- Anticoagulant (1)
- Anticoagulation (1)
- Anticonvulsant (1)
- Anticonvulsants (1)
- Antigen test (1)
- Antigennachweis (1)
- Antimicrobial treatment (1)
- Antineoplastic agents (1)
- Antioxidant (1)
- Antioxidants (1)
- Antiproliferative (1)
- Antiretroviral therapy (1)
- Anwendbarkeit (1)
- Anxiety (1)
- Anxiolytic pharmacological therapy (1)
- Aortic aneurysm (1)
- Aortic input function (1)
- Aperiodic (1)
- Aphantasia (1)
- Apixaban (1)
- Apoptotic cell death (1)
- Appendectomy (1)
- Ara h2-specific IgE (1)
- ArchT (1)
- Archaebacterial Lipids (1)
- Aromatase inhibitors (1)
- Arrhythmia syndromes (1)
- Arteria ophthalmica (1)
- Arteriovenous malformation (1)
- Arthroplasty (1)
- Artificial feeding bioassays (1)
- Asparaginase (1)
- Aspirin (1)
- Astrocytoma (1)
- Ataxia (1)
- Ataxia score (1)
- Athlete (1)
- Atm (1)
- Atomoxetine (1)
- Atrial Fibrillation (1)
- Atrial fibrillation (1)
- Atrial fibrillation classification (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention deficit (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Attentional bias (1)
- Auditory rehabilitation (1)
- Auditory system (1)
- Aurora kinase (1)
- Autism (1)
- Autism Spectrum disorder (1)
- Autoimmune response (1)
- Autoimmune vasculopathy (1)
- Autoimmunity (1)
- Automated sRNA analysis (1)
- Axiography (1)
- Ayahuasca (1)
- Ayurveda (1)
- Ayurvedic herbal products (1)
- Azan (1)
- B cell cancer (1)
- B cell differentiation (1)
- B cells (1)
- B-cell (1)
- B-cell transcription factors (1)
- B.1.1.529 (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- B3GNT2 (1)
- BA.4 (1)
- BA.5 (1)
- BCORL1 (1)
- BCX7353 (1)
- BEACOPP (1)
- BET proteins (1)
- BEZ235 (1)
- BH3 mimetics (1)
- BMC (1)
- BMP4 (1)
- BNT2b2 (1)
- BPO (1)
- BPTF (1)
- BRD4 (1)
- Bacillus subtilis (1)
- Back scan (1)
- Bacteraemia (1)
- Bacteria (1)
- Bacteria-host interaction (1)
- Bacterial abundance (1)
- Bacterial adhesion (1)
- Bacterial leakage (1)
- Balance (1)
- Ballon-assisted enteroscopy (1)
- Balloon-expandable TAVI (1)
- Bamlanivimab (1)
- Barrier (1)
- Bartonella adhesin A (1)
- Bartonella grahamii (1)
- Bartonella henselae (1)
- Bartonella schoenbuchensis (1)
- Basal ganglia (1)
- Beckwith–Wiedemann syndrome (1)
- Beginners (1)
- Behandlungspfad (1)
- Behavioral tests (1)
- Behavioural ecology (1)
- Benign enlargement of the subarachnoid spaces (BESS) (1)
- Benign prostatic hyperplasia (1)
- Bentall operation (1)
- Berotralstat (1)
- Bevacizumab (1)
- Biceps brachii (1)
- Big Five (1)
- Biglycan (1)
- Bilateral sagittal split osteotomy (1)
- Billroth II gastroenterostomy (1)
- Billroth papillotome (1)
- Billroth’s operation-II (1)
- Bio safety (1)
- Bioenergetics (1)
- Biofilm (1)
- Biological profile (1)
- Biological sciences (1)
- Biomarker Discovery Study (1)
- Biomarkers (1)
- Biophysical models (1)
- Biophysics (1)
- Birth (1)
- Birth weight (1)
- Bis-azido-NAD+ Analog (1)
- Black cohosh (1)
- Black cohosh induced liver injury (1)
- Bleeding Risk (1)
- Blindness (1)
- Blocked occlusion (1)
- Blood coagulation disorder (1)
- Blood loss (1)
- Blood loss calculator (1)
- Blood loss formula (1)
- Blood management (1)
- Blood plasma (1)
- Blood pressure (1)
- Blood sample handling (1)
- Blood sampling (1)
- Bloodstream infections (1)
- Blutspenderscreening (1)
- Blutung (1)
- Blutungskontrolle (1)
- Blutübertragbare Virusinfektionen (1)
- Body sway (1)
- Bone cement implantation syndrome (1)
- Bone conduction devices (1)
- Bone defect (1)
- Bone diseases, Metabolic (1)
- Bone dust (1)
- Bone marrow aspiration (1)
- Bone metastases (1)
- Bone regeneration (1)
- Bone remodelling (1)
- Bone substitute (1)
- Bone tissue engineering (1)
- Bone tumor (1)
- Borrelia (1)
- Borrelia burgdorferi (1)
- Bowel obstruction (1)
- Brachial artery (1)
- Brachytherapy (1)
- Bradycardia (1)
- Brain DNA methylation (1)
- Brain asymmetry (1)
- Brain injuries (1)
- Brain metastasis (1)
- Brain tumor (1)
- Brain tumor surgery (1)
- Breast cancer survivers (1)
- Breast conserving surgery (1)
- Brodalumab (1)
- Browsertool (1)
- Burkholderia arboris (1)
- Burkitt’s lymphoma (1)
- Burns (1)
- C1 inhibitor (1)
- CAD-CAM (1)
- CAD/ CAM crown (1)
- CAD/CAM (1)
- CAD/CAM crown (1)
- CAM (1)
- CAPON (1)
- CAR (1)
- CBC (1)
- CCC-2 (1)
- CCL2 (1)
- CD16 (1)
- CD34+ cell enumeration (1)
- CD34 + cells (1)
- CD36 (1)
- CD4+ T cells (1)
- CD40 (1)
- CD44 (1)
- CD45RA Depletion (1)
- CD47 (1)
- CD62L (1)
- CD62p+Exosomes (1)
- CD8+ T cells (1)
- CDH13 (1)
- CDI (1)
- CDK-cyclin axis (1)
- CDK2 (1)
- CDK4/6 inhibitors (1)
- CDK9 (1)
- CEBPD (1)
- CEST EPI (1)
- CHEPs (1)
- CHRDL1 (1)
- CIM (1)
- CIOMS (1)
- CK2α (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- CLOCC (1)
- CMR (1)
- CNDAC (1)
- CNS tumor (1)
- COPD (1)
- COVID (1)
- COVID 19 pandemic (1)
- COVID-19 epitope signatures (1)
- COVID-19 pandemic (1)
- COVID-19 vaccination (1)
- COVID-19, Primary care (1)
- COVID‐19 (1)
- CQL (1)
- CRBN (1)
- CRISPR screen (1)
- CRISPR/Cas (1)
- CRP (1)
- CRPC (1)
- CRT (1)
- CT dual-energy computed tomography (1)
- CTGF (1)
- CTLA-4 (1)
- CXCL12 (1)
- CXCL13 (1)
- CXCR3 antagonism (1)
- CXCR4 (1)
- CYP450 (1)
- CaMPARI (1)
- Cabozantinib (1)
- Caenorhabditis elegans (1)
- Calcium (1)
- Calcium calmodulin kinase (1)
- Calcium gluconate (1)
- Calprotectin (1)
- Cancer development (1)
- Cancer genomics (1)
- Cancer progression (1)
- Cancer survivors (1)
- Cancer-specific survival (1)
- Candida (1)
- Cannabis (1)
- Capnography (1)
- Capsaicin (1)
- Capsule endoscopy, video (1)
- Carbapenemase (1)
- Cardiac arrest (1)
- Cardiac biomarkers (1)
- Cardiac implantable electronic devices (1)
- Cardiac infarction (1)
- Cardiac rehabilitation (1)
- Cardiac remodeling (1)
- Cardiac resynchronization therapy (1)
- Cardio-oncology (1)
- Cardiology (1)
- Cardiotoxicity (1)
- Cardiovascular biology (1)
- Cardiovascular disease (1)
- Cardiovascular disease risk (1)
- Cardiovaskuläre Erkrankungen (1)
- Care home (1)
- Carotid injury (1)
- Cartilage (1)
- Cartilage Biology (1)
- Casirivimab (1)
- Caspase-8 (1)
- Catheters (1)
- Catumaxomab (1)
- Causality assessment. (1)
- Cell Biology (1)
- Cell Death (1)
- Cell Metabolism (1)
- Cell Migration (1)
- Cell Signaling (1)
- Cell Surface Receptor (1)
- Cell division (1)
- Cell surface proteoglycans (1)
- Cell-based Assays (1)
- Cellular Immune Response (1)
- Cellular energy metabolism (1)
- Cellular network formation (1)
- Cement gap (1)
- Centers for Disease Control and Prevention (1)
- Central Europe (1)
- Ceramides (1)
- Cerebral hypoperfusion (1)
- Cerebral oxygen saturation (1)
- Cerebrospinal Fluid (1)
- Cerebrospinal fluid (1)
- Cerebrovascular disorders (1)
- Cezanne (1)
- ChAdOx1-S (1)
- Chaperone (1)
- Checkpoint Inhibitor (1)
- Chemokines (1)
- Chemoprevention (1)
- Chemotherapy (1)
- Chikungunya (1)
- Child abuse (1)
- Child and adolescent psychotherapy (1)
- Chimeric Antigen Receptor (CAR) (1)
- Cholinergic (1)
- Chondrocytes (1)
- Chrna7 knockout (1)
- Chromodomains (1)
- Chronic inflammation (1)
- Chronic lymphocytic leukemia (1)
- Cine (1)
- Circadian (1)
- Circulating MiRNA (1)
- Clavien–Dindo classification (1)
- Click chemistry (1)
- Climate inequity (1)
- Clinical Global Impression of Change (1)
- Clinical efficacy (1)
- Clinical genetics (1)
- Clinical management (1)
- Clinical pathway (1)
- Clinical pharmacology (1)
- Clinical phenotype (1)
- Clinical practice guidelines (1)
- Clinical trial (1)
- Clinical trials (1)
- Clip (1)
- ClpB (1)
- Coagulation (1)
- Cochleaimplantation (1)
- Cochlear Implant (1)
- Coenzyme Analogue (1)
- Coenzyme Binding (1)
- Coeval folding and boudinage (1)
- Cognitive (1)
- Cognitive behavioural therapy (1)
- Cognitive dysfunction (1)
- Cognitive enhancers of exposure therapy (1)
- Cognitive impairment (1)
- Coherent infomax (1)
- Cohort studies (1)
- Cold hardiness (1)
- Cold tolerance (1)
- Collagen-based biomaterial (1)
- Colloids (1)
- Colonic neoplasms (1)
- Colony stimulating factor 1 receptor (1)
- Colorimetric blood loss estimation (1)
- Combined surgical therapy (1)
- Combustion (1)
- Comorbidities (1)
- Complete response (1)
- Completed suicide (1)
- Complex Formation (1)
- Complex decongestive therapy (1)
- Complex elbow fractures (1)
- Complicated stage (1)
- Comprehensive complication index (1)
- Compression stocking (1)
- Computational biophysics (1)
- Computational neuroscience (1)
- Computational sRNA analysis (1)
- Computational science (1)
- Computed Tomography (1)
- Computed tomography imaging (1)
- Computed tomography, X-ray (1)
- Computer hardware (1)
- Computer science (1)
- Computer-Assisted (1)
- Computer-unterstützte (1)
- Concurrent CNS diseases (1)
- Cone-beam computed tomography (1)
- Confinement (1)
- Congenital (1)
- Congenital diaphragmatic hernia (1)
- Connective tissue (1)
- Connectivity (1)
- Connectomics (1)
- Conometric connection (1)
- Consensus document (1)
- Consensus statement (1)
- Conservative treatment (1)
- Constipation (1)
- Constitution (1)
- Constriction (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Continuous renal replacement therapy (1)
- Contrast agent (1)
- Control (1)
- Conventional and unconventional ubiquitination (1)
- Conventional dendritic cells (1)
- Convolutional Neural Networks (1)
- Cooperation (1)
- Copy number (1)
- Corneal tomography (1)
- Corona pandemic (1)
- Corona virus (1)
- Coronary artery disease (1)
- Coronary heart disease (1)
- Coronavirus (1)
- Coronaviruses (1)
- Cortical degeneration (1)
- Cortical thickness (1)
- Cost-effectiveness (1)
- Costs (1)
- Course (1)
- Craniomaxillofacial injuries (1)
- Cre-recombinase (1)
- Crisis (1)
- Critical size (1)
- Crohn’s disease (1)
- Cross-frequency coupling (1)
- Cue-P3 (1)
- Culex pipiens (1)
- Culex pipiens biotypes pipiens/molestus (1)
- Culicidae (1)
- Culture positive (1)
- Curcumis sativus (1)
- Custom-made mouthguard (1)
- Cuticular hydrocarbons (1)
- Cyanoacrylate (1)
- Cyclin T1 (1)
- Cyclosporin A (1)
- CysLTR1 (1)
- Cystatin C (1)
- Cystic fibrosis (1)
- Cytochrome P450 (1)
- Cytochrome P450 enzymes (1)
- Cytokines (1)
- Cytokines Induction (1)
- Cytoreductive nephrectomy (1)
- Cytotoxicity (1)
- D-amino acid oxidase (1)
- DAA (1)
- DBS (1)
- DC-NK cell interaction (1)
- DCK (1)
- DNA (1)
- DNA Adducts (1)
- DNA integrity (1)
- DNA mismatch repair (1)
- DNA-PK (1)
- DNA-based identification (1)
- DOMS (1)
- DPPIV (1)
- DST (1)
- DVI (1)
- DWI (1)
- Dark triad (1)
- Data Analysis (1)
- Data preprocessing (1)
- Data processing (1)
- Data reduction (1)
- Data structure detection (1)
- Daubert criteria (1)
- De-isolation (1)
- Dead space (1)
- Decision Confidence (1)
- Decision support (1)
- Decontamination (1)
- Decorin (1)
- Deep learning (1)
- Deep neural network (1)
- Deep vein thrombosis (1)
- Defibrillation (1)
- Deformation oblique layer (1)
- Degrader design (1)
- Dehydrogenase (1)
- Dehydrogenases (1)
- Dendritic Cells (1)
- Dengue (1)
- Density equalizing mapping (1)
- Density-equalizing mapping (1)
- Dental Tissues (1)
- Dental air (1)
- Dental casts (1)
- Dental education (1)
- Dental implants (1)
- Dental practice (1)
- Dentists (1)
- Depression stigma (1)
- Dermatitis (1)
- Detection (1)
- Detection workflow (1)
- Developmental Biology (1)
- Developmental programming (1)
- Developmental trajectory (1)
- Developmentally adapted cognitive processing therapy (1)
- Device (1)
- Dexamethasone (1)
- Dexterity (1)
- Diagnose (1)
- Diagnostic dye (1)
- Diagnostic error (1)
- Diagnostic imaging (1)
- Diagnostic test (1)
- Diagnostic tests (1)
- Diet (1)
- Dietary HDAC inhibitor (1)
- Dietary supplements (1)
- Dieulafoy’s lesion (1)
- Differential Thermoanalysis (1)
- Difficult Airway Management (1)
- Diffusion magnetic resonance imaging (1)
- Digital (1)
- Digital pathology (1)
- Digital subtraction angiography (1)
- Digital workshops (1)
- Dimethyltryptamine (1)
- Diphtheria (1)
- Diptera (1)
- Direct measurement (1)
- Direct oral anticoagulation (1)
- Direct-acting antivirals (1)
- Disaster victim identification (1)
- Discitis (1)
- Discovery (1)
- Disease progression (1)
- Diseases (1)
- Disintegration (1)
- Dislocations of the knee (1)
- Distribution limits (1)
- Dizygotic ectopic (1)
- Dome-and-basin structure (1)
- Donor screening (1)
- Dorsal root ganglia (1)
- Dose response (1)
- Dot-probe task (1)
- Double balloon enteroscopy (1)
- Double-blind placebo-controlled trial (1)
- Downgrading (1)
- Dravet (1)
- Droplets (1)
- Drospirenon (1)
- Drug addiction (1)
- Drug resistance (1)
- Drug susceptibility testing (1)
- Drug targets (1)
- Drug therapy (1)
- Dual-energy computed tomography (1)
- Duodenum (1)
- Dural onlays (1)
- Dysfibrinogenämia (1)
- Dysfunctional social assumptions (1)
- Dysphagia (1)
- D’Amico classification (1)
- E-health (1)
- EBRT (1)
- ECMO (1)
- EGFRvIII mutation (1)
- EHL concentrates (1)
- ELISA (1)
- EMR1 (1)
- EMT (1)
- ENIGMA (1)
- EP300 (1)
- EQ5D5L (1)
- EQA scheme (1)
- ER-phagy (1)
- ERAL1 (1)
- ERK inhibitor (1)
- ERK1/2 signaling (1)
- ESBL (1)
- ESR Spectroscopy (1)
- ESR and Infrared Studies (1)
- Early (prenatal and postnatal) life experiences (1)
- Early setting (1)
- Ebola (1)
- Eccentric fixation (1)
- Ecological Momentary Assessment (EMA) (1)
- Ectopic pregnancy (1)
- Ectopic varices (1)
- Edoxaban (1)
- Effective half-life (1)
- Efficacy (1)
- Efficiency (1)
- Ejection fraction (1)
- Elderly trauma patient (1)
- Electric stimulation (1)
- Electrical stimulation (1)
- Electroconvulsive Therapy (1)
- Electroencephalography (1)
- Electrophysiology (1)
- Ellipticine (1)
- Elternurteil (1)
- Emergency room (1)
- Emergency treatment (1)
- Emotional intelligence (1)
- Empathy (1)
- Empty puparia (1)
- Ena/VASP proteins (1)
- Encephalitis Viruses (1)
- Endocrine system and metabolic diseases (1)
- Endocrine therapy (1)
- Endogenous retroviruses (ERV) (1)
- Endoluminal (1)
- Endometrial carcinoma (1)
- Endomicroscopy (1)
- Endorectal (1)
- Endoscopic papillotomy (1)
- Endoscopic retrograde cholangiography (1)
- Endoscopic sphincterotomy (1)
- Endoscopic treatment (1)
- Endoscopic ultrasound (1)
- Endothelial (1)
- Endothelial progenitor cells (1)
- Endothelial protein C receptor (1)
- Endothelial-to-mesenchymal transition (1)
- Energy (1)
- Energy metabolism (1)
- Energy-efficiency (1)
- Engraftment (1)
- Enterobacterales (1)
- Enterobacteriaceae (1)
- Entzündung (1)
- Environmental biotechnology (1)
- Environmental enrichment (1)
- Environmental impacts (1)
- Environmental sciences (1)
- Eosinophils (1)
- EpCAM positive tumor (1)
- Ephrin-B2–EphB4 (1)
- Epidural abscess (1)
- Epilepsiezentren (1)
- Epilepsy center (1)
- Epilepsy centers (1)
- Epileptic seizures (1)
- Epileptischer Anfall (1)
- Epithelialization (1)
- Epithelioma Cells (1)
- Epsilon (1)
- Equity (1)
- ErbB-signaling (1)
- Erythrophagocytosis (1)
- Estimated glomerular filtration rate (1)
- Eukaryotic sRNA (1)
- Europe (1)
- Euthanasie (1)
- Euthymic phase (1)
- Evaluation (1)
- Event related potentials (1)
- Event-related potential (1)
- Everolimus (1)
- Evidence-based (1)
- Evidence-based dentistry (1)
- Evidence-based drug discovery (1)
- Evidenz (1)
- Evidenzbasiert (1)
- Ewing sarcoma (1)
- Ewing-like (1)
- Exemestane (1)
- Exercise challenge (1)
- Exercise training (1)
- Exercise-induced asthma (1)
- Exhaled nitric oxide (1)
- Exoscope (1)
- Exosomal cytokines (1)
- Expansion (1)
- Expectation violation (1)
- Expert Systems (1)
- Expertensysteme (1)
- Explicit (1)
- External beam radiotherapy (1)
- Extracellular matrix proteins (1)
- Extracorporeal devices (1)
- Extracorporeal membrane oxygenation (1)
- Extraprostatic (1)
- Exudates and transudates (1)
- F4/80 (1)
- FABP (1)
- FAM134 (1)
- FAP (1)
- FAPI PET (1)
- FBK-R23 (1)
- FDG-PET/CT (1)
- FEV1 (1)
- FF-ATP synthase dimer (1)
- FFP3 respirator (1)
- FFPE (1)
- FGFR (1)
- FHIR Search (1)
- FIH1 (1)
- FOXO1 (1)
- FOXO3 (1)
- FPR (1)
- FSME-Virus (1)
- FTMT (1)
- FXR (1)
- Face masks (1)
- Facial nerve (1)
- FactorXIII Val34Leu polymorphism (1)
- Faktor V Leiden Mutation (1)
- Faktor XIII Val34Leu Polymorphismus (1)
- Fall (1)
- Falls (1)
- Famines (1)
- Fast Healthcare Interoperability Resources (1)
- Feasibility (1)
- Feasibility studies (1)
- Female subjects (1)
- Fendrr (1)
- Ferritinophagy (1)
- Ferroptosis (1)
- Fertility counseling (1)
- Fetal heart (1)
- Fibroblast (1)
- Fibrous dysplasia (1)
- Filariasis (1)
- Filariosis (1)
- Filgrastim (1)
- Filler (1)
- Finevo (1)
- Flavin mononucleotide (1)
- Fluid overload (1)
- Fluid therapy (1)
- Fluorescence (1)
- Focal Adhesion Kinase (1)
- Focal onset seizure (1)
- Follicular lymphoma (1)
- Follow-up treatment (1)
- Follow-ups (1)
- Fondaparinux (1)
- Food and Drug Administration (1)
- Forced expiratory volume in 1 s (1)
- Forensic examination (1)
- Forensic experts (1)
- Forensic pathology (1)
- Fracture (1)
- Fracture models (1)
- Fracture type (1)
- Frameshift (1)
- Frontobasal (1)
- Fruit fly (1)
- Frühsommermeningoenzephalitis (1)
- Fuchs endothelial dystrophy (1)
- Fukushima (1)
- Functional characterization (1)
- Functional connectivity (1)
- Functional electrical stimulation (1)
- Functional outcomes (1)
- Funktionelle Bildgebung (1)
- G-CSF (1)
- G207 (1)
- G2A (1)
- G3BP1 (1)
- GC–MS (1)
- GD2 (1)
- GDF11 (1)
- GFR (1)
- GIIb/IIIa-receptor (1)
- GLA deficiency (1)
- GMP (1)
- GPR4 (1)
- GRAND-SLAM (1)
- GSH (1)
- GTP cyclohydrolase (1)
- Gait analysis (1)
- Ganglionic (1)
- Gan–Dou–Fu–Mu decoction (GDFMD) (1)
- Gastric adenoma (1)
- Gastric cancer (1)
- Gastric motility (1)
- Gastritis (1)
- Gastroenterology (1)
- Gastrointestinal bleeding (1)
- Gastroschisis (1)
- Gaussian graphical models (1)
- Gender (1)
- Gene (1)
- Gene ontology (1)
- Gene sequencing (1)
- Gene therapy (1)
- Gene/Regulation (1)
- General Practitioner (1)
- General practice (1)
- Generalized procrustes analysis (1)
- Genetic heart disease (1)
- Genetic loci (1)
- Genetic networks (1)
- Genetic syndromes (1)
- Genetic techniques (1)
- Genome editing (1)
- Genome-wide association study (1)
- Genomic medicine (1)
- Geographical disparities (1)
- Gerinnungsfaktor XIII (1)
- Geschlecht (1)
- Gestagen-Monopräparate (1)
- Gesundheitspolitische Zuständigkeit (1)
- Gezielte Therapie (1)
- Glabella (1)
- Glaucoma (1)
- Gleason Grade Group (1)
- Gleason Grade group (1)
- Gleason grade group (1)
- Glioblastoma survival (1)
- Global networking (1)
- Global warming (1)
- Glomerulosclerosis (1)
- Glycolysis (1)
- Gradient boosting (1)
- Grading (1)
- Graft (1)
- Graft quality (1)
- Gram-negative bacteria (1)
- Granulocytes (1)
- Graph theory (1)
- Graphical LASSO (1)
- Graves’ disease (1)
- Gravimetric method (1)
- Greenhouse effect (1)
- Groin pain (1)
- Guidance (1)
- Guide profession (1)
- Guided bone regeneration (GBR) (1)
- Guided tissue regeneration (GTR) (1)
- Gut (1)
- Gut bacteria (1)
- GvL (1)
- H1N1 (1)
- HADS (1)
- HAE (1)
- HARS2 (1)
- HBsAg (1)
- HCC (1)
- HCC marker (1)
- HCMV (1)
- HDAC and BET inhibitor (1)
- HDAC4 (1)
- HDR-brachytherapy (1)
- HEOR (1)
- HER2 (1)
- HES (1)
- HIF (1)
- HIF-1α (1)
- HIF-2 (1)
- HIF-2α (1)
- HIF-2α, erythropoietin (1)
- HIPPO signalling (1)
- HIV protease inhibitors (1)
- HLA antibodies (1)
- HLHS (1)
- HNPCC (1)
- HOLEP (1)
- HOSO (1)
- HOTAIR (1)
- HPO (1)
- HPV infection (1)
- HPV-positive OPSCC (1)
- HRCT (1)
- HSC (1)
- HSCT (1)
- HSP (hereditary spastic paraplegia) (1)
- HSV type specific antibodies (1)
- HSV-1 (1)
- HSV-typenspezifische Antikörper (1)
- HVPG (1)
- Haematocrit (1)
- Haematologic diseases (1)
- Haemodialysis (1)
- Haemophilia (1)
- Haemophilie A (1)
- Halogenobenzimidazoles (1)
- Hard-tissue trauma (1)
- Hardware erosion (1)
- Hawaii Department of Health (1)
- HeLa cells (1)
- Head and neck cancer (1)
- Head bandage (1)
- Head neck cancer (1)
- Health care workers (1)
- Health policy (1)
- Health sciences (1)
- Health services (1)
- Health surveys (1)
- Health technology assessment (1)
- Healthcare (1)
- Healthcare personnel (1)
- Healthcare resource utilisation (1)
- Healthcare structure (1)
- Healthy Living Index (HLI) (1)
- Healthy men (1)
- Healthy stem cell donors (1)
- Heart defects (1)
- Heart rate (1)
- Heart transplantation (1)
- Heartrate (1)
- Heat Shock Protein (HSP) (1)
- Heat shock protein 27 (1)
- Hematologic adverse events (1)
- Hematoma (1)
- Hematopoietic stem cell (1)
- Hematopoietic stem cell transplant (1)
- Hematotoxicity (1)
- Hemispheric specialization (1)
- Hemobilia (1)
- Hemodynamics (1)
- Hemosiderin (1)
- Heparan Sulfate (1)
- Heparinsensitivität (1)
- Hepatic stellate cell (1)
- Hepatitis (1)
- Hepatitis C antibodies (1)
- Hepatitis C antigens (1)
- Hepatocellular carcinoma (HCC) (1)
- Herbal medicine (1)
- Herbalife products (1)
- Herbs induced liver injury (1)
- Hereditary angioedema (1)
- Herniated disk (1)
- Herpes Zoster Infektion (1)
- Heterogeneity (1)
- Heterologous prime-boost (1)
- Heterotopic pregnancy (1)
- Hierarchical drift-diffusion modeling (1)
- Hig1 (1)
- High altitude (1)
- High-risk prostate cancer (1)
- Highwire (1)
- Himalayas (1)
- Hip hemiarthroplasty (1)
- Hip revision (1)
- Hippocampal excitability (1)
- Hirschsprung disease (1)
- Hispanic–Latino race/ethnicity (1)
- Histological analysis (1)
- Histology (1)
- Hodgkin lymphoma (1)
- Holmium laser enucleation (1)
- Home Care Services [MeSH] (1)
- Honolulu Queen’s Medical Center (1)
- Hormonal (1)
- Hormone receptor positive breast cancer (1)
- Hospital (1)
- Human chorionic villi mesenchymal stromal cells (1)
- Human pancreas (1)
- Human primary proximal tubular cells (1)
- Human retroelements (1)
- Human visual cortex (1)
- Hyaluronan (1)
- Hydrofluoric acid (1)
- Hydromineral (1)
- Hydroxyethyl starch (1)
- Hymenoptera venom allergy (1)
- Hyperactivity (1)
- Hyperscanning (1)
- Hypertensive disorders in pregnancy (1)
- Hypoxia inducible factor 1 alphal (1)
- Hypoxia-inducible factor-1α (HIF-1α) (1)
- Hörrehabilitation (1)
- IAP (1)
- IAP Proteins (1)
- IAP-IAP (1)
- ICAM-1 (1)
- ICD (1)
- ICG (1)
- ICH M13A draft guideline (1)
- ICL (1)
- ICL V4c (1)
- IDH mutation (1)
- IFN-β (1)
- IFT (1)
- IGF-1 (1)
- IGF1 (1)
- IL-17 (1)
- IL-17A (1)
- IL-1b (1)
- IL-1β (1)
- IL-33 (1)
- IL-38 (1)
- INR (1)
- IPSS (1)
- IR (1)
- IRF-3 (1)
- IVUS (1)
- Idelalisib (1)
- Identifier (1)
- Identifikation (1)
- Identifizierung von Katastrophenopfern (1)
- IgA deficiency (1)
- Ileostomy (1)
- Ileus (1)
- Image processing (1)
- Imagery (1)
- Imdevimab (1)
- Immunbiology (1)
- Immune checkpoint inhibitors (1)
- Immune complex vasculitis (1)
- Immune paralysis (1)
- Immune status (1)
- Immune system (1)
- Immunity (1)
- Immunoassay (1)
- Immunodeficiency (1)
- Immunogenetics (1)
- Immunoglobulins (1)
- Immunomodulatory agents (1)
- Immunophenotyping (1)
- Immunosuppression (1)
- Immuno‑histochemistry (1)
- Impella (1)
- Impfraten (1)
- Impfstoff (1)
- Impfung (1)
- Implant osseointegration (1)
- Implantable cardioverter-defibrillator (1)
- Implicit (1)
- Implicit Processing (1)
- Implicit Association Test (1)
- Implicit motives (1)
- Impoverishment (1)
- Impulse generator (1)
- Imrt (1)
- In vitro (1)
- In vivo (1)
- In vivo electrophysiology (1)
- In-Hospital Emergencies (1)
- In-TIPS thrombosis (1)
- Inactivation (1)
- IncX (1)
- Incidence rate (1)
- Incidental prostate cancer (1)
- Incontinence (1)
- Indication for fertility preservation (1)
- Indirect treatment comparison (ITC) (1)
- Individual differences (1)
- Individualized therapy (1)
- Indocyanine green (1)
- Indonesia (1)
- Inducible nitric oxide synthase (iNOS) (1)
- Induction therapy (1)
- Inequality (1)
- Inferior vena cava thrombus (1)
- Inflammasome (1)
- Inflammatory bowel disease (1)
- Inflammatory fibroid polyp (1)
- Inflammatory pattern (1)
- Influenza (1)
- Influenza vaccination (1)
- Information theory (1)
- Infrared Raman (1)
- Inguinal hernia (1)
- Inguinal pain (1)
- Inherited arrhythmic syndrome (1)
- Injuries (1)
- Injury (1)
- Injury Severity Score (ISS) (1)
- Innate immunity (1)
- Inpatient hospital cases (1)
- Insulin (1)
- Insulin resistance (1)
- Integrated Pulmonary Index (1)
- Integration (1)
- Integrative Network Analysis (1)
- Integrin (1)
- Intensive care (1)
- Intention attribution (1)
- Interaction (1)
- Interferon-α (1)
- Interferon-λ, (1)
- Interleukin-10 (1)
- Interleukin-22 (1)
- Interleukin-36 (1)
- Intermediate-risk (1)
- International normalized ratio (1)
- Internet-based therapy (1)
- Interoperability (1)
- Interposition (1)
- Interpretation Bias (1)
- Intersectoral care (1)
- Interstitial pneumonia (1)
- Intervention (1)
- Intervention development (1)
- Interventional oncological treatment (1)
- Intervertebral disc displacement (1)
- Interview (1)
- Interviews (1)
- Intestinal fistula (1)
- Intestinal metaplasia (1)
- Intimal-medial thickness (1)
- Intraoperative blood salvage (1)
- Intraoperative procedure (1)
- Intraoperative test (1)
- Intravenous antibiotic therapy (1)
- Intravenous iron (1)
- Intrinsic Disorder (1)
- Intrinsic resistance (1)
- Intubation (1)
- Ionization State (1)
- Iron deficiency (1)
- Ischemia (1)
- Isocitrate dehydrogenase (1)
- Isoflurane (1)
- Isoforms (1)
- Isothermal amplification (1)
- Ixodes (1)
- Ixodes ricinus (1)
- JAK2V617F (1)
- JNK (1)
- Jaw (1)
- Jaw surgery (1)
- Joint actions (1)
- Joint loading (1)
- Jurkat (1)
- K-homology RNA-binding domain (1)
- K3EDTA plasma sampling (1)
- KCCQ (1)
- KCNQ1 (1)
- KLHL11 (1)
- KPS (1)
- Kallikrein inhibitor (1)
- Kappa (1)
- Kava (1)
- Kava hepatotoxicity (1)
- Keap1-Nrf2 (1)
- Ki-67 (1)
- Kidney diseases (1)
- Kidneys (1)
- Kindes- und Jugendalter (1)
- Knee joint sound (1)
- Knee osteoarthritis (1)
- Knee surgery (1)
- Knees (1)
- Kolorektales Karzinom (1)
- Kontrazeption (1)
- Kutner, Luis (1)
- Körpermodifizierung (1)
- L1-norm SVM (1)
- LAMTOR1 (1)
- LARS2 (1)
- LASS (1)
- LC-MS-Based Clinical Research (1)
- LC-MS-based lipid mediator analysis (1)
- LCD-Array (1)
- LDHB (1)
- LEOSS (1)
- LPS (1)
- LQTS (1)
- LSCC (1)
- LSD1 (1)
- LSEC (1)
- Laborpersonal (1)
- Lactate Dehydrogenase (1)
- Laminin (1)
- LanCL2 (1)
- Landmark (1)
- Language delay (1)
- Large vessel occlusion (1)
- Laryngeal Tube (1)
- Laser interstitial thermal therapy (1)
- Lasers (1)
- Lateral flow antigen testing (1)
- Lateral flow immunoassay (1)
- Learning and memory (1)
- Lee type, functional outcome (1)
- Lee-type (1)
- Legal medicine (1)
- Legionella pneumophila (1)
- Leigh syndrome (1)
- Leishmaniasis (1)
- Lemperle (1)
- Lennox-Gastaut syndrome (1)
- Leukemia (1)
- Leukocyte depletion filter (1)
- Lifestyle (1)
- Ligand post-insertion (1)
- Lipedema (1)
- Lipid Transition Temperature (1)
- Lipid peroxidation (1)
- Lipid solution (1)
- Liposuction (1)
- Liquor cerebrospinalis (1)
- Liver (1)
- Liver Fibrosis (1)
- Liver Transplantation (1)
- Liver biopsy (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Liver histology (1)
- Liver injury (1)
- Loa loa (1)
- Local field potential (1)
- Lockdown (1)
- Long interspersed nuclear elements (LINE) (1)
- Long non-coding RNA (1)
- Long non-coding RNAs (1)
- Long noncoding RNA (1)
- Long-COVID (1)
- Long-term continence (1)
- Long-term follow-up (1)
- Long-term results (1)
- Long-term-measurements (1)
- Longchain polyunsaturated fatty acids (1)
- Low grade glioma (1)
- Low-dose radiation therapy (1)
- Low-virulent infection (1)
- Lung cancer (1)
- Lung development (1)
- Lung function (1)
- Lung neoplasms (1)
- Lung ultrasound (1)
- Lyme Disease (1)
- Lyme borreliosis (1)
- Lyme disease (1)
- Lyme-Borreliose (1)
- Lymphangiectasia (1)
- Lymphocyte subpopulations (1)
- Lymphom (1)
- Lymphoma (1)
- Lymphoma Cells (1)
- Lymphopenia Mortality (1)
- Lysophosphatidic acids (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- M2-PK (1)
- MAP Kinases (MAPKs) (1)
- MAP kinase (1)
- MDD (1)
- MEIS (1)
- MEIS homeodomain protein (1)
- MEK inhibitor (1)
- MEN1 (1)
- MGMT (1)
- MGMT promoter (1)
- MID task (1)
- ML-IAP (1)
- MLH1 (1)
- MLKL (1)
- MMPs (1)
- MN1 (1)
- MR spectroscopy (1)
- MRI-negative epilepsy (1)
- MS (1)
- MT: Non-coding RNAs (1)
- MTHFR-Mutation (1)
- MTHFR-mutation (1)
- MTOR inhibitor (1)
- MTRasym (1)
- MTT assay (1)
- MUTARS® RS Cup System (1)
- MUTARS® RS cup system (1)
- MVPA (1)
- MYC (1)
- MYCBP2 (1)
- MYCN amplification (1)
- Machine Learning (1)
- Macrophage (1)
- Magnet dislocation (1)
- Magnetic resonance (1)
- Maintenance therapy (1)
- Major Depressive Disorder (1)
- Makrophagen (1)
- Malaria (1)
- Malate Dehydrogenases (1)
- Malignancy (1)
- Malignant meningioma (1)
- Malnutrition (1)
- Management (1)
- Manchester scar scale (1)
- Mandatory Vaccinations (1)
- Marburg virus (1)
- Marginal integrity (1)
- Masking effect (1)
- Masquelet technique (1)
- Mass disaster (1)
- Massenkatastrophe (1)
- Mastoiditis (1)
- Matching-adjusted indirect comparison (MAIC) (1)
- Materials science (1)
- Maternal separation (1)
- Mathematical biosciences (1)
- Mathematical functions (1)
- Maxillofacial reconstruction (1)
- Maxillofacial surgery (1)
- Maxillofacial trauma (1)
- Mean erythrocyte volume (1)
- Mechanical ventilation (1)
- Median nerve (1)
- Medical Oncology (1)
- Medical history (1)
- Medical study (1)
- Meersseman test (1)
- Membrane proteins (1)
- Membrane-Phloretin Interaction (1)
- Meningioma (1)
- Mental disorder (1)
- Mental health and psychiatry (1)
- Mental health therapies (1)
- Meta-analysis (1)
- Metabolic dysfunction (1)
- Metabolic models (1)
- Metabolic syndrome (1)
- Metabolic vulnerabilities (1)
- Metabolism (1)
- Metabolomic profile (1)
- Metacognition (1)
- Metal clip (1)
- Metalloproteinases (1)
- Metastasis (1)
- Metastasis-directed therapy (1)
- Metastatic (1)
- Metastatic castration-resistant prostate cancer (1)
- Metastatic renal cell carcinoma (1)
- Metformin (1)
- Methanol (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Method validation (1)
- Methods (1)
- Methylation (1)
- Methylmercury Containing Inactivator (1)
- Methylphenidate (1)
- MiR-29 (1)
- MiSpEx-network (1)
- Michael acceptor (1)
- Micro computed tomography (1)
- MicroRNAs (1)
- Microbiology and Infectious Disease (1)
- Microbiology, Virology & Host Pathogen Interaction (1)
- Microbiome (1)
- Microenvironment (1)
- Microfilaremia (1)
- Microgap (1)
- Microglia (1)
- Microparticles (1)
- Microplastic (1)
- Microstructural impairment (1)
- Mid-intestinal bleeding (1)
- Migrant health (1)
- Mild chronic inflammation (1)
- Mild hypoxia (1)
- Mineralization (1)
- Mini-monovision (1)
- Minimal invasive dentistry (1)
- Mitochondrial Apoptosis (1)
- Mitochondrial Metabolism (1)
- Mitochondrial Permeability Transition (1)
- Mitochondrial ROS (1)
- Mitochondrial Transport (1)
- Mitochondrial complex I (1)
- Mitosis (1)
- Mixed Lipid Phases (1)
- Mixed hearing loss (1)
- Mmp12 (1)
- Mobilization (1)
- Model organisms (1)
- Molecular Biology (1)
- Molecular Chaperone (1)
- Molecular diagnosis (1)
- Molecular diagnostics (1)
- Molecular glue (1)
- Molecular mimicry (1)
- Molecular subtypes (1)
- Monetary incentive delay (1)
- Mongolian spot (1)
- Monitoring (1)
- Monoacylglycerol lipase (1)
- Monoclonal antibody (mAb) (1)
- Monocyte gene expression (1)
- Mood (1)
- Morbidity (1)
- Morphologie (1)
- Mosquito (1)
- Mosquito crop (1)
- Mosquito-plant interaction (1)
- Motility (1)
- Motivation (1)
- Motor-cognitive (1)
- Mountain (1)
- Mouse (1)
- Mouse models (1)
- Multi-Omics (1)
- Multi-motive grid (1)
- Multi-stakeholder approach (1)
- Multi-syndrome classification (1)
- Multidrug-resistance (1)
- Multidrug-resistant organisms (1)
- Multiligament instability (1)
- Multimedication (1)
- Multimodal Modeling (1)
- Multiparametric MRI (1)
- Multiplate (1)
- Multiple Transport Systems (1)
- Multiple sclerosis (1)
- Multiple-indication review (1)
- Multiplex immunoassay (1)
- Multiset independent component analysis (1)
- Multivariate analysis (1)
- Muscle (1)
- Muscle analysis (1)
- Muscle damage (1)
- Muscle pain (1)
- Musculoskeletal abnormalities (1)
- Musculoskeletal mechanics (1)
- Musculoskeletal problems (1)
- Music (1)
- Mutations (1)
- Myalgia (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myiasis (1)
- Myocardial infarction (MI) (1)
- Myocardial injury (1)
- Myocardial perfusion (1)
- Myocardial remodeling (1)
- Myopia (1)
- N-glycosylation (1)
- N471D strumpellin knock-in mice (1)
- N501Y (1)
- NAD + Analogues (1)
- NAD+-Analogs (1)
- NADP+ Analogues (1)
- NAD⊕-Isomer (1)
- NCOA4 (1)
- NET (1)
- NF-kB (1)
- NF-κB pathway (1)
- NFkB (1)
- NFκB (1)
- NGS sequencing (1)
- NIRS (1)
- NIS (1)
- NK Receptor (1)
- NK cell (1)
- NK cell subsets (1)
- NK-92 (1)
- NLPHL (1)
- NLRP3 inflammasomes (1)
- NO (1)
- NOS-I (1)
- NOS1AP (1)
- NR4A2 (1)
- NR4A3 (1)
- NSBB (1)
- NTDs (1)
- NTM (1)
- NURF (1)
- NVBP (1)
- Nachweisverfahren (1)
- Nadelstichverletzungen (1)
- Nanoplastic (1)
- Natural Killer (NK) Cell (1)
- Natural killer cells (1)
- Necroptosis (1)
- Necrosis (Necrotic Death) (1)
- Necrotizing enterocolitis (1)
- Needs Assessment [MeSH] (1)
- Negative appendectomy rate (1)
- Neglected tropical diseases (1)
- Negligence (1)
- Nek1 (1)
- Neoadjuvant systemic therapy (1)
- Neoadjuvant treatment (1)
- Neonatal surgery outcome (1)
- Nephrectomy (1)
- Neural coding (1)
- Neural goal function (1)
- Neural stem cells (1)
- NeuroSAFE (1)
- Neurodegenerative syndromes (1)
- Neurodevelopmental disorder (1)
- Neuroendocrine tumor (1)
- Neuroepithelial (1)
- Neuroepithelial tumor (1)
- Neurofeedback (1)
- Neurofilament light chain (1)
- Neuroligins (1)
- Neuromuscular exercise (1)
- Neurooncology (1)
- Neuropilin (1)
- Neuropsychiatric disorders (1)
- Neurosurgery (1)
- Neurotoxicity (1)
- Neurovascular damage (1)
- Neurovascular lesion (1)
- Nevus of Ito (1)
- Nevus of Ota (1)
- New E3-ligase ligands (1)
- NfL (1)
- Niche (1)
- Nicotine (1)
- Nitric oxide (1)
- Nkx2-5 (1)
- Non-Hodgkin lymphoma (1)
- Non-abusive head trauma (NAHT) (1)
- Non-apoptotic functions (1)
- Non-cylindrical folds (1)
- Non-diffractive EDOF-IOL (1)
- Non-expert MRI (1)
- Non-small cell lung cancer (1)
- Non-tuberculous mycobacteria (1)
- Non-vitamin K antagonist oral anticoagulants (1)
- Nonaerosolizing treatment (1)
- Nonoperative management (1)
- Nonpenetrating (1)
- Nontuberculous mycobacteria (1)
- Noradrenergic (1)
- Norepinephrine (1)
- Normative modeling (1)
- Notch signaling (1)
- Nox (1)
- Nox inhibition (1)
- Nox4 (1)
- Nrf-2 (1)
- Nukleinsäureamplifikationstest (NAT) (1)
- Null responder (1)
- Number of platelets (1)
- Nutrition (1)
- OA (1)
- OCT (1)
- OGR1 (1)
- OHIP-G14 (1)
- OHRQoL (1)
- ORP (1)
- OSA (1)
- OSCE (1)
- OTU domain-containing protein 7B (OTUD7B) (1)
- OXA-23 (1)
- OXA-484 (1)
- OXA-58 (1)
- OXPHOS (1)
- Oberflächenantigen-Mutante (1)
- Observational (1)
- Obsessive-compulsive disorder (1)
- Obstetrics and gynecology (1)
- Occlusion (1)
- Occlusion treatment (1)
- Occupational health (1)
- Ocular tuberculosis (1)
- Older adult (1)
- Older patient (1)
- Older patients (1)
- Olfactory groove meningioma (1)
- Olfactory system (1)
- Oligodendroglioma (1)
- Oligometastatic (1)
- Omega lipids (1)
- Omicron variant BA.1 (1)
- Omphalocele (1)
- Oncogenes (1)
- One-leg stand (1)
- Online Survey (1)
- Online education (1)
- Open Science (1)
- Open pulmonary tuberculosis (1)
- Ophthalmoplegia (1)
- Opinion (1)
- Opioid system (1)
- Opioids (1)
- Opportunistic infections (1)
- Optical phenomena (1)
- Oral and maxillofacial surgery (1)
- Oral anticoagulation (1)
- Oral food challenge (1)
- Oral immunotherapy (OIT) (1)
- Oral therapy (1)
- Orbital fracture (1)
- Organ failure (1)
- Organ injury (1)
- Organ preservation (1)
- Organ-confined (1)
- Orthodontic tooth movement (1)
- Orthopaedics (1)
- Oscillating saws (1)
- Ossifying fibroma (1)
- Osteocalcin (1)
- Osteoporotic fractures (1)
- Otorhinolaryngological (1)
- Outcomes research (1)
- Outpatients (1)
- Ovarian cancer treatment (1)
- Over-the-scope clip (1)
- Overweight (1)
- Overwintering (1)
- Oxa1/YidC/Alb3 Membrane Insertases (1)
- Oxidative phosphorylation (1)
- OxyELITE Pro (1)
- Oxygen extraction fraction (1)
- P2X7 receptor (1)
- PAC-1 (1)
- PAD-test (1)
- PAM (1)
- PAPR (1)
- PATZ1 (1)
- PBBM (1)
- PBSC (1)
- PBX (1)
- PCA (1)
- PD-1 (1)
- PDPK1 (1)
- PFOA (1)
- PFOS (1)
- PGC-1α (1)
- PHR1 (1)
- PI3K (1)
- PI3K inhibitor (1)
- PI3K/mTor inhibition (1)
- PLAGL1 (1)
- PLGA (1)
- PMA (1)
- PMI (1)
- PML (1)
- PMMA (1)
- POCT (1)
- POR (1)
- PPAR (1)
- PPAR-γ (1)
- PPTC7 (1)
- PRF (1)
- PRG5 (1)
- PRNT (1)
- PROTAC (1)
- PRRT (1)
- PSA (1)
- PTEN (1)
- PTEN inducible kinase 1 (1)
- PTM (1)
- PTSD (1)
- PV loop (1)
- PWI (1)
- PacBio SMRT sequencing (1)
- Pacemaker (1)
- Paediatric cancer (1)
- Paediatric trauma patients (1)
- Pain management (1)
- Pain scale MWA (1)
- Palacos reaction (1)
- Palliative Care [MeSH] (1)
- Pandemie (1)
- Papillon-Lefèvre syndrome (1)
- Paracoccus denitrificans (1)
- Parasympathetic (1)
- Parenteral nutrition (1)
- Parkinson's disease (1)
- Particle load reduction (1)
- Particle number size distribution (1)
- Particle size distribution (1)
- Particle toxicity (1)
- Particulate matter (1)
- Particulates (1)
- Pathogenicity (1)
- Pathogens (1)
- Pathology (1)
- Pathophysiology (1)
- Patient Outcome Assessment [MeSH] (1)
- Patient Reported Outcome Measures [MeSH] (1)
- Patient and public Involvement (1)
- Patient care (1)
- Patient information (1)
- Patient manikins (1)
- Patient outcome assessment (1)
- Patient participation (1)
- Patient perspective (1)
- Patient preference (1)
- Patient*inneninformation (1)
- Patientenverfügung (1)
- Pediatric fracture (1)
- Pediatric oncology (1)
- Pediatric stem cell transplantation (1)
- Pediatric surgery (1)
- Pelargonium sidoides questionable hepatotoxicity (1)
- Pelvic (1)
- Pentose Pathway (1)
- Per1−/−-mice (1)
- Perceived stigma (1)
- Percutaneous endoscopic gastrostomy (1)
- Percutaneous pinning (1)
- Percutaneous ultrasound (1)
- Peri-implant disease (1)
- Periodic (1)
- Periodontal trauma (1)
- Periodontitis grades B and C (1)
- Peripheral blood smears (1)
- Periprocedural anticoagulation (1)
- Peritoneal macrophages (1)
- Peritumoural oedema (1)
- Peri‑implantitis (1)
- Peroxidase (1)
- Perrault syndrome (1)
- Persistence SARS-CoV-2 antibodies (1)
- Persistent organic pollutants (1)
- Personal medicine (1)
- Personal protective equipment (1)
- Personal stigma (1)
- Personalisierte translationale Therapie (1)
- Personality inventory (1)
- Personalized Medicine (1)
- Personalized medicine (1)
- Pertussis (1)
- Petri net (1)
- Peutz–Jeghers syndrome (1)
- Phakic (1)
- Phalangeal fractures (1)
- Phantoms (imaging) (1)
- Pharmacokinetics (1)
- Pharmacotherapy (1)
- Pharmacovigilance (1)
- Phase 3 (1)
- Phase 3 trial (1)
- Phase I clinical trial (1)
- Phase-reset (1)
- Phenotypic plasticity (1)
- Phenylketonuria (PKU) (1)
- Philadelphia chromosome-positive acute leukemia (1)
- Phlyctenule (1)
- Phosphohydrolases (1)
- Photoaffinity Labeling (1)
- Physical and mental health (1)
- Physical comorbidities (1)
- Physical self-perception (1)
- Physics (1)
- Physiotherapy (1)
- Placental organoids (1)
- Plasma (1)
- Plastic pollution (1)
- Plastics (1)
- Platelets (1)
- Play (1)
- Pleasure (1)
- Pneumocystis jirovecii (1)
- Podospora anserina (1)
- Point of care (1)
- Point-of-care wound diagnostics (1)
- Poly-Pore (1)
- Polygenic risk score (1)
- Polyposis syndrome (1)
- Polyunsaturated fatty acid mediators (1)
- Polyunsaturated fatty acids (1)
- Ponatinib (1)
- Population dynamics (1)
- Portal veins (1)
- Portuguese population (1)
- Positron emission tomography (1)
- Post mortem examination (1)
- Post mortem interval (1)
- Post-cesarean (1)
- Post-mortem genetic screening (1)
- Post-offence drinking (1)
- Post-thaw recovery (1)
- Post-traumatic stress disorder (1)
- Postmortem (1)
- Postmortem interval (1)
- Postoperative anatomy (1)
- Posttraumatic stress disorder (1)
- Postural sway (1)
- Posture analysis (1)
- Potassium iodide (1)
- Poverty (1)
- Powered air-purifying respirator (1)
- Praeklampsie (1)
- Pre-operative radiotherapy (1)
- Precision medicine (1)
- Prediction (1)
- Prediction of locoregional recurrence (1)
- Predictive Modeling (1)
- Predictive model (1)
- Predictive processing (1)
- Predictors (1)
- Predominant polarity (1)
- Preeclampsia (1)
- Presbyopia (1)
- Pressure distribution (1)
- Pressure measuring plate (1)
- Preventive medicine (1)
- Primary care (1)
- Primary cilium (1)
- Primary molars (1)
- Primärversorgung (1)
- Principal component analysis (1)
- Prisoners (1)
- Prisons (1)
- Probability density (1)
- Probability distribution (1)
- Procedural skills (1)
- Professional dance (1)
- Proficiency testing (1)
- Prognostic markers (1)
- Prognostic models (1)
- Progranulin (1)
- Promoters (1)
- Propensity score matching (1)
- Proposal (1)
- Protease inhibitor therapy (1)
- Protein (1)
- Protein Domains (1)
- Protein Expression (1)
- Protein Folding (1)
- Protein Motifs (1)
- Protein Targeting (1)
- Protein Translocation (1)
- Protein interactions (1)
- Protein-Lipid Interaction (1)
- Protein-Protein Interactions (1)
- Protein-translocation (1)
- Prothrombinmutation (1)
- Protocol (1)
- Proton density (1)
- Proximal (1)
- Prävention (1)
- Pseudophakia (1)
- Pseudoprogression (1)
- Psoriatic arthritis (1)
- Psychiatric disorders (1)
- Psychiatric traits (1)
- Psychiatry (1)
- Psychophysics (1)
- Pteridine (1)
- Pulmonary edema (1)
- Pulmonary hypertension (1)
- Pulmonary hypoplasia (1)
- Pumpkin seeds (1)
- Purdue Pegboard (1)
- Pyogenic (1)
- Pyogenic spondylodiscitis (1)
- Python (1)
- Qualitative Research [MeSH] (1)
- Qualitative research (1)
- Qualitative study (1)
- Quality control (1)
- Quality of Health Care [MeSH] (1)
- Quantitative (q)T2 mapping (1)
- Quantitative Imaging (1)
- Quantitative MRI (1)
- Quantitative features (1)
- Quantitative magnetic resonance imaging (1)
- Quantra (1)
- Quarantine (1)
- Quasi-longitudinal study (1)
- Quinolones (1)
- RAF (1)
- RARP (1)
- RAS (1)
- RAS pathway (1)
- RCC (1)
- RDoC (1)
- RESLES (1)
- RET (1)
- RGAG1 (1)
- RIP (1)
- RIPK1 (1)
- RMS (1)
- RNA chaperone (1)
- RNA sequencing (1)
- RNA stability (1)
- RNA therapy (1)
- RNA turnover (1)
- RNA virus (1)
- RNA-binding protein (1)
- RNA-sequencing (1)
- RNA/MicroRNA (1)
- RNAP II (1)
- RND (1)
- RNF4 (1)
- ROC analyses (1)
- ROC analysis (1)
- ROC-Analysen (1)
- ROS1 (1)
- RT-PCR-detection (1)
- Rab7 (1)
- Rabbit (1)
- Race (1)
- Radiation Oncology (1)
- Radiation necrosis (1)
- Radiochemotherapy (1)
- Radiofrequency ablation (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Radiology (1)
- Radiosurgery (1)
- Ragulator complex (1)
- Ramadan (1)
- Ramucirumab (1)
- Random forest (1)
- Randomisation (1)
- Randomized Controlled Trial (1)
- Randomized controlled trial (1)
- Randomized controlled trials (1)
- Rcf1 (1)
- Reactogenicity (1)
- Ready-made mouthguard (1)
- Real world study (1)
- Real-time MRI (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- Receptors/Nuclear (1)
- Recurrence (1)
- Recurrent episodes (1)
- Redox dependent epigenetic modifications (1)
- Redox-sensitive transcription factor (1)
- Redundancy (1)
- Referral (1)
- Refractive changes (1)
- Refractive lense exchange (1)
- Refractory ALL (1)
- Refractory AML (1)
- RegJoint™ (1)
- Regeneration (1)
- Region (1)
- Registries (1)
- Regret (1)
- Regulatory agencies. (1)
- Rehabilitation outcome (1)
- Rehabilitationsergebnis (1)
- Relapse surveillance (1)
- Relaxometry (1)
- Renal cell carcinoma (1)
- Renal vein thrombus (1)
- Representative survey (1)
- Reproducibility (1)
- Reproducibility/stability (1)
- Research data (1)
- Research design (1)
- Research investment (1)
- Research patterns (1)
- Research validity (1)
- Resection (1)
- Residual myometrial thickness (1)
- Resilience (1)
- Respiratory infections (1)
- Response control (1)
- Responsibility of healthcare policy (1)
- Restenosis (1)
- Resting-state (1)
- Retinal diseases (1)
- Retinoic acid (1)
- Retrospective study (1)
- Return to work (1)
- Reverse electron transfer (1)
- Reward anticipation (1)
- Reward system (1)
- Rh Antigens (1)
- Rhabdomyoma (1)
- Rho-kinase (1)
- Ribosomal RNA (1)
- Ridge preservation (1)
- Riftia pachyptila (1)
- Risikofaktoren (1)
- Risikokommunikation (1)
- Risk assessment (1)
- Risk communication (1)
- Risk factor (1)
- Risk stratification (1)
- Risk-stratification (1)
- Rivaroxaban (1)
- Robotic-assisted radical prostatectomy (1)
- Rodents (1)
- Roussel Uclaf Causality Assess- ment Method (RUCAM) (1)
- Routinely Collected Health Data [MeSH] (1)
- S1P (1)
- S1P lyase (1)
- S1P5 (1)
- S1PR5 (1)
- S63845 (1)
- SAH (1)
- SAMHD1 (1)
- SARS CoV 2 (1)
- SARS coronavirus (1)
- SARS-COV-2 (1)
- SARS-CoV-2-specific T cells (1)
- SARS-CoV2 (1)
- SARS-CoV‑2 (1)
- SCA2 (1)
- SCCHN (1)
- SCD14 (1)
- SCN5A (1)
- SEAP (1)
- SEC (1)
- SEC-ICP-DRC-MS (1)
- SEER (1)
- SELEX (1)
- SENP (1)
- SF-12 (1)
- SF-36 (1)
- SGPL1 (1)
- SGPL1 knockout cell line (1)
- SH- (S-S)-Groups (1)
- SH-SY5Y neuroblastoma cells (1)
- SIDS (1)
- SIRPalpha (1)
- SIRT1 (1)
- SKALE score (1)
- SLAM-seq (1)
- SLC6a3 (1)
- SLC7A11 (1)
- SLUG (1)
- SMOC1 (1)
- SNORD95 (1)
- SOD (1)
- SPG8 (1)
- SPPL3 (1)
- SSTI (1)
- STAT1 (1)
- STAT3 (1)
- SUD (1)
- SUDEP (1)
- SVR (1)
- Safety culture (1)
- Safety perspectives (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Sampling protocol (1)
- Sandfly (1)
- Sanger Sequencing (1)
- Sapacitabine (1)
- Sarcoma (1)
- Sarcophagidae (1)
- Satisfaction (1)
- Saudi Arabia (1)
- Scalp defect (1)
- Scanner models (1)
- Scheduling of radiotherapy (1)
- Scheimpflug imaging (1)
- Sclerotic glomeruli (1)
- Screening (1)
- Screening-ELISA (1)
- Screeningfragebogen (1)
- Scrofulous keratitis (1)
- Seasonal variation (1)
- Second donation (1)
- Sedation (1)
- Sedatives (1)
- Seizures (1)
- Self-esteem (1)
- Self-expandable TAVI (1)
- Self-renewal (1)
- Senescence (1)
- Separation of ADP-Binding Enzymes (1)
- Sepsis (1)
- Sequelae (1)
- Sequencing (1)
- Serious injured children (1)
- Serology (1)
- Serum (1)
- Serum biomarker (1)
- Shared information (1)
- Sharp injuries (1)
- Short bowel syndrome (1)
- Shoulder luxation (1)
- Side effect (1)
- Side effects (1)
- Siderosis (1)
- Signal Recognition Particle (1)
- Signal intensity (1)
- Signs and symptoms (1)
- Silver diamine fluoride (1)
- Simulated patients (1)
- Simulation training (1)
- Single nucleotide polymorphism (1)
- Single positive core biopsy (1)
- Single-cell RNA sequencing (1)
- Single-leg hop for distance (1)
- Single-treatment (1)
- Skeletal health (1)
- Skeletal joints (1)
- Skeletal muscles (1)
- Skull base (1)
- Sleep (1)
- Slow Cortical Potentials, SCP (1)
- Smac mimetics (1)
- Smad (1)
- Small Leucine-rich Proteoglycan (SLRP) (1)
- Small RNA analysis (1)
- Small vessel disease (1)
- Small-bowel endoscopy (1)
- Smoking habits (1)
- Smooth muscle cells (1)
- Social Phobia (1)
- Social brain (1)
- Social cognition (1)
- Social decision-making (1)
- Social determinants (1)
- Social differences (1)
- Social neuroscience (1)
- Socio-economic analysis (1)
- Sociocognitive predictors (1)
- Sociodemographic characteristics (1)
- Socioeconomic analysis (1)
- Socioeconomic indices (1)
- Socket healing (1)
- Socket preservation (1)
- Sodium chloride (1)
- Soft tissue healing (1)
- Soft tissue sarcoma (1)
- Software (1)
- Solar insolation (1)
- Soluble epoxide hydrolase (1)
- Sonication (1)
- Sonography (1)
- Sparse models (1)
- Spatial Attention (1)
- Specific Synthesis (1)
- Speech (1)
- Speech discrimination (1)
- Sphk1 (1)
- Sphk2 (1)
- Spinal cord (1)
- Spinal fractures (1)
- Spinal injuries (1)
- Spinal surgery (1)
- Spine care (1)
- Spine fractures (1)
- Spine infection (1)
- Spinocerebellar ataxia type 2 (1)
- Spirochetes (1)
- Spondylitis (1)
- Spondylodiscitis (1)
- Sports and exercise medicine (1)
- Sprachverstehen (1)
- Spread of Excitation (1)
- Sputum smear-negative (1)
- Stability (1)
- Stage at presentation (1)
- Stakeholder participation (1)
- Standard dataset (1)
- Standard reference values (1)
- Static MRI (1)
- Statin (1)
- Stationäre Krankenhausfälle (1)
- Statistical analysis (1)
- Stem cell dose (1)
- Stem cell enumeration (1)
- Stereotactic ablative body radiotherapy (1)
- Sterols (1)
- Stigma (1)
- Stigma scale (1)
- Stimulant (1)
- Sting challenge (1)
- Stoppa approach (1)
- Streptomyces hydrogenans (1)
- Stress vulnerability/resilience genes (1)
- Striatum (1)
- Stroke Risk (1)
- Stroke genetics (1)
- Stroke unit (1)
- Structured written feedback (1)
- Sub-zero exposure (1)
- Subependymal giant cell astrocytoma (1)
- Subjective effects (1)
- Subventricular zone (1)
- Sudden Cardiac Death (SCD) (1)
- Sudden cardiac death (1)
- Sudden infant death syndrome (1)
- Sugar feeding (1)
- Suicidality (1)
- Suicide attempt (1)
- Sulfhydryl Groups (1)
- Sulphoraphane (1)
- Sunlight (1)
- Support vector machine (1)
- Supraglottic Airway Devices (1)
- Supratentorial (1)
- Surgical blood loss (1)
- Surgical education (1)
- Surgical oncology (1)
- Surgical site infection (1)
- Surgical therapy (1)
- Survey (1)
- Suspension (1)
- Sustained attention (1)
- Sustained virologic response (1)
- Sustained virological response (1)
- Swallowing (1)
- Syk Kinase (1)
- Symmetrical blocked occlusion (1)
- Sympathetic (1)
- Sympathetic nervous system (1)
- Synapse (1)
- Synaptic organizer (1)
- Synaptosomal preparation (1)
- Syndecan-1 (1)
- Synergy (1)
- Synovial sarcoma (1)
- Synthetic biology (1)
- Syrian hamster (1)
- Systems & Computational Biology (1)
- T Cell Biology (1)
- T cell (1)
- T cell receptor (1)
- T cells (1)
- T helper cell differentiation (1)
- T-bet (1)
- T-cell development (1)
- T-cell receptor (1)
- T-cell receptor (TCR) (1)
- T-cells (1)
- T2 (1)
- TACE (1)
- TAM (1)
- TAMs (1)
- TB-therapy (1)
- TBI (1)
- TBK1 (1)
- TDAG8 (1)
- TEPT (1)
- TGF-α (1)
- TGF-β1 (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TGR(mREN2)27 (1)
- THRLBCL (1)
- TIGAR (1)
- TIRADS (1)
- TLR4 (1)
- TME (1)
- TMT (1)
- TOR signalling (1)
- TRAIL (1)
- TRIMs (1)
- TRP Channels (1)
- TRP2 (1)
- TRPA1 (1)
- TRPM8 (1)
- TRPV4 (1)
- TSP-4 (1)
- TTFields (1)
- TTW nodules (1)
- TUR-P (1)
- TURP (1)
- TWNK (1)
- Taekwondoka (1)
- Tailored therapy (1)
- Takotsubo Syndrome (1)
- Tamoxifen (1)
- Tar (1)
- Targeted delivery (1)
- Targeted sequencing (1)
- Targeted therapies (1)
- Targeted therapy (1)
- Tattoo (1)
- Technical data (1)
- Tempo-parietal junction (1)
- Temporomandibular joint (1)
- Temporomandibular joint dysfunction (1)
- Terminal ileitis (1)
- Test assay (1)
- Testing (1)
- Tetanus (1)
- Tetrahydrobiopterin (1)
- Thalidomide (1)
- Theft (1)
- Therapeutic adherence (1)
- Therapeutic anticoagulation (1)
- Therapeutic competence (1)
- Therapie (1)
- Therapies (1)
- Therapy (1)
- Thermogenesis (1)
- Thermoplasma acidophilum Membranes; Tetraetherlipids (1)
- Thoracic trauma (1)
- Thorax (1)
- Thrombophilie (1)
- Thrombose (1)
- Thrombotic thrombocytopenic purpura (1)
- Thumb carpometacarpal joint osteoarthritis (1)
- Thyroid (1)
- Thyroid Cancer Cells (1)
- Tick (1)
- Tick-Borae (1)
- Tick-Born Diseases (1)
- Tick-borne diseases (1)
- Time of death (1)
- Time trend (1)
- Tissue engineering (1)
- Tissue expander (1)
- Tissue microarray (1)
- Tissue-specificity (1)
- Tobacco (1)
- Tocilizumab (1)
- Toll-like Receptor (TLR) (1)
- Toluidine blue (1)
- Tomography (1)
- Tooth Development (1)
- Tooth segmentation (1)
- Total elbow arthroplasty (1)
- Total hip arthroplasty (1)
- Touchscreen (1)
- Toxic liver disease (1)
- Toxicity (1)
- Toxins (1)
- Traditional Chinese Medicine (TCM) (1)
- Traditional Indian Medicine (1)
- Trafficking (1)
- Trail (1)
- Traits of medical students (1)
- Trajectories (1)
- Transarterial chemoembolization (1)
- Transcatheter stage 1 (1)
- Transcranial direct current stimulation (1)
- Transcription (1)
- Transcription factor (1)
- Transcription regulation (1)
- Transcriptional regulatory elements (1)
- Transcriptomics (1)
- Transdifferentiation (1)
- Transfer learning (1)
- Transfusion practice (1)
- Transgenic mice (1)
- Transitional fractures 3D printing (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transjugular intrahepatic portosystemic shunt (1)
- Translation (1)
- Translation proteomics (1)
- Translationsregulation (1)
- Transplant logistics (1)
- Transplantation Centers (1)
- Transurethral resection of the prostate (1)
- Trauma centre (1)
- TraumaRegister DGU® (1)
- TraumaRegister DGU® (TR-DGU) (1)
- Traumatic brain injury (1)
- Traumatic dental injury (1)
- Traumatology (1)
- Travel regulations (1)
- Travel times (1)
- Treatment effectiveness (1)
- Treatment management (1)
- Treatment rates (1)
- Treatment response (1)
- Treg cell (1)
- Trimeric autotransporter adhesins (1)
- Trisomy 21 (1)
- Troponin (1)
- Truncating mutation (1)
- Truncus arteriosus (1)
- Tuberous sclerosis complex (1)
- Tumor cell (1)
- Tumor subtype (1)
- Tumor therapy (1)
- Tumour immunology (1)
- Type 1 diabetes (1)
- Type three hypersensitivity (1)
- Tyrosine kinase inhibitor (TKI) (1)
- Tyrosinemia (1)
- UBA domain (1)
- UGCG (1)
- UHPLC-MS (1)
- UPR (1)
- USA (1)
- USP28 (1)
- USP32 (1)
- Ubiquitin Ligase (1)
- Ubiquitin ligase (1)
- Ubiquitin signaling (1)
- Ubiquitin-binding module (1)
- Ubiquitination (1)
- Ubiquitylation (1)
- Ulixertinib (1)
- Uncertainty (1)
- Undergraduate (1)
- Undergraduate education (1)
- Understanding (1)
- Undiagnosed patients (1)
- Unique information (1)
- Upgrading (1)
- Upper airway infection (1)
- Urachal cancer (1)
- Urachus carcinoma (1)
- Urethral cancer (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Urine (1)
- Urologic tumors (1)
- Urological oncology (1)
- Uterus (1)
- V4 (1)
- VEGF receptor 2 internalization and signaling (1)
- VEGF receptors (1)
- VF (1)
- VGAT-ChR2 (1)
- VHL (1)
- VIM (1)
- VRE (1)
- VT (1)
- VUS (1)
- VX-2 (1)
- Vaccine (1)
- Vagus nerve (1)
- Vagus nerve stimulation (1)
- Validation (1)
- Valvular cardiomyopathy (1)
- Variant of concern (1)
- Variceal bleeding (1)
- Vascular cognitive disorder (VCD) – Paranoid hallucinatory syndrome – Late-onset trauma-related symptoms – Depression – Assertive community treatment (ACT) (1)
- Vascular disease (1)
- Vasculitis (1)
- Vasospasm (1)
- Venous Thromboembolism (1)
- Venous thromboembolism (1)
- Venous thrombosis (1)
- Ventilators (1)
- Ventricular arrhythmia (1)
- Ventricular arrhythmias (1)
- Ventricular tachyarrhythmia (1)
- Venöse Thrombose/Genetik (1)
- Versorgungsstruktur (1)
- Vertebral body (1)
- Vibroarthrography (1)
- Video rasterstereography (1)
- Videorasterstereography (1)
- Viral hepatitis (1)
- Viral infection (1)
- Viral load (1)
- Viral oncology (1)
- Virological testing (1)
- Virologie (1)
- Virology (1)
- Virtual noncalcium reconstructions (1)
- Virtual patients (1)
- Virulence (1)
- Virus trapping (1)
- Virusisolierung (1)
- Viruslast (1)
- Visual Perception (1)
- Visual quality (1)
- Visual-field localizer (1)
- Volume reduction of thyroid nodules (1)
- Volunteer donor (1)
- Von Hippel–Landau (1)
- WASH complex subunit 5 (1)
- WIPI2 (1)
- WIPI2b (1)
- Wastewater-based epidemiology (WBE) (1)
- Water contamination (1)
- Watertight Dural closure (1)
- Weight distribution (1)
- Western Blotting (1)
- Western blot (1)
- Western diet (1)
- White blood cells (1)
- White matter hyperintensity (1)
- Whole slide images (1)
- Wilson disease (WD) (1)
- Winter survival (1)
- Wnt (1)
- Working memory capacity (1)
- Wounds and injuries (1)
- X-ray computed (1)
- X-ray crystallography (1)
- XCL1/XCR1 axis (1)
- XIAP (1)
- Yeast-2-Hybrid (1)
- Yoga (1)
- Zebrafish (1)
- Zeckenübertragene Erkrankungen (1)
- Zentrifugalanalysator (1)
- Zika Virus (1)
- Zika fever (1)
- Zuckerkandl’s tubercle (1)
- Zymosan-induced peritonitis (1)
- [18F]FET PET (1)
- aGVHD (1)
- abdominal aortic aneurysm (1)
- ablation (1)
- abscisic acid (1)
- abscopal effect (1)
- acarboxyprothrombin (1)
- accident (1)
- acetabular fracture (1)
- acetaminophen (1)
- acne inversa (1)
- acoustic radiation force impulse (1)
- acquired LQT syndrome (1)
- action (1)
- activated clotting time measurement (1)
- activated factor XIII (1)
- acute decompensation (1)
- acute infections (1)
- acute lymphoblastic leukemia (1)
- acute pain (1)
- acute respiratory distress syndrome (1)
- acute stroke (1)
- acute stroke care (1)
- acute-on-chronic liver failure (1)
- additive manufacturing (1)
- adenosine (1)
- adiabatic saturation (1)
- adipocytes (1)
- adipose-derived mesenchymal stem/stromal cells (1)
- adjuvant chemotherapy (1)
- adolescence (1)
- adolescent (1)
- adolescents (1)
- adrenergic therapy (1)
- adult neurogenesis (1)
- advanced melanoma (1)
- adversity (1)
- aged (1)
- agent-based modeling (1)
- agent-based models (1)
- agility (1)
- agreeableness (1)
- air abrasive (1)
- albumin (1)
- alcohol (1)
- alcoholic fatty liver disease (1)
- alcoholic hepatitis (1)
- alcoholic liver disease (1)
- aligners (1)
- allogeneic donor (1)
- allogeneic hematological stem cell transplantation (1)
- allogeneic hematopoietic stem cell transplantation (1)
- allogeneic stem cell transplant (1)
- allostasis (1)
- alpha band (1)
- alpha receptor (1)
- alpha-fetoprotein (1)
- alpha-galactosidase A deficiency (1)
- alpha-synuclein (1)
- alpha7 nicotinic acetylcholine receptor (1)
- alphaSynuclein (1)
- alteplase (1)
- alternative matrices (1)
- alternative splicing (1)
- alveolar ridge augmentation (1)
- amide proton transfer (1)
- amino acids (1)
- amisulpride (1)
- amphiregulin (1)
- amygdalin (1)
- amyotrophic lateral sclerosis (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anaemia walk-in clinic (1)
- anaplastic large cell lymphoma (1)
- anesthesia (1)
- aneurysm (1)
- angioedema control test (1)
- angiography (1)
- angiokeratoma diffuse (1)
- animal models (1)
- anorectal malformation (1)
- anorexia nervosa (1)
- anti-CD3 antibody (1)
- anti-EGFR therapy (1)
- anti-HBc (1)
- anti-bacterial agents (1)
- anti-idiotypes (1)
- anti-inflammatory agent (1)
- anti-inflammatory drug (1)
- anti-neural autoantibodies (1)
- antiadhesive composites (1)
- antiangiogenic therapy (1)
- antiangiogenic therapy resistance (1)
- antibacterial composites (1)
- antibacterial therapy (1)
- antibiotic prophylactic therapy (1)
- antibiotic prophylaxis (1)
- antibiotics (1)
- anticipation (1)
- anticoagulant (1)
- anticoagulation (1)
- antiepileptic drug (1)
- antifungal agents (1)
- antifungal therapy (1)
- antigen detection (1)
- antihelix shaping (1)
- antimicrobial stewardship (1)
- antioxidant (1)
- antiviral agents (1)
- antiviral drugs (1)
- antiviral signaling (1)
- anxiety (1)
- anxiety disorders (1)
- aortic aneurysm (1)
- aortic root replacement (1)
- aortic valve repair (1)
- aortic valve stenosis (1)
- aortic valve-sparing (1)
- apex (1)
- aphrodisin (1)
- apical constriction (1)
- apical polarity (1)
- apolipoprotein B (1)
- aptamer (1)
- aptamer modeling (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- arachidonic acid (1)
- arachidonic acid (AA) (1)
- arbeitsbedingte Infektionen (1)
- arterial stiffness (1)
- articular cartilage (1)
- articular chondrocytes (1)
- artifacts (1)
- artificial feeding (1)
- artificial intelligence (AI) (1)
- aryl hydrocarbon receptor (1)
- asparaginyl endopepdidase (AEP) (1)
- aspiration (1)
- aspirin (1)
- assembly (1)
- assembly factor (1)
- asthma (1)
- asymptomatic temporal encephaloceles (1)
- at-risk mental state (1)
- ataxia (1)
- atezolizumab (1)
- atomic power (1)
- atopic dermatitis (1)
- atrial fibrillation (1)
- attachment (1)
- attachment loss (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- atypical EGFR mutations (1)
- auditory (1)
- auditory cortex (1)
- auditory fMRI (1)
- augmentation (1)
- autism (1)
- autoantibodies (1)
- autobiographical memories (1)
- autogenous tooth roots (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- automatic scene classification (1)
- autophagy inhibition (1)
- autophagy-dependent cell death (1)
- awake surgery (1)
- azacitidine (1)
- azoospermia (1)
- bacteremia (1)
- bacterial leakage (1)
- bacterial viability (1)
- bacteriophages (1)
- ball (1)
- ballet (1)
- bariatric surgery (1)
- basilar artery occlusion (BAO) (1)
- bats (1)
- behavior (1)
- behavioral inhibition (1)
- behavioural rhythms (1)
- benchmarking (1)
- benfooxythiamine (1)
- best medical treatment (1)
- beta-band activity (1)
- beta-blocker (1)
- beta-lactamases (1)
- beta2-adrenoceptor (1)
- bevacizumab (1)
- bibliometric analysis (1)
- bilateral (1)
- bile (1)
- bile acids (1)
- binocular vision (1)
- bio imaging (1)
- bioactive lipids (1)
- bioavailability (1)
- biochemical relapse free survival (1)
- bioequivalence (1)
- biofilm (1)
- bioimaging (1)
- bioinformatics (1)
- biologization (1)
- bioluminescence (1)
- biomolecular analysis (1)
- biorelevant dissolution (1)
- biotin deficiency (1)
- bipolar disorder (1)
- bladder neck stenosis (1)
- blinatumomab (1)
- blood borne infection (1)
- blood cell mutations (1)
- blood coagulation (1)
- blood coagulation factor XIII (1)
- blood concentrates (1)
- blood culture (1)
- blood donor screening (1)
- blood-brain barrier (1)
- bloodborne viruses (1)
- bloodstream infections (1)
- blutübertragbare Infektionskrankheiten (1)
- body plethysmography (1)
- body sway (1)
- body weight distribution (1)
- bone augmentation (1)
- bone barrow (1)
- bone marrow microenvironment (1)
- bone metastasis (1)
- bone tissue (1)
- bone tissue engineering (1)
- bone-regeneration (1)
- bowel dysfunction (1)
- bowel management (1)
- brachytherapy (1)
- brain (1)
- brain disorders (1)
- brain function (1)
- brain imaging (1)
- brain infection (1)
- brain networks (1)
- brain shift (1)
- brain signal complexity (1)
- brain tumor (1)
- breast tumor (1)
- bromodomain and extraterminal (BET) protein (1)
- bronchial epithelium (1)
- bulimia nervosa (1)
- buparlisib (1)
- burden of disease (1)
- burden of illness (1)
- burkholderia (1)
- burkholderia cepacia complex infections (1)
- bypass (1)
- c-MET (1)
- c-MYC (1)
- cAMP (1)
- cGMP (1)
- cabazitaxel (1)
- caesarean scar (1)
- caesarean section (1)
- callous-unemotional traits (1)
- calprotectin (1)
- calretinin (1)
- cancer cell metabolism (1)
- cancer immunotherapy (1)
- cancer information (1)
- cancer metastases (1)
- cancer surveillance (1)
- cancer therapy (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabinoid receptors (1)
- cannabis (1)
- carbapenem resistance (1)
- carbapenemases (1)
- cardiac autonomic regulation (1)
- cardiac differentiation (1)
- cardiac magnetic resonance (1)
- cardiac regeneration (1)
- cardiac remodeling (1)
- cardiac reprogramming (1)
- cardiocerebral resuscitation (1)
- cardiomyocyte apoptosis (1)
- cardiomyocyte proliferation (1)
- cardiomyocytes (1)
- cardiopulmonary resuscitation (1)
- cardiothoracic surgery (1)
- cardiovascular management (1)
- cardiovascular system (1)
- casein kinase 2 (1)
- caspase-1 (1)
- castration resistance (1)
- cataract surgery (1)
- cataract surgery workflow (1)
- catecholamine excess (1)
- cathepsin L inhibitor (1)
- cell barrier integrity (1)
- cell culture (1)
- cell death (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell lines (1)
- cell proliferation regulating inhibitor of protein phosphatase 2A (1)
- cellular heterogeneity (1)
- cellular inflammatory response (1)
- cellular therapies (1)
- cellular toxicity (1)
- central nervous system (1)
- central spasticity (1)
- ceramide synthase (1)
- cerebral imaging (1)
- cerebral ischemia (1)
- cerebral metastasis (1)
- cerebral palsy (1)
- cerebral pseudoprogression (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- cerebral vasospasm (CVS) (1)
- cerebrovascular disease (1)
- cerumen (1)
- cetuximab (1)
- channelrhodopsin (1)
- chaperone-mediated autophagy (1)
- chelator (1)
- chemokines (1)
- chemoprotection (1)
- chemorefractory metastatic colorectal cancer (1)
- chemoresistance (1)
- chemotaxis (1)
- chernobyl (1)
- childhood cancer (1)
- childhood epilepsy (1)
- children and adolescents (1)
- chimeric antigen receptor (CAR) (1)
- cholesterol (1)
- cholinergic system (1)
- chromaffin cell (1)
- chronic (1)
- chronic granulomatous disease (1)
- chronic hepatitis C (1)
- chronic hypoxia (1)
- chronic infections (1)
- chronic inflammation (1)
- chronic myeloid leukemia (1)
- circular RNA (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- clear cell renal cell carcinoma (1)
- clear cell sarcoma (1)
- clear lens exchange (1)
- climate change genomics (1)
- clindamycin (1)
- clinical decision support (1)
- clinical decision-making (1)
- clinical high at-risk mental state (1)
- clinical immunology (1)
- clinical node positive (1)
- clinical outcome (1)
- clinical research (1)
- clinical stage (1)
- clinical study (1)
- clinical teaching (1)
- clinically important restrictions and symptoms (1)
- clinically relevant dissolution specifications (1)
- clonal haematopoiesis (1)
- clonal transfer (1)
- cluster analysis (1)
- cluttering (1)
- coagulation (1)
- cochlear implant (1)
- cochlear implants (1)
- cognitive ability (1)
- cognitive aging (1)
- cognitive impairment (CI) (1)
- cognitive interventions (1)
- cold atmospheric plasma (1)
- collagen (1)
- collagen membranes (1)
- collective cell migration (1)
- colon (1)
- colony formation (1)
- colorectal cancer (CRC) (1)
- combination therapy (1)
- combined modality therapy (1)
- comorbidities (1)
- comorbidity (1)
- complementary/alternative medicine (CAM) (1)
- complete response (1)
- complex coronary interventions (1)
- complex systems (1)
- compound screen (1)
- computational knowledge-discovery (1)
- computational pathology (1)
- computer-assisted (1)
- concordance (1)
- conduct disorder (1)
- congenital diaphragmatic hernia (1)
- congenital disorders of autophagy (1)
- congenital duodenal obstruction (1)
- conical coupling (1)
- connective tissue (1)
- connective tissue growth factor (1)
- connectivity (1)
- conometric connection (1)
- consensus (1)
- consensus classification (1)
- consensus data set (1)
- consensus paper (1)
- conservative dentistry (1)
- contamination (1)
- continuity of care (1)
- contraception (1)
- control of menstrual bleeding (1)
- convulsive seizures (1)
- coping (1)
- copper free strain-promoted azide alkyne cycloaddition (SPAAC) (1)
- core expression (1)
- cornea donor (1)
- corona virus (1)
- coronally advanced flap (1)
- coronary imaging (1)
- corpus callosum (1)
- cortex (1)
- cortex-based alignment (1)
- cortical impact (1)
- corticospinal tracts (1)
- corticosteroid drugs (1)
- corticosteroids (1)
- cost analysis (1)
- cost containment (1)
- cost of illness (1)
- cost-effective (1)
- counseling (1)
- counselling (1)
- covalent drugs (1)
- criteria (1)
- critical size defect (1)
- critical-size defect (1)
- critically ill patients (1)
- cross reactivity (1)
- cross-frequency coupling (1)
- cross-linking (1)
- cryoelectron microscopy (1)
- cryopreservation (1)
- culpa asociada a trauma (1)
- cyclic nucleotide analogues (1)
- cyclic nucleotide binding proteins (1)
- cyclin Y (1)
- cycling (1)
- cyclooxygenase 2 (1)
- cyclooxygenase-2 (1)
- cyclopentenone prostaglandins (1)
- cystic fibrosis (1)
- cytochrome P450 (1)
- cytochrome P450 enzymes (1)
- cytochrome P450 reductase (1)
- cytochrome c oxidase (complex IV) (1)
- cytochrome c oxidase I (COI) (1)
- cytokine (1)
- cytokine storm (1)
- cytokine(s) (1)
- cytosolic free calcium (1)
- cytotoxic T lymphocyte (1)
- cytotoxic lymphocytes (1)
- cytotoxicity (1)
- dance teacher (1)
- data analysis (1)
- data management (1)
- data quality (1)
- data repositories (1)
- data sharing (1)
- de novo transcription (1)
- death rates (1)
- debris (1)
- decision tree (1)
- decompressive craniectomy (1)
- deep learning (1)
- deep vein thrombosis (1)
- default mode network (1)
- deferred treatment (1)
- degradation (1)
- delay (1)
- delayed cerebral ischemia (DCI) (1)
- delayed diagnosis (1)
- delayed treatment (1)
- delirium (1)
- delivery mode (1)
- delta (1)
- demineralized bone matrix (1)
- dendrite morphogenesis (1)
- dendritic cell (1)
- dendritic cells (1)
- dengue vector (1)
- dental academic degrees (1)
- dental assistant (1)
- dental education (1)
- dental educationcation (1)
- dental implants (1)
- dental school (1)
- dental treatment concept (1)
- dentist (1)
- dentist’s chair design (1)
- dentoalveolar surgery (1)
- deproteinized bovine bone matrix (DBBM) (1)
- depth perception (1)
- desensitization (1)
- detection task (1)
- deubiquitylation (deubiquitination) (1)
- diabetes complication (1)
- diagnostic imaging (1)
- diagnostic window (1)
- diagnostics (1)
- diagnostisches Fenster (1)
- diet (1)
- differential expression (1)
- diffuse marrow involvement (1)
- diffusion-weighted magnetic resonance imaging (1)
- digital decision-support (1)
- digital one-piece casting (1)
- digital pressing technology (1)
- digital workflow (1)
- dihydrocannabidiol (1)
- diphtheria toxin (1)
- direct-acting antiviral (DAA) treatment (1)
- discontinuation (1)
- disease outbreaks (1)
- disease progression (1)
- disease vectors (1)
- dislocation (1)
- disordered iron metabolism (1)
- distributed analysis (1)
- dobutamine stress (1)
- docetaxel (1)
- docetaxel (DX) resistance (1)
- doctoral degrees (1)
- donor safety (1)
- dopamine transporter (1)
- dorsal attention network (1)
- double immune checkpoint inhibition (1)
- double negative (1)
- double-pigtail stents (1)
- downgrading (1)
- doxorubicin (1)
- doxycycline (1)
- drinking (1)
- drospirenone (1)
- drug (1)
- drug abstinence (1)
- drug discovery (1)
- drug repurposing (1)
- drug–drug interactions (1)
- drug–gene interactions (1)
- drug–g–gene interactions (1)
- dual-energy (1)
- dynamic causal modeling (1)
- dynamic system (1)
- dysbetalipoproteinemia (1)
- dysfibrinogenemia (1)
- early detection (1)
- early onset (1)
- early-onset prostate cancer (1)
- eating disorders (1)
- echo planar imaging (1)
- economic burden (1)
- edentulous (1)
- education (1)
- efferocytosis (1)
- efficiency (1)
- efflux pump (1)
- egg sampling (1)
- egr-1 (1)
- eicosanoid (1)
- elastin (1)
- electrical coupling (1)
- electroanatomical mapping (1)
- electrode design (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- electrolytic cleaning (1)
- electron transfer (1)
- electron transfer chain (1)
- electronic adherence measurement (1)
- electronic diaries (1)
- electrophilic fatty acids (1)
- electrophoresis (1)
- element speciation (1)
- eligibility (1)
- elite athletes (1)
- emergency care (1)
- emicizumab (1)
- enamel matrix derivatives (1)
- encephalopathy (1)
- endodontic curriculum (1)
- endodontic education (1)
- endodontics (1)
- endoscopic retrograde cholangiography (1)
- endothelial dysfunction (1)
- endourology (1)
- endovascular recanalization (1)
- endovascular thrombectomy (1)
- ensemble cNN (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- environmental tobacco smoke (1)
- enzyme activity assay (1)
- epidemics (1)
- epidermal growth factor (1)
- epidural (1)
- epilepsy surgery (1)
- epileptic encephalopathy (1)
- episodic memory (1)
- epithelial-to-mesenchymal transition (EMT) (1)
- epoxyeicosatrienoic acid (1)
- erastin (1)
- erectile dysfunction (1)
- erythropoiesis (1)
- essential thrombocythemia (ET) (1)
- essential tremor (1)
- estrogen (1)
- ethanol (1)
- ethnicity (1)
- euthymic (1)
- everyday life (1)
- everyday tasks (1)
- evidence-based guideline (1)
- evolution (1)
- exclusion of very low profiles (1)
- executive functions (1)
- exosome (1)
- experimental pain models (1)
- expert witness statement (1)
- extracellular signal-regulated kinase (1)
- extraskeletal (1)
- eye movements (1)
- eye tracking (ET) (1)
- fMLP (1)
- factor V Leiden mutation (1)
- factor XIII (1)
- faecal microbiota transfer (1)
- familial amyloid nephropathy with urticaria and deafness (1)
- famotidine (1)
- fasting insulin (1)
- fat grafting (1)
- fat pad resection (1)
- fatigue (1)
- fatty acid (1)
- fatty acid synthesis (1)
- feasibility study (1)
- febrile neutropenia (1)
- fecal incontinence (1)
- fecal microbiota transfer (1)
- fecal occult blood test (1)
- federated feasibility queries (1)
- feedback control (1)
- female subjects (1)
- females (1)
- fenfluramine (1)
- ferric carboxymaltose (1)
- ferric derisomaltose (1)
- ferroportin (1)
- ferroptosis (1)
- ferumoxytol (1)
- fetal loss (1)
- fibrin-glue-spray technique (1)
- fibrinolysis (1)
- fibrosis imaging (1)
- first-time shoulder dislocation (1)
- fluorescence (1)
- fluorescence in situ hybridization (FISH) (1)
- focal cortical dysplasia (1)
- focal therapy (1)
- fondaparinux (1)
- fondaparinux sodium (1)
- foreign body reaction (1)
- formula diet (1)
- fractionation (1)
- fracture strength (1)
- fracture strength equation (1)
- fragile-X-associated tremor-ataxia syndrome (1)
- fragment screening (1)
- fragment-size analyses (ACE2; CQ11) (1)
- frequency of attacks (1)
- fronto-temporal lobar dementia (1)
- fronto-temporal-lobar-dementia (1)
- frontotemporal dementia (1)
- full-arch restoration (1)
- function (1)
- functional connectivity (1)
- functional connectome acute (1)
- functional magnetic resonance imaging (1)
- fungal infection (1)
- fungal sinusitis (1)
- fungal sugar (1)
- fusion (1)
- fusion kinase (1)
- fäkaler okkulter Stuhltest (1)
- gait symmetry (1)
- gangliosides (1)
- gargle lavage (1)
- gasotransmitters (1)
- gastrointestinal (1)
- gastrointestinal stromal tumours (1)
- gefitinib (1)
- gel (1)
- gender (1)
- gender differences (1)
- gene regulation (1)
- gene signature (1)
- general practitioners (1)
- genetic diversity (1)
- genetic variability (1)
- genetic variants (1)
- genetically caused iron imbalance (1)
- genome (1)
- genotype G (1)
- geriatric patients (1)
- geriatrics (1)
- gestational hypertension (1)
- gingival recession therapy (1)
- glioblastoma cells (1)
- glioblastoma survival (1)
- glioma microenvironment (1)
- glioma stem-like cells (1)
- global health (1)
- globosides (1)
- glomerulus (1)
- glucose and lipid metabolism (1)
- glucose-6-phosphate dehydrogenase (1)
- glucosylceramide (1)
- glucosylceramides (1)
- glutamate (1)
- glycobiology (1)
- glycoconjugate (1)
- glycoproteins (1)
- glycosyltransferase (1)
- gp100 (1)
- graft-vs-host disease (1)
- granule polarization (1)
- graph theory (1)
- graphic 3D models (1)
- gravity (1)
- great height (1)
- grisel syndrome (1)
- growth inhibition (1)
- guided tissue regeneration (1)
- guideline (1)
- haNK (1)
- habitat (1)
- haemophilia (1)
- haemophilia A (1)
- harmonization (1)
- hatching (1)
- head and neck neoplasms (1)
- head and neck squamous cell carcinoma (1)
- health behavior (1)
- health care (1)
- health data (1)
- health database (1)
- health education (1)
- health information interoperability (1)
- health services research (1)
- health-care personnel (1)
- health-related quality of life (1)
- health-relatedquality of life (1)
- healthcare personnel (1)
- healthcare system (1)
- healthcare workers (1)
- healthy control (1)
- hearing loss (1)
- heart neoplasms (1)
- heart rate (1)
- heart rate control (1)
- hematological (1)
- hematotoxicity (1)
- hemophilia (1)
- hemophilia a (1)
- hemorrhagic transformation (1)
- heparan sulfate proteoglycans (1)
- heparin sensitivity (1)
- hepatic stellate cells (1)
- hepatitis (1)
- hepatitis B (1)
- hepatitis B surface antigen (1)
- hepatitis B virus (1)
- hepatitis C virus (HCV) (1)
- hepatitis D (1)
- hepatocellular cancer (1)
- hepatotoxicity (1)
- herb-induced liver injury (HILI) (1)
- hereditary angioedema (1)
- hereditary dystopic lipidosis (1)
- herpes simplex virus type 1 (1)
- herpes simplex virus type 2 (1)
- herpes zoster (1)
- heterogeneity (1)
- hidradenitis suppurativa (1)
- hierarchical clustering (1)
- high risk (1)
- high sensitive C-reactive protein (1)
- high throughput screening (1)
- high-altitude adaptation (1)
- high-altitude pulmonary hypertension (1)
- high-content screen (1)
- high-fat-diet (1)
- high-risk (1)
- high-risk neuroblastoma (1)
- high-throughput screening (1)
- hip osteoarthritis (hip OA) (1)
- hippocampal sclerosis (1)
- histamine (1)
- histological outcomes (1)
- histone deacetylase (1)
- histopathological growth pattern (1)
- holistic treatment (1)
- home training (1)
- homeodomain protein (1)
- homeostasis (1)
- hospital admission (1)
- hospital length of stay (1)
- host matrix- pathogen interaction (1)
- host-microbe interaction (1)
- human MSCs (1)
- human allogeneic hematopoietic cell transplantation (1)
- human behaviour (1)
- human factors (1)
- human genomics (1)
- human immunodeficiency virus (1)
- human intestinal microbiota (1)
- human monoclonal antibody (1)
- human olfaction (1)
- human research (1)
- human rhabdomyosarcoma (1)
- human subjects (1)
- human-liver chimeric mouse model (1)
- humans (1)
- hybrid abutment (1)
- hybrid materials (1)
- hybrid production (1)
- hybridization (1)
- hybrids (1)
- hydrogen peroxide (1)
- hydrogen sulfide (H2S) (1)
- hydroxylation (1)
- hyperactivity (1)
- hyperalgesia (1)
- hypercholesterolemia (1)
- hypersensitivity (1)
- hypertriglyceridemia (1)
- hypertrophy (1)
- hypnotics and sedatives (1)
- hypobaric hypoxia (1)
- hypophosphatemia (1)
- hypoxia inducible factor 1 alpha (1)
- hypoxia-inducible factor-2α (1)
- iCBT (1)
- idiopathic pulmonary fibrosis (1)
- idiosyncratic drug-induced liver injury (DILI) (1)
- image-guided tissue acquisition (1)
- imaging (1)
- imaging genetics (1)
- imaging protocol (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune checkpoint inhibitors (ICI) (1)
- immune defense (1)
- immune escape (1)
- immune host defense (1)
- immune infiltration (1)
- immune monitoring (1)
- immune related adverse events (irAE) (1)
- immune therapy (1)
- immuno-oncotherapy (1)
- immunological risk (1)
- immunosenescence (1)
- immunosuppression (1)
- impulsivity (1)
- in silico (1)
- in situ (1)
- in vitro models (1)
- in vivo (1)
- in vivo dosimetry (1)
- inborn errors of immunity (1)
- incidence (1)
- incontinence (1)
- individual differences (1)
- indoor air (1)
- induction chemotherapy (1)
- induction regimen (1)
- induction therapy (1)
- inertial motion capture (1)
- inertial motion units (1)
- inertial sensors (1)
- infection control (1)
- infection precaution (1)
- infectious disease (1)
- infectivity (1)
- inferior frontal gyrus (1)
- inflammasome (1)
- inflammatory reaction (1)
- informal care (1)
- infrapatellar fat pad (1)
- inguinal hernia (1)
- inherited (1)
- inhibitor (1)
- inhibitors (1)
- inhibitory control (1)
- inhibitory interneurons (1)
- injury (1)
- injury pattern (1)
- injury prevention (1)
- inner membrane morphology (1)
- inosine (1)
- inositol signaling (1)
- instructional film and video (1)
- insula (1)
- insulin resistance (1)
- insulin sensitivity (1)
- insurance data (1)
- integrate-and-fire (1)
- integrated stress response (1)
- integrative neuromotor training (1)
- integrin (1)
- intellectual disability (1)
- intelligence (1)
- intensive care admission and mortality (1)
- inter-individual variability (1)
- interactions (1)
- interferon induction (1)
- interferon sensitivity (1)
- interferon type III (1)
- interim positron emissiontomography (1)
- interleukin-1beta (1)
- interleukin-22 (1)
- international transport (1)
- internet (1)
- interstitial multicatheter brachytherapy (1)
- intervenciones cognitivas (1)
- intestinal iron loss (1)
- intestinal manipulation (1)
- intracellular (1)
- intracellular multiplication (1)
- intracerebral hemorrhage (ICH) (1)
- intracranial hemorrhage (1)
- intrahepatic cholangiocarcinoma (1)
- intranasal administration (1)
- intraoperatively molded (1)
- intraoral scanning (1)
- intrauterine Wachstumsretardierung (1)
- intrauterine growth restriction (1)
- intravenous iron (1)
- intravenous iron therapy (1)
- intrinsic and innate immune response (1)
- invasive fungal disease (1)
- invasive fungal infection (1)
- inverse spacer (1)
- inverse stage migration (1)
- investigational (1)
- inflammation (1)
- iron deficiency anemia (1)
- iron isomaltoside (1)
- iron-trafficking (1)
- irritable bowel syndrome (1)
- jejunoileal atresia (1)
- joint contact forces (1)
- joint innervation (1)
- joint load (1)
- juvenile myelomonocytic leukemia (1)
- kaffir lime (1)
- keratinized mucosa (1)
- kidney function (1)
- kidney transplantation (1)
- knee adduction moment (1)
- knee osteoarthritis (1)
- laboratory testing (1)
- laboratory worker (1)
- lacto/neo-lacto series GSLs (1)
- landrace pigs (1)
- language impairment (1)
- laparoscopic inguinal hernia repair (1)
- laser-induced thermotherapy (1)
- lasso regression (1)
- latent factor mixed model (1)
- layer-specificity (1)
- learning and memory (1)
- left atrial appendage occlusion (1)
- legislation (1)
- legumain (1)
- leisure-time activity (1)
- lenalidomide (1)
- length of stay (1)
- leptin receptor-deficient mouse (1)
- leucocytes (1)
- leukaemia (1)
- leukemia (1)
- leukocytes (1)
- leukodystrophy (1)
- leukotriene (1)
- lichen extracts (1)
- life table (1)
- life-expectancy (1)
- lifestyle (1)
- light irradiation (1)
- limitations (1)
- lipid droplets (1)
- lipidomics (1)
- lipofilling (1)
- lipofuscin (1)
- lipoproteins (1)
- lipoxin (1)
- lipoxin A4 (1)
- lipoxygenase inhibitor (1)
- liquid chromatography–mass spectrometry (1)
- live-cell imaging (1)
- live/dead staining (1)
- liver X receptor (1)
- liver damage (1)
- liver metastasis (1)
- liver steatosis (1)
- liver stiffness (1)
- liver volume (1)
- local antibiotics (1)
- local drug delivery (1)
- local preemptive analgesia (1)
- local recurrence (1)
- local treatment (1)
- location (1)
- locator (1)
- locusts (1)
- logistic models (1)
- long non-coding RNAs (1)
- long term (1)
- long-term outcome (1)
- long-term potentiation (1)
- long-term prophylaxis (1)
- long-term results (1)
- loss of B-cell phenotype (1)
- loss-of-function (1)
- loving-kindness meditation (1)
- low density lipoprotein receptor (1)
- low risk (1)
- low-back-pain (1)
- low-carbohydrate (1)
- low-dose irradiation (1)
- lower leg fracture (1)
- lppr5 (1)
- lung development (1)
- lung fibrosis (1)
- lung function (1)
- lung tumor heterogeneity (1)
- lungs (1)
- lymph node (1)
- lymph node metastases (1)
- lymphocytes (1)
- lysophospholipids (1)
- lysosomal-dependent cell death (1)
- lysosome (1)
- mCRPC (1)
- mRNA stability (1)
- mRNA1273 (1)
- mTOR inhibitor (1)
- mTORC1 (1)
- macaque (1)
- machine learning (ML) (1)
- magnetoencephalography (1)
- male (1)
- malignancies (1)
- malignancy (1)
- malignant melanoma (1)
- mammary carcinoma (1)
- manganese (1)
- mappers (1)
- mapping-algorithms (1)
- marginal fit (1)
- marked lymph node (1)
- marker (1)
- mass spectrometry (1)
- maternity protection law (1)
- mathematical analysis (1)
- mathematical modeling (1)
- matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (1)
- mechanical accuracy (1)
- mechanical recanalization (1)
- mechanical ventilation (1)
- mechanotransduction (1)
- medical device (1)
- medical informatics (1)
- medical risk factors (1)
- medication adherence rate (1)
- medication management (1)
- medication review (1)
- meditación de bondad amorosa (1)
- medizinische Beschäftigte (1)
- medizinisches Personal (1)
- medulloblastoma (1)
- membrane protein complex (1)
- membrane remodeling (1)
- membrane-less organelles (1)
- membranous urethra (1)
- membranous urethral stricture (1)
- meningioma (1)
- mental distress (1)
- mental health (1)
- mesangial cells (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal cells (1)
- mesial temporal lobe epilepsy (1)
- meta-analysis (1)
- metabolic alterations (1)
- metabolic liver disease (1)
- metabolic rewiring (1)
- metastases (1)
- metastatic renal cell carcinoma (1)
- methacarn (1)
- miR (1)
- miR-142-3p (1)
- miR-181 (1)
- miR-21 (1)
- miR-6862-5p (1)
- michael acceptor (1)
- microbial colonization (1)
- microbiology (1)
- microbiome (1)
- microcentrifugal analyzer (1)
- microdissection (1)
- microlaparoscopy (1)
- microsomal ethanol oxidizing system (1)
- microstates (1)
- microstimulation (1)
- microsurgery (1)
- microvesicles (1)
- microwave ablation (1)
- mid-IR spectroscopy (1)
- mid-term urinary continence (1)
- middle-aged (1)
- migration (1)
- mild cognitive impairment (1)
- mineralization (1)
- minimal invasive (1)
- minimal residual disease (1)
- minimally invasive surgery (1)
- minimally invasive therapy (1)
- minocycline (1)
- miscarriage (1)
- mitochondrial antiviral signaling protein (MAVS) (1)
- mitochondrial disease (1)
- mitochondrial metabolism (1)
- mitochondrial morphology (1)
- mitochondrial respiration (1)
- mitral regurgitation (1)
- mitral valve surgery (1)
- mixed infection (1)
- mixed lineage kinase domain-like (1)
- model builder software (1)
- modeling (1)
- modelling (1)
- models (1)
- mold (1)
- molecular adaptation (1)
- molecular biology (1)
- molecular diagnostic techniques (1)
- molecular dynamics (1)
- molecular marker (1)
- molecular modeling (1)
- molecular neuroscience (1)
- molecular subtyping (1)
- molecular surveillance (1)
- molecular typing (1)
- monkeypox (1)
- monoacylglycerol lipase (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- monotherapy (1)
- monotype abutment (1)
- monsoon (1)
- mood (1)
- morbidity (1)
- morphometry (1)
- mortality analysis (1)
- mortality risk (1)
- motor functions (1)
- motor-control-exercise (1)
- mouse (1)
- mouse models (1)
- mouse tumor model (1)
- mouthwash (1)
- mouthwash solution (1)
- mtLSU quality control (1)
- mucormycetes (1)
- mucormycosis (1)
- multi-material 3D printing (1)
- multi-scale models (1)
- multicenter study (1)
- multidisciplinary-therapy (1)
- multidrug resistance (1)
- multidrug resistance protein 4 (1)
- multiparametric magnetic resonance imaging (1)
- multiplex immunohistochemistry (1)
- multiplexed immunofluorescence (1)
- multisensory integration (1)
- multislice imaging (1)
- multispectral flow cytometry (1)
- multivoxel pattern analysis (1)
- musculoskeletal inflammation (1)
- musculoskeletal modeling (1)
- musculoskeletal repair (1)
- musculoskeletal system (1)
- mutation (1)
- mutism (1)
- myeloproliferative neoplasms (MPN) (1)
- myocardial efficiency (1)
- myocardial fibrosis (1)
- myocardial ischaemia (1)
- myocardial power (1)
- nNOS (1)
- nasal swab (1)
- natural killer (1)
- natural selection (1)
- natural sounds (1)
- necroptosis (1)
- needlestick injury (1)
- neoadjuvant chemoradiotherapy (1)
- neoadjuvant chemotherapy (1)
- neoadjuvant immunochemotherapy (1)
- neoadjuvant therapy (1)
- neonate (1)
- neoplasm metastasis (1)
- neovascularization (1)
- nephropathy (1)
- nerve-sparing surgery (1)
- neural correlates (1)
- neuregulin 1 (1)
- neurexin (1)
- neuroblast (1)
- neuroblastoma (1)
- neurocognition (1)
- neurocognitive outcome (1)
- neurocritical care (1)
- neurodegenerative diseases (1)
- neurodevelopment (1)
- neurodevelopmental disorde (1)
- neuroendocrine (1)
- neuroendocrine tumor (1)
- neuroethology (1)
- neurogenic bowel (1)
- neuroimaging (1)
- neurological complication (1)
- neurological manifestations (1)
- neurological side effects (1)
- neurology (1)
- neuronal silencing (1)
- neurooncology (1)
- neuropathy (1)
- neuropeptide (1)
- neuropeptides (1)
- neuroprotection (1)
- neurotransmitter (1)
- neurysmal subarachnoid hemorrhage (aSAH) (1)
- neutralizing antibody (1)
- neutropenia (1)
- neutrophil elastase (1)
- newly diagnosed glioblastoma (1)
- niedermolekulares Heparin (1)
- nitroalkene (1)
- nitroalkylation (1)
- nitroglycerin (1)
- nociceptors (1)
- nodular lymphocyte-predominant Hodgkin lymphoma (1)
- noise (1)
- nomogram (1)
- non-alcoholic fatty liver disease (1)
- non-aneurysmal (1)
- non-aneurysmal SAH (1)
- non-coding RNA (1)
- non-contact injuries (1)
- non-neutropenic episode (1)
- non-organ confined stage (1)
- non-perimesencephalic (1)
- non-small cell lung cancer (1)
- non-small-cell lung cancer (1)
- non-surgical periodontal therapy (1)
- noninvasive blood glucose analysis (1)
- nonsense-mediated mRNA decay (1)
- nontraumatic atlantoaxial rotatory subluxation (1)
- noradrenaline (1)
- norepinephrine (1)
- normal liver cells (1)
- novel technologies (1)
- nuclear cardiology (1)
- nuclear factor 2 (erythroid-derived 2-like factor) (NFE2L2) (Nrf2) (1)
- nuclear magnetic resonance (NMR) (1)
- nuclear power plant (1)
- nuclear receptor (1)
- nuclear receptor-related 1 (1)
- nucleic acid amplification test(NAT) (1)
- nucleic acid amplification test (1)
- nucleic acid docking (1)
- nucleic acid lateral flow immunoassay (1)
- nucleolus (1)
- nucleoredoxin (1)
- nutrient endocytosis (1)
- nutrition - clinical (1)
- nymphs (1)
- observational study (1)
- obstetric complications (1)
- obstetric pain (1)
- obstetrics (1)
- occupational immediate-type reactions (1)
- occupationally acquired viral infections (1)
- oedema (1)
- olfactory testing (1)
- olive mill wastewater (OMWW) (1)
- oluble epoxide hydrolase (1)
- oncogenesis (1)
- oncogenic RAS (1)
- oncogenic signaling (1)
- oncological exercise therapy (1)
- oncomodulation (1)
- online intervention (1)
- online research (1)
- online survey (1)
- open (1)
- open field behavior (1)
- open science (1)
- open skill exercise (1)
- operating microscope (1)
- optogenetics (1)
- oral and maxillofacial surgery (1)
- oral cavity cancer (1)
- oral drug products (1)
- oral health (1)
- oral health burden (1)
- oral progestins (1)
- orale Gestagene (1)
- ordinary differential equation (1)
- ordinary differential equations (ODE) (1)
- organ preservation (1)
- organic nitrates (1)
- organotypic culture (1)
- orthopaedic patients (1)
- orthopoxvirus (1)
- osteoblast (1)
- osteoclasts (1)
- osteogenic differentiation (1)
- other cause mortality (1)
- otoplasty (1)
- outbreak (1)
- outpatient care (1)
- outpatients (1)
- outside-in signaling (1)
- ovarian cancer (1)
- overdenture (1)
- overtreatment (1)
- overweight (1)
- oviposition (1)
- oviposition substrate (1)
- ovitrap (1)
- oxaliplatin (1)
- oxidized low density lipoprotein (1)
- oxythiamine (1)
- p-eIF2α (1)
- p16 (1)
- p21Cip1/CDKN1A (1)
- p38 MAPK (1)
- p53 pathway (1)
- pH (1)
- pH-dependent solubility (1)
- pIOL (1)
- pad-test (1)
- pain intensity (1)
- pain management (1)
- paired samples (1)
- palliative care (1)
- palliative care services (1)
- pancreatic ductal adenocarcinoma (1)
- pannexin-1 (1)
- paper-based detection (1)
- parabolic flight (1)
- paracrine signaling (1)
- parent rating (1)
- partial differential equation (1)
- passive smoke (1)
- pathogen (1)
- pathogenicity (1)
- pathology (1)
- patient centered care (1)
- patient data (1)
- patient preferences (1)
- patient safety (1)
- patient-centred care (1)
- patient-reported outcomes (1)
- patient–doctor relationship (1)
- patient’s decree (1)
- pediatric intensive care (1)
- pediatric robotic surgery (1)
- pediatric solid tumors (1)
- pelvic trauma (1)
- pembrolizumab (1)
- pentaerythritol tetranitrate (1)
- peptide receptor radionuclide therapy (1)
- perceptual closure (1)
- percutaneous thermal ablation (1)
- perforant path transection (1)
- peri-implant disease (1)
- peri-implantitis treatment (1)
- pericytes (1)
- periimplantitis (1)
- perimesencephalic (1)
- periodontal diseases (1)
- periodontal risk factors (1)
- periodontal treatment (1)
- periodontal– systemic disease interactions (1)
- peripheral blood stem cell collection (1)
- peripheral injury (1)
- peritoneal macrophages (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- peroxisome proliferator-activated receptor (1)
- persistent periodontal pockets (1)
- personalized (1)
- phagocytes (1)
- phantom study (1)
- pharmaco-fMRI (1)
- pharmacodynamics (1)
- pharmacoepigenetics (1)
- pharmacogenetics (1)
- pharmacological data science (1)
- pharmacological plasticity (1)
- pharmacophore model (1)
- phase I (1)
- phase IV (1)
- phase separation (1)
- phenoconversion (1)
- phenotypic screening; (1)
- pheromone (1)
- phosphatidylethanolamines (1)
- phospholipid (1)
- phosphoproteomics (1)
- photodynamic therapy (1)
- photothermal detection (1)
- physical performance (1)
- physiotherapy (1)
- phytosterols (1)
- pimozide (1)
- pitch (1)
- placenta (1)
- planimetric measurement (1)
- plasma (1)
- plasma C-peptide (1)
- plasma jet (1)
- plasmid (1)
- platelet hyperactivity (1)
- platelet substitution (1)
- platelet-rich-fibrin (1)
- platinum-based chemotherapy (1)
- plppr5 (1)
- pneumocystis (1)
- point of care (1)
- point-of-care diagnostics (1)
- pole concept of goiter growth (1)
- polo-like kinases (1)
- poly(A)-tail (1)
- poly-LacNAc (1)
- polyQ (1)
- polycythemia vera (PV) (1)
- polymer infiltrated ceramic network (1)
- polymeric micelle (1)
- polypept(o)ide (1)
- polyunsaturated fatty acid (1)
- portal pressure (1)
- portal vein (1)
- positron-emissions-tomography (1)
- post-caesarean uterus (1)
- post-exercise hypotension (1)
- post-radiotherapy recurrence (1)
- post-transcriptional regulation (1)
- posterior circulation (1)
- posterior fossa tumor (1)
- posterior horn (1)
- posteroinferior horn (1)
- postgraduate edu (1)
- postinfectious bronchiolitis obliterans (1)
- postmonsoon (1)
- postmortem blood samples (1)
- postnatal care (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- posttranslational modification (PTM) (1)
- potassium channel (1)
- poxvirus (1)
- pre-professional (1)
- precision medicine (1)
- precision weighting (1)
- preclinical (1)
- prediabetes and type 2 diabetes (1)
- predictive biomarker (1)
- prefrontal cortex (1)
- prehabilitation (1)
- prenatal diagnostic (1)
- prepontine (1)
- preventive health services (1)
- preventive strategies (1)
- primary biliary cholangitis (1)
- primary health care (1)
- primary immunodeficiency (1)
- primary myelofibrosis (PMF) (1)
- primary ovarian insufficiency (1)
- print and press (1)
- prion-like (1)
- private brands (1)
- product performance (1)
- production (1)
- professional dance (1)
- professional soccer players (1)
- progestin mono-preparation (1)
- prognostic marker (1)
- prognostic scores (1)
- progranulin (1)
- promyelocytic leukemia nuclear bodies (1)
- prone position (1)
- propensity score matching (1)
- prostaglandin (1)
- prostate cancer (PCa) (1)
- prostate neoplasia (1)
- prostate neoplasm (1)
- prostatectomy (1)
- protease inhibitor (1)
- proteasomal processing escape (1)
- protein aggregation (1)
- protein complexes (1)
- protein evolution (1)
- protein folding (1)
- protein phosphorylation (1)
- protein–protein interaction (1)
- proteoglycan (1)
- proteostasis (1)
- prothrombin induced by vitamin K absence-II (1)
- prothrombin mutation (1)
- proton pumping (1)
- proton-sensing GPCR (1)
- protruding ear (1)
- pseudomonas aeruginosa (1)
- psoriatic arthritis (1)
- psychiatric comorbidity (1)
- psychiatric disorder (1)
- psychiatric disorders (1)
- psychogenic non-epileptic seizures (1)
- psychosocial factors (1)
- publication output (1)
- pulmonary failure (1)
- pulmonary fibrosis (1)
- pulmonary ventilation (1)
- pulse wave velocity (1)
- pulsed SILAC (1)
- pulsed-field (1)
- purification (1)
- qRT-PCR (1)
- quantitative RUCAM (1)
- quantitative magnetic resonance imaging (1)
- quantum cascade laser (QCL) (1)
- query (1)
- quiescence (1)
- rRNA chaperone ERAL1 (1)
- race (1)
- race/ethnicity disparities (1)
- radiation dosage (1)
- radiation dosimetry (1)
- radiation protection (1)
- radiation-induced (1)
- radio sensitivity (1)
- radioimmunotherapy (1)
- radiomics (1)
- radiosensitization (1)
- randomized (1)
- randomized controlled trial (1)
- range expansion (1)
- rapid gastric emptying (1)
- rare disease (1)
- rare mendelian disorders (1)
- rat calvaria defect (1)
- rat femur critical size defect (1)
- rat model (1)
- rats (1)
- re-exposure (1)
- re-irradiation (1)
- reactive coordination (1)
- real world (1)
- real-world (1)
- realist synthesis (1)
- recall (1)
- rechallenge (1)
- recombinase polymerase amplification (1)
- recovery (1)
- recurrence pattern (1)
- recurrent cholangitis (1)
- recurrent urinary tract infections (1)
- red cells (1)
- redox status (1)
- reduced kidney function (1)
- reduction potential (1)
- refractive lens exchange (1)
- refractive surgery (1)
- regenerative therapy (1)
- regulatory T cell (1)
- regulatory T helper cells (1)
- reintroduction (1)
- relapsing–remitting multiple sclerosis (1)
- relaxometry (1)
- remodeling (1)
- renal dysfunction (1)
- renal failure (1)
- renal fibroblasts (1)
- renal inflammation (1)
- renal transplantation (1)
- renal tubular epithelial cells (1)
- replicative fitness (1)
- reproducibility (1)
- research database (1)
- research funding (1)
- research incentives (1)
- resectability (1)
- resin nano ceramics (1)
- resistance (1)
- resistant epilepsy (1)
- resolution (1)
- resolution of inflammation (1)
- resolvin (1)
- respiratory failure (1)
- respiratory infections (1)
- response (1)
- response inhibition (1)
- rest period (1)
- resting-state fMRI (1)
- resveratrol (1)
- reticulocyte haemoglobin (1)
- reticulocyte hemoglobin equivalent (1)
- retrospective studies (1)
- retrovirus (1)
- reverberation (1)
- revision knee arthroplasty (1)
- reward (1)
- reward probabilities (1)
- rhabdomyosarcoma (1)
- rhinovirus (1)
- ribonucleotide reductase (1)
- rifampicin (1)
- rifampin (1)
- risk assessment (1)
- risk factor (1)
- risk of malignancy (1)
- risk stratification (1)
- rituximab (1)
- robot-guided stereotaxy (1)
- robotic-assisted (1)
- robotically assisted surgery (1)
- robotics (1)
- room simulation (1)
- rotary ATPase mechanism (1)
- rotational thromboelastometry (1)
- sEH (1)
- sRNA (1)
- sRNA tool (1)
- safety attitudes questionnaire (1)
- salience network (1)
- saliva (1)
- salvage mastectomy (1)
- sampling (1)
- sarcoma (1)
- scanner noise (1)
- scar (1)
- schwangerschaftsinduzierter Hypertonus (1)
- screening (1)
- screening ELISA (1)
- screening questionnaire (1)
- searchlight analysis (1)
- seasonal adaption (1)
- second line therapy (1)
- second-line immunotherapy (1)
- second-line treatment / 2L treatment (1)
- secondary data analysis (1)
- secondary progressive multiple sclerosis (1)
- secreted Ly-6/uPAR-related protein 1 (1)
- secretory phospholipase A (1)
- seed and soil (1)
- seizures (1)
- selection (1)
- self-collected samples (1)
- semiquinone (1)
- sensorineural hearing loss (1)
- sensory loss (1)
- sensory organ development (1)
- serologic screening (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- severely injured (1)
- severely injured patient (1)
- sex (1)
- sex differences (1)
- sexual arousal (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- shape (1)
- shared decision-making (1)
- shear stress (1)
- shikonin (SHI) (1)
- short bowel (1)
- short linear motif (1)
- short-course antibiotic therapy (1)
- short-term (1)
- shoulder instability (1)
- shoulder stabilization (1)
- siRNA analysis (1)
- siRNA lipid nanoparticles (LNPs) (1)
- siRNA quantification (1)
- sialic acid (1)
- signal transduction (1)
- signaling (1)
- simulation (1)
- single-cell RNA sequencing (1)
- single-cell proteomics (1)
- skin diseases (1)
- sleep (1)
- sleep deprivation (1)
- sleep disordered breathing (1)
- sleep quality (1)
- small bowel (1)
- small leucine-rich proteoglycans (1)
- small ubiquitin-related modifier (1)
- smoking behavior (1)
- smooth muscle cell (1)
- social anxiety (1)
- social communication (1)
- social recognition (1)
- socio-economic influences (1)
- socioeconomic factors (1)
- soft tissue sarcoma (1)
- software (1)
- solid tumor (1)
- sonoSens (1)
- sonography (1)
- sorafenib (1)
- sound localization (1)
- sound-induced flash illusion (1)
- spared nerve injury (1)
- sparse imaging (1)
- spatial learning (1)
- spatial specificity (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- speech and language pathologist (1)
- sphingosine (1)
- sphingosine 1-phosphate homologues (1)
- sphingosine 1-phosphate receptor (1)
- sphingosine kinase (1)
- spike mutation (1)
- spike protein (1)
- spina bifida (1)
- spinal bone metastasis (1)
- spinal infection (1)
- spinal metastasis (1)
- spine injury (1)
- spinocerebellar ataxia (1)
- splicing (1)
- split-mouth (1)
- sport (1)
- spreading (1)
- sprouting (1)
- sprouting angiogenesis (1)
- squamous cell carcinoma (1)
- stage (1)
- stage migration (1)
- stairs (1)
- stakeholder analysis (1)
- standard value (1)
- starvation (1)
- statin (1)
- statin treatment (1)
- statins (1)
- statistics (1)
- steady-state condition (1)
- steatosis (1)
- stem cell transplantation (1)
- stem cells (1)
- stent patency (1)
- stereotactic frame (1)
- stereotactic neurosurgery (1)
- stoma (1)
- stomach neoplasms (1)
- store brands (1)
- stress period (1)
- structure constraints (1)
- structure-function (1)
- strumpellin (1)
- study protocol (1)
- stuttering (1)
- subarachnoid hemorrhage (1)
- subdural hematoma (1)
- subgrouping (1)
- subpopulation (1)
- sudden cardiac death (1)
- sulfatides (1)
- sulfur-oxidizing symbiont (1)
- sunitinib (1)
- superficial vein (1)
- superparamagnetic iron oxide nanoparticles (1)
- support (1)
- suprachiasmatic nucleus (1)
- surface antigen mutant (1)
- surgical complications (1)
- surgical procedures (1)
- surrogate ELISA (1)
- swallowing (1)
- swarming (1)
- symbiosis (1)
- sympathetic (1)
- sympathetic nervous system (1)
- symptoms (1)
- synaesthesia (1)
- synoviocytes (1)
- synovitis (1)
- synovium (1)
- tDCS (1)
- tVNS (1)
- tachycardia (1)
- taller-than-wide (1)
- target (1)
- targeted axillary dissection (1)
- targeted sequencing (1)
- taste buds (1)
- tauopathies (1)
- tauopathy (1)
- temporal encephaloceles (1)
- testosterone (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- tetrahydrocannabinol (1)
- theory of mind (1)
- therapeutic anticoagulation (1)
- therapy response (1)
- thermal ablation (1)
- theta band (1)
- thrombectomy (1)
- thrombin (1)
- thromboembolism (1)
- thrombophilia (1)
- thrombospondins (1)
- thromboxane (1)
- thymic selection (1)
- tibial fracture (1)
- tight junctions (1)
- tip cell filopodia formation (1)
- tissue microstructure (1)
- tissue reconstruction (1)
- tissue segmentation (1)
- tivantinib (1)
- toddler’s fracture (1)
- tolerability (1)
- tolerance (1)
- tooth transplantation (1)
- topical administration (1)
- topographical pattern (1)
- toric intraocular lens (1)
- torticollis (1)
- total knee replacement (1)
- toxic milk mice (TX mice) (1)
- toxicity (1)
- tracking (1)
- traditional Chinese medicine (TCM) (1)
- trafficking (1)
- training (1)
- trans (1)
- transcription (1)
- transcription factors (1)
- transcriptional cyclin-dependent kinase (1)
- transcriptome (1)
- transcriptomics (1)
- transduction (1)
- transfer entropy (1)
- transferrin (1)
- transforming growth factor-β (1)
- transglutaminase (1)
- transient elastography (1)
- transjugular intrahepatic portosystemic shunt (1)
- translation (1)
- translational investigation (1)
- translational study (1)
- translatome (1)
- translatomics (1)
- transmission (1)
- transovarial transmission (1)
- transplant-free survival (1)
- transplantation (1)
- transstadial transmission (1)
- trauma registry (1)
- trauma-related guilt (1)
- trauma-related shame (1)
- traumatic injury (1)
- traumaticbraininjury(TBI) (1)
- treatment outcome (1)
- treatment resistance (1)
- treatment response (1)
- trials registry (1)
- triglycerides (1)
- trimeric autotransporters adhesin (1)
- triplex (1)
- trophoblast organoids (1)
- trophoblasts (1)
- trough levels (1)
- tumor (1)
- tumor growth (1)
- tumor immunity (1)
- tumor immunology (1)
- tumor spheroids (1)
- tumor stroma (1)
- tumor therapy (1)
- tumor-associated macrophages (TAM) (1)
- tunnel technique (1)
- type 1 diabetes (1)
- type 2 diabetes (1)
- tyrosine hydroxylase (1)
- tyrosine kinase inhibitor (TKI) (1)
- tyrosine kinase receptor signaling (1)
- ubiquitin hydrolase (1)
- ubiquitin ligase (1)
- ultra-high risk for psychosis (1)
- ultrasonic cleaning (1)
- ultrasound (1)
- unacceptable antigen mismatches (1)
- unconventional T cell (1)
- undifferentiated pleomorphic sarcoma (1)
- unilateral (1)
- unilateral hip osteoarthritis (1)
- unmethylated MGMT (1)
- upstaging (1)
- urethal stricture (1)
- urethral stricture (1)
- urethroplasty (1)
- urothelial carcinoma (1)
- ursodeoxycholic acid (1)
- uterine wall (1)
- uveal melanoma (1)
- v-ATPase (1)
- vaccination rates (1)
- vaccine uptake rate (1)
- vaccine uptake rates (1)
- vaccine, (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- vaginal breech (1)
- vaginal hysterectomy (1)
- variable silent delay (1)
- variant of concern (1)
- variants of concern (1)
- vascular disease (1)
- vascular integrity (1)
- vasodilation (1)
- vector (1)
- vemurafenib (1)
- venous thromboembolic events (1)
- venous thrombosis (1)
- ventral otoplasty (1)
- ventral striatum (1)
- ventral tegmental area (1)
- ventralis intermedius nucleus (1)
- ventricular tachycardia (1)
- vergence (1)
- vergüenza asociada a trauma (1)
- vertical transmission (1)
- vertigo (1)
- very high-risk (1)
- very low density lipoproteins (1)
- vestibular function (1)
- viral fitness (1)
- viral load (1)
- viral replication (1)
- virologic failure (1)
- virus (1)
- virus isolation (1)
- visual cortex (1)
- visual search (VS) (1)
- vitamin k antagonists (1)
- vocational (1)
- volumetric measurement technology (1)
- von Willebrand disease (1)
- von Willebrand's disease (1)
- von-Willebrand-Syndrom (1)
- voxel-wise analyses (1)
- wastewater-based epidemiology (WBE) (1)
- wearable sensors (1)
- wearable-cardioverter defibrillator (1)
- whole genome pooled sequencing (1)
- whole-genome sequencing (1)
- women (1)
- work place evaluation (1)
- workflow development (1)
- wound exudate (1)
- wound healing (1)
- wound infection (1)
- wound repair (1)
- xenograft (1)
- yellow fever mosquito (1)
- yellow flags (1)
- younger (1)
- zinc protoporphyrin (1)
- Übergewicht (1)
- ß-amyloid (1)
- β-HCG (1)
- β-ᴅ-2′-Deoxyribosides (1)
- β2-adrenoceptor (1)
- fibrogenesis (1)
- fingolimod (1)
Institute
- Medizin (1871)
- Biochemie, Chemie und Pharmazie (27)
- Biowissenschaften (27)
- Biochemie und Chemie (23)
- Georg-Speyer-Haus (23)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (19)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (19)
- Frankfurt Institute for Advanced Studies (FIAS) (16)
- Ernst Strüngmann Institut (12)
- MPI für Biophysik (10)
Background and purpose: Transient splenial oedema, also known as reversible splenial lesion syndrome (RESLES), is a rare magnetic resonance imaging (MRI) finding that presents as a round or ovoid focal oedema in the posterior corpus callosum, and is associated with a wide range of clinical conditions. The aetiology of RESLES is not fully clear. We aimed to investigate conflicting pathophysiological hypotheses by measuring local glucose metabolism in patients with RESLES.
Methods: We retrospectively analysed patients with RESLES after reductions in antiseizure medications during in-hospital video electroencephalography monitoring. We measured local glucose uptake using positron emission tomography/computed tomography and compared matched cohorts of patients with and without MRI evidence of RESLES using nonparametric tests.
Results: Local glucose metabolism in the splenium of seven patients with RESLES was not significantly different from the glucose metabolism of the seven patients in the matched cohort. This was true using both regular and normalized standardized glucose uptake value calculation methods (p = 0.902 and p = 0.535, respectively).
Conclusion: We found no evidence of local glucose hypometabolism in RESLES, which supports previous pathophysiological considerations that suggest that RESLES is an intercellular, intramyelinic oedema rather than a typical intracellular cytotoxic oedema, which is not reversible.
Recent data have suggested that performing recanalizing therapies in ischemic stroke might lead to an increased risk of acute symptomatic seizures. This applies to both intravenous thrombolysis and mechanical thrombectomy. We therefore determined the frequency of acute symptomatic seizures attributable to these two recanalization therapies using a large, population-based stroke registry in Central Europe. We performed two matched 1:1 case–control analyses. In both analyses, patients were matched for age, stroke severity on admission and pre-stroke functional status. The first analysis compared patients treated with intravenous thrombolysis to a non-recanalization control group. To isolate the effect of mechanical thrombectomy, we compared patients with both mechanical thrombectomy and intravenous thrombolysis to those with only intravenous thrombolysis treatment in a second analysis. From 135,117 patients in the database, 13,356 patients treated with only intravenous thrombolysis, and 1013 patients treated with both intravenous thrombolysis and mechanical thrombectomy were each matched to an equivalent number of controls. Patients with intravenous thrombolysis did not suffer from clinically apparent acute symptomatic seizures significantly more often than non-recanalized patients (treatment = 199; 1.5% vs. control = 237; 1.8%, p = 0.07). Mechanical thrombectomy in addition to intravenous thrombolysis also was not associated with an increased risk of acute symptomatic seizures, as the same number of patients suffered from seizures in the treatment and control group (both n = 17; 1.7%, p = 1). In a large population-based stroke registry, the frequency of clinically apparent acute symptomatic seizures was not increased in patients who received either intravenous thrombolysis alone or in conjunction with mechanical thrombectomy.
Background: Tuberous sclerosis complex (TSC) is a monogenetic, multisystem disorder characterized by benign growths due to TSC1 or TSC2 mutations. This German multicenter study estimated the costs and related cost drivers associated with organ manifestations in adults with TSC.
Methods: A validated, three-month, retrospective questionnaire assessed the sociodemographic and clinical characteristics, organ manifestations, direct, indirect, out-of-pocket (OOP), and nursing care-level costs among adult individuals with TSC throughout Germany from a societal perspective (costing year: 2019).
Results: We enrolled 192 adults with TSC (mean age: 33.4 ± 12.7 years; range: 18–78 years, 51.6% [n = 99] women). Reported TSC disease manifestations included skin (94.8%) and kidney and urinary tract (74%) disorders, epilepsy (72.9%), structural brain defects (67.2%), psychiatric disorders (50.5%), heart and circulatory system disorders (50.5%), and lymphangioleiomyomatosis (11.5%). TSC1 and TSC2 mutations were reported in 16.7% and 25% of respondents, respectively. Mean direct health care costs totaled EUR 6452 (median EUR 1920; 95% confidence interval [CI] EUR 5533–7422) per patient over three months. Medication costs represented the major direct cost category (77% of total direct costs; mean EUR 4953), and mechanistic target of rapamycin (mTOR) inhibitors represented the largest share (68%, EUR 4358). Mean antiseizure drug (ASD) costs were only EUR 415 (6%). Inpatient costs (8%, EUR 518) and outpatient treatment costs (7%; EUR 467) were important further direct cost components. The mean care grade allowance as an approximator of informal nursing care costs was EUR 929 (median EUR 0; 95% CI EUR 780–1083) over three months. Mean indirect costs totaled EUR 3174 (median EUR 0; 95% CI EUR 2503–3840) among working-age individuals (< 67 years in Germany). Multiple regression analyses revealed mTOR inhibitor use and persistent seizures as independent cost-driving factors for total direct costs. Older age and disability were independent cost-driving factors for total indirect costs, whereas epilepsy, psychiatric disease, and disability were independent cost-driving factors for nursing care costs.
Conclusions: This three-month study revealed substantial direct healthcare, indirect healthcare, and medication costs associated with TSC in Germany. This study highlights the spectrum of organ manifestations and their associated treatment needs in the German healthcare setting. Trial registration: DRKS, DRKS00016045. Registered 01 March 2019, http://www.drks.de/DRKS00016045.
Proton pumping respiratory complex I (NADH:ubiquinone oxidoreductase) is a major component of the oxidative phosphorylation system in mitochondria and many bacteria. In mammalian cells it provides 40% of the proton motive force needed to make ATP. Defects in this giant and most complicated membrane-bound enzyme cause numerous human disorders. Yet the mechanism of complex I is still elusive. A group exhibiting redox-linked protonation that is associated with iron-sulfur cluster N2 of complex I has been proposed to act as a central component of the proton pumping machinery. Here we show that a histidine in the 49-kDa subunit that resides near iron-sulfur cluster N2 confers this redox-Bohr effect. Mutating this residue to methionine in complex I from Yarrowia lipolytica resulted in a marked shift of the redox midpoint potential of iron-sulfur cluster N2 to the negative and abolished the redox-Bohr effect. However, the mutation did not significantly affect the catalytic activity of complex I and protons were pumped with an unchanged stoichiometry of 4 H+/2e−. This finding has significant implications on the discussion about possible proton pumping mechanism for complex I.
Highlights
• Artificial intelligence systems for mechanically ventilated patients are increasing.
• The clinical and financial impact of these models are often unexamined.
• We developed a generic health-economic model for artificial intelligence systems.
• This model assesses the cost-effectiveness for many different scenarios.
• The developed framework is easily adjustable to other (clinical) situations.
Abstract
Purpose: The health and economic consequences of artificial intelligence (AI) systems for mechanically ventilated intensive care unit patients often remain unstudied. Early health technology assessments (HTA) can examine the potential impact of AI systems by using available data and simulations. Therefore, we developed a generic health-economic model suitable for early HTA of AI systems for mechanically ventilated patients.
Materials and methods: Our generic health-economic model simulates mechanically ventilated patients from their hospitalisation until their death. The model simulates two scenarios, care as usual and care with the AI system, and compares these scenarios to estimate their cost-effectiveness.
Results: The generic health-economic model we developed is suitable for estimating the cost-effectiveness of various AI systems. By varying input parameters and assumptions, the model can examine the cost-effectiveness of AI systems across a wide range of different clinical settings.
Conclusions: Using the proposed generic health-economic model, investors and innovators can easily assess whether implementing a certain AI system is likely to be cost-effective before an exact clinical impact is determined. The results of the early HTA can aid investors and innovators in deployment of AI systems by supporting development decisions, informing value-based pricing, clinical trial design, and selection of target patient groups.
Aim: Comparison of the clinical efficacy (digitally volumetric, aesthetic, patient-centred outcomes) of tunnel technique (TUN) with subepithelial connective tissue graft (CTG) versus coronally advanced flap (CAF) with enamel matrix derivate (EMD) 5 years after gingival recession therapy. Materials and methods: In 18 patients contributing 36 RT1 recessions, study models were collected at baseline and follow-ups. Optical scans assessed recessions computer-assisted [recession depth, recession reduction (RECred), complete root coverage (CRC), percentage of root coverage (RC), pointwise (pTHK) and mean areal (aTHK) marginal soft tissue thickness]. Root coverage aesthetic Score (RES) was used for aesthetic evaluation and visual analogue scales for patient-centred data collection applied. Results: Sixty months after surgery, 50.0% (TUN+CTG) and 0.0% (CAF+EMD) of sites showed CRC (p = 0.0118), 82.2% (TUN+CTG) and 32.0% (CAF+EMD) achieved RC, respectively (p = 0.0023). CTG achieved significantly better RECred (TUN+CTG: 1.75±0.74 mm; CAF+EMD: 0.50 ± 0.39 mm; p = 0.0009) and aTHK (TUN+CTG: 0.95 ± 0.41 mm; CAF+EMD: 0.26 ± 0.28 mm; p = 0.0013). RES showed superior outcomes (p = 0.0533) for TUN+CTG (6.86 ± 2.31) compared to CAF+EMD (4.63 ± 1.99). The study failed to find significant differences related to patient-centred outcomes (TUN+CTG: 8.30 ± 2.21; CAF+EMD: 7.50 ± 1.51; p = 0.1136). Conclusions: Five years after treatment, CTG resulted in better clinical and aesthetic outcomes than CAF+EMD. Increased THK was associated with improved outcomes for RECred and RC.
We aimed to evaluate the factors associated with hemorrhage (HA) of melanoma brain metastases (MBM) after Cyberknife stereotactic radiosurgery (SRS) in the modern era of systemic therapy. A total of 55 patients with 279 MBM were treated in 93 fractions. The median age, SRS dose, radiological follow-up, and time to HA were 60.4 years, 20 Gy, 17.7 months, and 10.7 months, respectively. Radiologically evident HA was documented in 47 (16.8%) metastases. Of the 55 patients, 25 (45.4%) suffered an HA. Among those, HA caused grade 3 toxicity in 10 patients (40%) and grade 1 symptoms in 5 patients (20%). Ten patients (40%) with HA experienced no toxicity. Logistic regression revealed the use of anticoagulants and the administration of systemic therapy within 7/15 days from SRS to be predictive for HA. When considering the HA causing grade 3 symptomatology, only the use of anticoagulants was significant, with the delivery of whole brain radiation therapy (WBRT) before the HA narrowly missing statistical significance. Our retrospective analysis showed that the administration of modern systemic therapy within 7/15 days from SRS may contribute to HA of MBM, though it appears safe, at least concerning grade 3 toxicity. The use of anticoagulants by the time of SRS significantly increased the risk of HA.
Background and Objectives: We tested if a novel combination of predictors could improve the accuracy of outcome prediction after transfemoral transcatheter aortic valve implantation (TAVI). Materials and Methods: This prospective study recruited 169 participants (49% female; median age 81 years). The primary endpoint was midterm mortality; secondary endpoints were acute Valve Academic Research Consortium (VARC)-3 complication rate and post-TAVI in-hospital length of stay (LoS). EuroSCORE II (ESII), comorbidities (e.g., coronary artery disease), eGFR (estimated glomerular filtration rate; based on cystatin C), hemoglobin, creatinine, N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) levels and patient-reported outcome measures (PROMs, namely EuroQol-5-Dimension-5-Levels, EQ5D5L; Kansas City Cardiomyopathy Questionnaire, KCCQ; clinical frailty scale, CFS) at baseline were tested as predictors. Regression (uni- and multi-variate Cox; linear; binary logistic) and receiver operating characteristic (ROC)-curve analysis were applied. Results: Within a median follow-up of 439 (318–585) days, 12 participants died (7.1%). Independent predictors of mortality using multivariate Cox regression were baseline eGFR (p = 0.001) and KCCQ (p = 0.037). Based on these predictors, a Linear Prediction Score (LPS1) was calculated. The LPS1-area under the curve (AUC)-value (0.761) was significantly higher than the ESII-AUC value (0.597; p = 0.035). Independent predictors for LoS > 6 days (the median LoS) were eGFR (p = 0.028), NTproBNP (p = 0.034), and EQ5D5L values (p = 0.002); a respective calculated LPS2 provided an AUC value of 0.677 (p < 0.001). Eighty participants (47.3%) experienced complications. Male sex predicted complications only in the univariate analysis. Conclusions: The combination of KCCQ and eGFR can better predict midterm mortality than ES II alone. Combining eGFR, NTproBNP, and EQ5D5L can reliably predict LoS after TAVI. This novel method improves personalized TAVI risk stratification and hence may help reduce post-TAVI risk.
Background: The aim of this study was to identify pre-operative parameters able to predict length of stay (LoS) based on clinical data and patient-reported outcome measures (PROMs) from a scorecard database in patients with significant aortic stenosis who underwent TAVI (transfemoral aortic valve implantation). Methods: 302 participants (51.7% males, age range 78.2–84.2 years.) were prospectively recruited. After computing the median LoS value (=6 days, range = 5–8 days), we implemented a decision tree algorithm by setting dichotomized values at median LoS as the dependent variable and assessed baseline clinical variables and PROMs (Clinical Frailty Scale (CFS), EuroQol-5 Dimension-5 Levels (EQ-5D) and Kansas City Cardiomyopathy Questionnaire (KCCQ)) as potential predictors. Results: Among clinical parameters, only peripheral arterial disease (p = 0.029, HR = 1.826) and glomerular filtration rate (GFR, cut-off < 33 mL/min/1.73 m2, p = 0.003, HR = 2.252) were predictive of LoS. Additionally, two PROMs (CFS; cut-off = 3, p < 0.001, HR = 1.324 and KCCQ; cut-off = 30, p = 0.003, HR = 2.274) were strong predictors. Further, a risk score for LoS (RS_LoS) was calculated based on these predictors. Patients with RS_LoS = 0 had a median LoS of 5 days; patients RS_LoS ≥ 3 had a median LoS of 8 days. Conclusions: based on the pre-operative values of the above four predictors, a personalized prediction of LoS after TAVI can be achieved.
Aim: The aim of this study was to measure cortico-cortical connectivity in multiple sclerosis (MS) patients by TMS-evoked potential (TEP) latencies in EEG evoked by transcranial magnetic stimulation (TMS) of the hand area of the primary motor cortex of one hemisphere. TEPs were recorded on the stimulated- and at the homologue site in the non-stimulated contralateral hemisphere. Both interhemispheric directions were tested. Interhemispheric latencies of the two main reproducible TEPs, the positive component at 60 ms and the negative component at 100 ms (P60 and N100, respectively), were expected to be significantly prolonged in MS-patients compared to healthy volunteers.
Material and methods: The study compared interhemispheric propagation of P60 and N100 in groups of 12 patients with early-stage relapsing-remitting MS (RRMS) and 16 age- and gender-matched healthy controls. The study was approved by the Ethics Committee of the Medical Faculty of the Goethe-University of Frankfurt/Main and conformed to the latest revision of the Declaration of Helsinki of 2008. TEPs were recorded by means of EEG and their latencies were statistically evaluated in 10 channels around the stimulation site and in 10 corresponding electrodes in the non-stimulated contralateral hemisphere. Interhemispheric conduction time was calculated by the difference of TEP latency in non-stimulated vs. stimulated hemisphere.
Results: An ANOVA on interhemispheric conduction time showed a significant prolongation for the N100 from left to right hemisphere in MS compared to controls, while no group differences were found for the P60 and the N100 from right to left hemisphere.
Conclusion: The results provide first evidence that the N100 may constitute an interesting marker to measure interhemispheric conduction delays in early-stage RRMS. The specificity of the present finding and its relation to fiber tract pathology should be examined in further correlative analyses with diffusion tensor imaging and other structural MRI data.
The interaction of Eph receptor tyrosine kinases with their transmembrane ligands; the ephrins, is important for the regulation of cell-cell communication. Ephrin-Eph signaling is probably best known for the discrimination of arterial and venous territories by repulsion of venous endothelial cells away from those with an arterial fate. Ultimately, cell repulsion is mediated by initiating the collapse of the actin cytoskeleton in membrane protrusions. Here, we investigated the role of the Ena/VASP family of actin binding proteins in endothelial cell repulsion initiated by ephrin ligands. Human endothelial cells dynamically extended sheet-like lamellipodia over ephrin-B2 coated surfaces. While lamellipodia of control siRNA transfected cells rapidly collapsed, resulting in a pronounced cell repulsion from the ephrin-B2 surfaces, the knockdown of Ena/VASP proteins impaired the cytoskeletal collapse of membrane protrusions and the cells no longer avoided the repulsive surfaces. Mechanistically, ephrin-B2 stimulation elicited the EphB-mediated tyrosine phosphorylation of VASP, which abrogated its interaction with the focal adhesion protein Zyxin. Nck2 was identified as a novel VASP binding protein, which only interacted with the tyrosine phosphorylated VASP protein. Nck links Eph-receptors to the actin cytoskeleton. Therefore, we hypothesize that Nck-Ena/VASP complex formation is required for actin reorganization and/or Eph receptor internalization downstream of ephrin-Eph interaction in endothelial cells, with implications for endothelial navigation and pathfinding.
Endothelial tip cells are essential for VEGF-induced angiogenesis, but underlying mechanisms are elusive. The Ena/VASP protein family, consisting of EVL, VASP, and Mena, plays a pivotal role in axon guidance. Given that axonal growth cones and endothelial tip cells share many common features, from the morphological to the molecular level, we investigated the role of Ena/VASP proteins in angiogenesis. EVL and VASP, but not Mena, are expressed in endothelial cells of the postnatal mouse retina. Global deletion of EVL (but not VASP) compromises the radial sprouting of the vascular plexus in mice. Similarly, endothelial-specific EVL deletion compromises the radial sprouting of the vascular plexus and reduces the endothelial tip cell density and filopodia formation. Gene sets involved in blood vessel development and angiogenesis are down-regulated in EVL-deficient P5-retinal endothelial cells. Consistently, EVL deletion impairs VEGF-induced endothelial cell proliferation and sprouting, and reduces the internalization and phosphorylation of VEGF receptor 2 and its downstream signaling via the MAPK/ERK pathway. Together, we show that endothelial EVL regulates sprouting angiogenesis via VEGF receptor-2 internalization and signaling.
Membrane-Phloretin Interaction, Infrared Raman, ESR Spectroscopy The transport inhibitor phloretin was bound to human red cell membrane and the concomitant structural changes were observed by spectroscopic methods. By the spin labeling method a decrease in fluidity of the membrane was found at 1 and 10 |iM concentrations of the reagent. This result was obtained with the 2-(3-Carboxypropyl)-4,4-dimethyl-2-tridecyl-3-oxazolidinyloxyl, and the 2-(14-Carboxytetradecyl)-2-ethyl-4,4-dimethyl-3-oxazolidinyloxyl lipid spin labels. Infrared spectroscopy of modified membranes revealed an intensity increase of the POO~ band at about 1250 cm-1. Moreover, a shift of the peak at 1050 cm -1 to 1100 cm-1 was observed in the presence of phloretin. Raman spectroscopy of the membranes did not contradict the results found with infrared and ESR spectroscopy: In the phloretin modified membrane we observed a lack of the band at 1085 cm-1, which leads to suggest that the POO" and/or C-C regions are less fluid. Changes of the extracted red cell membrane lipids were less characteristic, and the results differed from those found in red cell membrane.
With the introduction of the virtual allocation crossmatch in the Eurotransplant (ET) region in 2023, the determination of unacceptable antigen mismatches (UAM) in kidney transplant recipients is of utmost importance for histocompatibility laboratories and transplant centers. Therefore, a joined working group of members from the German Society for Immunogenetics (Deutsche Gesellschaft für Immungenetik, DGI) and the German Transplantation Society (Deutsche Transplantationsgesellschaft, DTG) revised and updated the previous recommendations from 2015 in light of recently published evidence. Like in the previous version, a wide range of topics is covered from technical issues to clinical risk factors. This review summarizes the evidence about the prognostic value of contemporary methods for HLA antibody detection and identification, as well as the impact of UAM on waiting time, on which these recommendations are based. As no clear criteria could be determined to differentiate potentially harmful from harmless HLA antibodies, the general recommendation is to assign all HLA against which plausible antibodies are found as UAM. There is, however, a need for individualized solutions for highly immunized patients. These revised recommendations provide a list of aspects that need to be considered when assigning UAM to enable a fair and comprehensible procedure and to harmonize risk stratification prior to kidney transplantation between transplant centers.
Patients with ataxia-telangiectasia (A-T) suffer from progressive cerebellar ataxia, immunodeficiency, respiratory failure, and cancer susceptibility. From a clinical point of view, A-T patients with IgA deficiency show more symptoms and may have a poorer prognosis. In this study, we analyzed mortality and immunity data of 659 A-T patients with regard to IgA deficiency collected from the European Society for Immunodeficiencies (ESID) registry and from 66 patients with classical A-T who attended at the Frankfurt Goethe-University between 2012 and 2018. We studied peripheral B- and T-cell subsets and T-cell repertoire of the Frankfurt cohort and survival rates of all A-T patients in the ESID registry. Patients with A-T have significant alterations in their lymphocyte phenotypes. All subsets (CD3, CD4, CD8, CD19, CD4/CD45RA, and CD8/CD45RA) were significantly diminished compared to standard values. Patients with IgA deficiency (n = 35) had significantly lower lymphocyte counts compared to A-T patients without IgA deficiency (n = 31) due to a further decrease of naïve CD4 T-cells, central memory CD4 cells, and regulatory T-cells. Although both patient groups showed affected TCR-ß repertoires compared to controls, no differences could be detected between patients with and without IgA deficiency. Overall survival of patients with IgA deficiency was significantly diminished. For the first time, our data show that patients with IgA deficiency have significantly lower lymphocyte counts and subsets, which are accompanied with reduced survival, compared to A-T patients without IgA deficiency. IgA, a simple surrogate marker, is indicating the poorest prognosis for classical A-T patients. Both non-interventional clinical trials were registered at clinicaltrials.gov 2012 (Susceptibility to infections in ataxia-telangiectasia; NCT02345135) and 2017 (Susceptibility to Infections, tumor risk and liver disease in patients with ataxia-telangiectasia; NCT03357978)
Introduction: Cesarean section (CS) rates are increasing worldwide. One constant indication is the breech presentation at term. By offering external cephalic version (ECV) and vaginal breech delivery CS rates can be further reduced. Objective: This study aimed to analyze the ECV at 38 weeks of gestation with the associate uptake rate, predicting factors, success rate, and complications at a tertiary healthcare provider in Germany specializing in vaginal breech delivery. Methods: We conducted a prospective cohort study with retrospective data acquisition. All women with a singleton fetus in breech presentation presenting after 34 weeks of gestation for counseling between 2013 and 2017 were included. ECV impact factors were analyzed using logistic regression. Results: A total of 1,598 women presented for breech birth planning. ECV was performed on 353 patients. The overall success rate was 22.4%. A later week of gestation (odds ratio [OR] 1.69), an abundant amniotic fluid index (AFI score) (OR 5.74), fundal (OR 3.78) and anterior (OR 0.39) placental location, and an oblique lie (OR 9.08) were significantly associated with successful ECV in our population. No major complications were observed. The overall vaginal delivery rates could be increased to approximately 14% with ECV. Conclusion: The demand for alternative birth modes other than CS for breech birth is high in the area of Frankfurt, Germany. Our study offers evidence of the safety of ECV at 38 weeks. Centers with expertise in vaginal breech delivery and ECV can reduce CS-rates. To further establish vaginal breech delivery and ECV as alternate options, the required knowledge and skill should be implemented in the revised curricula.
The cell—cell signaling gene CDH13 is associated with a wide spectrum of neuropsychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), autism, and major depression. CDH13 regulates axonal outgrowth and synapse formation, substantiating its relevance for neurodevelopmental processes. Several studies support the influence of CDH13 on personality traits, behavior, and executive functions. However, evidence for functional effects of common gene variation in the CDH13 gene in humans is sparse. Therefore, we tested for association of a functional intronic CDH13 SNP rs2199430 with ADHD in a sample of 998 adult patients and 884 healthy controls. The Big Five personality traits were assessed by the NEO-PI-R questionnaire. Assuming that altered neural correlates of working memory and cognitive response inhibition show genotype-dependent alterations, task performance and electroencephalographic event-related potentials were measured by n-back and continuous performance (Go/NoGo) tasks. The rs2199430 genotype was not associated with adult ADHD on the categorical diagnosis level. However, rs2199430 was significantly associated with agreeableness, with minor G allele homozygotes scoring lower than A allele carriers. Whereas task performance was not affected by genotype, a significant heterosis effect limited to the ADHD group was identified for the n-back task. Heterozygotes (AG) exhibited significantly higher N200 amplitudes during both the 1-back and 2-back condition in the central electrode position Cz. Consequently, the common genetic variation of CDH13 is associated with personality traits and impacts neural processing during working memory tasks. Thus, CDH13 might contribute to symptomatic core dysfunctions of social and cognitive impairment in ADHD.
Proton-pumping complex I of the mitochondrial respiratory chain is among the largest and most complex membrane protein complexes. The enzyme contributes substantially to oxidative energy-conversion in eukaryotic cells. Its malfunctions are implicated in many hereditary and degenerative disorders. Here, we report the X-ray structure of mitochondrial complex I at 3.6- 3.9 Å resolution describing in detail the central subunits that execute the bioenergetic function. A continuous axis of basic and acidic residues running centrally through the membrane arm connects the ubiquinone reduction site in the hydrophilic arm to four putative proton-pumping units. The binding position for a substrate analogous inhibitor and blockage of the predicted ubiquinone binding site provide a model for the ‘deactive’ form of the enzyme. The proposed transition into the active form is based on a concerted structural rearrangement at the ubiquinone reduction site rendering support for a two-state stabilization-change mechanism of protonpumping.
Highlights
• Deletion of SPPL3 promotes resistance of malignant B cells to NK cell cytotoxicity
• Loss of SPPL3 blocks ligand binding to NK receptors via increased N-glycosylation
• B3GNT2 deletion reduces LacNAc addition and restores SPPL3-KO cell sensitivity to NK cells
• SPPL3-deficient cells are enriched in tetra-antennary N-glycans with LacNAc elongations
Summary
Natural killer (NK) cells are primary defenders against cancer precursors, but cancer cells can persist by evading immune surveillance. To investigate the genetic mechanisms underlying this evasion, we perform a genome-wide CRISPR screen using B lymphoblastoid cells. SPPL3, a peptidase that cleaves glycosyltransferases in the Golgi, emerges as a top hit facilitating evasion from NK cytotoxicity. SPPL3-deleted cells accumulate glycosyltransferases and complex N-glycans, disrupting not only binding of ligands to NK receptors but also binding of rituximab, a CD20 antibody approved for treating B cell cancers. Notably, inhibiting N-glycan maturation restores receptor binding and sensitivity to NK cells. A secondary CRISPR screen in SPPL3-deficient cells identifies B3GNT2, a transferase-mediating poly-LacNAc extension, as crucial for resistance. Mass spectrometry confirms enrichment of N-glycans bearing poly-LacNAc upon SPPL3 loss. Collectively, our study shows the essential role of SPPL3 and poly-LacNAc in cancer immune evasion, suggesting a promising target for cancer treatment.
Thioredoxin 1 and thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1α
(2007)
Hypoxia inducible factor 1 (HIF-1), a key regulator for adaptation to hypoxia, is composed of HIF-1alpha and HIF-1beta. In this study, we present evidence that overexpression of mitochondria-located thioredoxin 2 (Trx2) attenuated hypoxia-evoked HIF-1alpha accumulation, whereas cytosolic thioredoxin 1 (Trx1) enhanced HIF-1alpha protein amount. Transactivation of HIF-1 is decreased by overexpression of Trx2 but stimulated by Trx1. Inhibition of proteasomal degradation of HIF-1alpha in Trx2-overexpressing cells did not fully restore HIF-1alpha protein levels, while HIF-1alpha accumulation was enhanced in Trx1-overexpressing cells. Reporter assays showed that cap-dependent translation is increased by Trx1 and decreased by Trx2, whereas HIF-1alpha mRNA levels remained unaltered. These data suggest that thioredoxins affect the synthesis of HIF-1alpha. Trx1 facilitated synthesis of HIF-1alpha by activating Akt, p70S6K, and eIF-4E, known to control cap-dependent translation. In contrast, Trx2 attenuated activities of Akt, p70S6K, and eIF-4E and provoked an increase in mitochondrial reactive oxygen species production. MitoQ, a mitochondria specific antioxidant, reversed HIF-1alpha accumulation as well as Akt activation under hypoxia in Trx2 cells, supporting the notion of translation control mechanisms in affecting HIF-1alpha protein accumulation.
Slack (sequence like a Ca2+ -activated K + channel; also termed Slo2.2, Kcnt1, or KNa 1.1) is a Na+ -activated K + channel that is highly expressed in the peripheral and central nervous system. Previous studies have shown that Slack is enriched in the isolectin B4binding, non-peptidergic subpopulation of C-fiber sensory neurons and that Slack controls the sensory input in neuropathic pain. Recent single-cell RNA-sequencing studies suggested that Slack is highly co-expressed with transient receptor potential (TRP) ankyrin 1 (TRPA1) in sensory neurons. By using in situ hybridization and immunostaining we confirmed that Slack is highly co-localized with TRPA1 in sensory neurons, but only to a minor extent with TRP vanilloid 1. Mice lacking Slack globally or conditionally in sensory neurons (SNS-Slack─/─ ), but not mice lacking Slack conditionally in neurons of the spinal dorsal horn (Lbx1-Slack─/─ ), displayed increased pain behavior after intraplantar injection of the TRPA1 activator allyl isothiocyanate. Patch-clamp recordings with cultured primary neurons and in a HEK-293 cell line transfected with TRPA1 and Slack revealed that Slack-dependent K + currents are modulated in a TRPA1-dependent manner. Taken together, these findings highlight Slack as a modulator of TRPA1-mediated activation of sensory neurons.
Furthermore, we investigated the contribution of Slack in the spinal dorsal horn to pain processing. Lbx1-Slack ─/─ mice demonstrated normal basal pain sensitivity and Complete Freund’s Adjuvant-induced inflammatory pain. Interestingly, we observed a significantly increased spared nerve injury (SNI)-induced neuropathic pain hypersensitivity in Lbx1-Slack ─/─ mutants compared to control littermates. Moreover, we tested the effects of pharmacological Slack activation in the SNI model. Systemic and intrathecal, but not intraplantar administration of the Slack opener loxapine significantly alleviated SNI-induced hypersensitivity in control mice, but only slightly in Lbx1Slack ─/─ mice, further supporting the inhibitory function of Slack in spinal dorsal horn neurons in neuropathic pain processing.
Altogether, our data suggest that Slack in sensory neurons controls TRPA1-induced pain, whereas Slack in spinal dorsal horn neurons inhibits peripheral nerve injury induced neuropathic pain. These data provide further insights into the molecular mechanisms of pain sensation.
Background: Prostate cancer is a major health concern in aging men. Paralleling an aging society, prostate cancer prevalence increases emphasizing the need for efcient diagnostic algorithms.
Methods: Retrospectively, 106 prostate tissue samples from 48 patients (mean age,
66 ± 6.6 years) were included in the study. Patients sufered from prostate cancer (n = 38) or benign prostatic hyperplasia (n = 10) and were treated with radical prostatectomy or Holmium laser enucleation of the prostate, respectively. We constructed tissue microarrays (TMAs) comprising representative malignant (n = 38) and benign (n = 68) tissue cores. TMAs were processed to histological slides, stained, digitized and assessed for the applicability of machine learning strategies and open–source tools in diagnosis of prostate cancer. We applied the software QuPath to extract features for shape, stain intensity, and texture of TMA cores for three stainings, H&E, ERG, and PIN-4. Three machine learning algorithms, neural network (NN), support vector machines (SVM), and random forest (RF), were trained and cross-validated with 100 Monte Carlo random splits into 70% training set and 30% test set. We determined AUC values for single color channels, with and without optimization of hyperparameters by exhaustive grid search. We applied recursive feature elimination to feature sets of multiple color transforms.
Results: Mean AUC was above 0.80. PIN-4 stainings yielded higher AUC than H&E and
ERG. For PIN-4 with the color transform saturation, NN, RF, and SVM revealed AUC of 0.93 ± 0.04, 0.91 ± 0.06, and 0.92 ± 0.05, respectively. Optimization of hyperparameters improved the AUC only slightly by 0.01. For H&E, feature selection resulted in no increase of AUC but to an increase of 0.02–0.06 for ERG and PIN-4.
Conclusions: Automated pipelines may be able to discriminate with high accuracy between malignant and benign tissue. We found PIN-4 staining best suited for classifcation. Further bioinformatic analysis of larger data sets would be crucial to evaluate the reliability of automated classifcation methods for clinical practice and to evaluate potential discrimination of aggressiveness of cancer to pave the way to automatic precision medicine.
Background: Compound flaps offer the advantage of one stage defect reconstruction respecting all relevant tissues and early functional recovery by optimal vascularity of all components. Due to its specific vascular anatomy and the three-dimensional donor site, compound flaps with bone components may result in higher complication rates compared to soft tissue compound flaps. The meta-analysis summarizes the available evidence and evaluates whether bone components are a risk factor for periprocedural complications in upper extremity multidimensional defect reconstruction. Method: PubMed and Embase were searched for all publications addressing compound free flaps for upper extremity defect reconstruction with bone or soft tissue components published between January 1988 and May 2018. The methodological quality was assessed with the American Society of Plastic Surgeons Evidence Rating Scale for Therapeutic Studies. Flap loss, thrombosis rate, early infection, hematoma, seroma, as well as donor site complications were extracted and analyzed. Results: Twelve out of 1157 potentially eligible studies (evidence-III) comprising 159 patients were finally included with publication bias for all summarized complication rates. Complication rates for flaps with/ without bone components were: total flap loss 5%, 95% CI = 3%–10% (6%/5%); partial flap loss 8%, 95% CI = 5%–15%, (9%/8%); arterial/venous thrombosis 7%, 95% CI = 4%–12%, (8%/5%)/14%, 95% CI = 9%–21% (16%/6%, P < .05) with higher risk for flaps with bone components; infection 6%, 95% CI = 3%–12% (6%/6%); hematoma 6%, 95% CI = 3%–11% (6%/5%); seroma 5%, 95% CI = 3%–10% (5%/5%); dehiscence 10%, 95% CI = 6%–17% (11%/9%). Conclusion: Compound flaps for upper extremity defect reconstruction including bone components have a higher venous thrombosis rate compared to compound soft-tissue flaps.
Forewarned is forearmed
(2009)
Simple Summary: Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge due to the lack of biomarkers indicating the optimal drug for each patient. This study analyzed blood samples of patients with predominant clear cell mRCC who were treated with the mTOR inhibitor everolimus after failure of one prior tumor therapy. In an exploratory approach, predictive blood biomarkers were searched. We found lower levels of the protein thrombospondin-2 (TSP-2) at the start of the therapy and higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation to be associated with therapy response. Of note, these blood biomarkers had a higher predictive value than baseline patient parameters or risk classifications. Polymorphisms in the mTOR gene appeared to be associated with therapy response, but were not significant. To conclude, it seems feasible to identify patients showing longtime responses to everolimus and possible to increase tumor therapy response rates based on biomarkers for individual therapy selection.
Abstract: There is an unmet need for predictive biomarkers in metastatic renal cell carcinoma (mRCC) therapy. The phase IV MARC-2 trial searched for predictive blood biomarkers in patients with predominant clear cell mRCC who benefit from second-line treatment with everolimus. In an exploratory approach, potential biomarkers were assessed employing proteomics, ELISA, and polymorphism analyses. Lower levels of angiogenesis-related protein thrombospondin-2 (TSP-2) at baseline (≤665 parts per billion, ppb) identified therapy responders with longer median progression-free survival (PFS; ≤665 ppb at baseline: 6.9 months vs. 1.8, p = 0.005). Responders had higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation (>27.14 nmol/L), associated with a longer median PFS (3.8 months vs. 2.2, p = 0.013) and improved overall survival (OS; 31.0 months vs. 14.0 months, p < 0.001). Baseline TSP-2 levels had a stronger relation to PFS (HR 0.36, p = 0.008) than baseline patient parameters, including IMDC score. Increased serum LDH levels two weeks after therapy initiation were the best predictor for OS (HR 0.21, p < 0.001). mTOR polymorphisms appeared to be associated with therapy response but were not significant. Hence, we identified TSP-2 and LDH as promising predictive biomarkers for therapy response on everolimus after failure of one VEGF-targeted therapy in patients with clear cell mRCC.
Objectives: To discuss optimal management of recurrent urinary tract infections (UTIs) in women. About every second woman experiences at least one UTI in her lifetime, of those 30% experience another UTI, and 3% further recurrences. Especially young healthy women without underlying anatomical deficiencies suffer from recurrent UTIs (rUTI), which are associated with significant morbidity and reduction in quality of life.
Methods: This is a narrative review, investigating publications dealing with recurrent UTI in women. Risk factors and options for management are discussed.
Results: The increased susceptibility of women to rUTI is based on the female anatomy in addition to behavioural, genetic, and urological factors. However, why some women are more likely than others to develop and maintain rUTI remains to be clarified. Invasive characteristics of certain uropathogenic Escherichia coli that are able to form extra- and intracellular biofilms and may therefore cause delayed release of bacteria into the bladder, may play a role in this setting. Treatment recommendations for an acute episode of rUTI do not differ from those for isolated episodes. Given the nature of rUTI, different prophylactic approaches also play an important role. Women with rUTI should first be counselled to use non-antibiotic strategies including behavioural changes, anti-adhesive treatments, antiseptics, and immunomodulation, before antibiotic prophylaxis is considered. In addition to the traditional treatment and prophylactic therapies, new experimental strategies are emerging and show promising effects, such as faecal microbiota transfer (FMT), a treatment option that transfers microorganisms and metabolites of a healthy donor’s faecal matter to patients using oral capsules, enemas, or endoscopy. Initial findings suggest that FMT might be a promising treatment approach to interrupt the cycle of rUTI. Furthermore, bacteriophages, infecting and replicating in bacteria, have been clinically trialled for UTIs.
Conclusion: Due to the limitation of available data, novel treatment options require further clinical research to objectify the potential in treating bacterial infections, particularly UTIs.
Druggability Evaluation of the Neuron Derived Orphan Receptor (NOR-1) Reveals Inverse NOR-1 Agonists
(2022)
The neuron derived orphan receptor (NOR-1, NR4A3) is among the least studied nuclear receptors. Its physiological role and therapeutic potential remain widely elusive which is in part due to the lack of chemical tools that can directly modulate NOR-1 activity. To probe the possibility of pharmacological NOR-1 modulation, we have tested a drug fragment library for NOR-1 activation and repression. Despite low hit-rate (<1 %), we have obtained three NOR-1 ligand chemotypes one of which could be rapidly expanded to an analogue comprising low micromolar inverse NOR-1 agonist potency and altering NOR-1 regulated gene expression in a cellular setting. It confirms druggability of the transcription factor and may serve as an early tool to assess the role and potential of NOR-1.
Highlights
• Reduced evoked theta activity in the deaf.
• Reduced theta-gamma and alpha-gamma cross-frequency couplings in the deaf.
• Stronger delta-alpha coupling in the deaf.
Abstract
Neurons within a neuronal network can be grouped by bottom-up and top-down influences using synchrony in neuronal oscillations. This creates the representation of perceptual objects from sensory features. Oscillatory activity can be differentiated into stimulus-phase-locked (evoked) and non-phase-locked (induced). The former is mainly determined by sensory input, the latter by higher-level (cortical) processing. Effects of auditory deprivation on cortical oscillations have been studied in congenitally deaf cats (CDCs) using cochlear implant (CI) stimulation. CI-induced alpha, beta, and gamma activity were compromised in the auditory cortex of CDCs. Furthermore, top-down information flow between secondary and primary auditory areas in hearing cats, conveyed by induced alpha oscillations, was lost in CDCs. Here we used the matching pursuit algorithm to assess components of such oscillatory activity in local field potentials recorded in primary field A1. Additionally to the loss of induced alpha oscillations, we also found a loss of evoked theta activity in CDCs. The loss of theta and alpha activity in CDCs can be directly related to reduced high-frequency (gamma-band) activity due to cross-frequency coupling. Here we quantified such cross-frequency coupling in adult 1) hearing-experienced, acoustically stimulated cats (aHCs), 2) hearing-experienced cats following acute pharmacological deafening and subsequent CIs, thus in electrically stimulated cats (eHCs), and 3) electrically stimulated CDCs. We found significant cross-frequency coupling in all animal groups in > 70% of auditory-responsive sites. The predominant coupling in aHCs and eHCs was between theta/alpha phase and gamma power. In CDCs such coupling was lost and replaced by alpha oscillations coupling to delta/theta phase. Thus, alpha/theta oscillations synchronize high-frequency gamma activity only in hearing-experienced cats. The absence of induced alpha and theta oscillations contributes to the loss of induced gamma power in CDCs, thereby signifying impaired local network activity.
In dengue-endemic countries such as Indonesia, Zika may be misdiagnosed as dengue, leading to underestimates of Zika disease and less foreknowledge of pregnancy-related complications such as microcephaly. Objective: To assess the attitudes of frontline physicians in a dengue-endemic country toward testing for Zika infection among patients with dengue-like illnesses. Methods: A cross-sectional online survey was conducted among general practitioners (GPs) in Indonesia. The survey assessed their attitude and also collected sociodemographic data, characteristics of their medical education, professional background, and workplace, and exposure to Zika cases. A two-step logistic regression analysis was used to assess possible variables associated with these attitudes. Results: A total of 370 GPs were included in the final analysis of which 70.8% had good attitude. Unadjusted analyses suggested that GPs who were 30 years old or older and those who had medical experience five years or longer had lower odds of having a positive attitude compared to those who aged younger than 30 years and those who had medical experience less than five years, OR: 0.58; 95%CI: 0.37, 0.91 and OR: 0.55; 95%CI: 0.35, 0.86, respectively. No explanatory variable was associated with attitude in the fully adjusted model. Conclusion: Our findings point to younger GPs with a shorter medical experience being more likely to consider testing for Zika infection among their patients presenting with dengue-like illnesses. Strategic initiatives may be needed to enhance older or longer-experienced physicians' capacity in diagnosing Zika infection.
The adult heart has a limited capacity to replace or regenerate damaged cardiac tissue following severe myocardial injury. Thus, therapies facilitating the induction of cardiac regeneration holds great promise for the treatment of end-stage heart failure, and for pathologies invoking severe cardiac dysfunction as a result of cardiomyocyte death. Recently, a number of studies have demonstrated that cardiac regeneration can be achieved through modulation and/or reprogramming of cardiomyocyte proliferation, differentiation, and survival signaling. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), are reported to play critical roles in regulating key aspects of cardiomyocyte physiologic and pathologic signaling, including the regulation of cardiac regeneration both in vitro and in vivo. In this review, we will explore and detail the current understanding of ncRNA function in cardiac regeneration, and highlight established and novel strategies for the treatment of heart failure through modulation of ncRNAs-driven cardiac regeneration.
Diabetes results from a decline in functional pancreatic β-cells, but the molecular mechanisms underlying the pathological β-cell failure are poorly understood. Here we report that large-tumor suppressor 2 (LATS2), a core component of the Hippo signaling pathway, is activated under diabetic conditions and induces β-cell apoptosis and impaired function. LATS2 deficiency in β-cells and primary isolated human islets as well as β-cell specific LATS2 ablation in mice improves β-cell viability, insulin secretion and β-cell mass and ameliorates diabetes development. LATS2 activates mechanistic target of rapamycin complex 1 (mTORC1), a physiological suppressor of autophagy, in β-cells and genetic and pharmacological inhibition of mTORC1 counteracts the pro-apoptotic action of activated LATS2. We further show a direct interplay between Hippo and autophagy, in which LATS2 is an autophagy substrate. On the other hand, LATS2 regulates β-cell apoptosis triggered by impaired autophagy suggesting an existence of a stress-sensitive multicomponent cellular loop coordinating β-cell compensation and survival. Our data reveal an important role for LATS2 in pancreatic β-cell turnover and suggest LATS2 as a potential therapeutic target to improve pancreatic β-cell survival and function in diabetes.
Background & Aims: Liver fibrosis arises from long-term chronic liver injury, accompanied by an accelerated wound healing response with interstitial accumulation of extracellular matrix (ECM). Activated hepatic stellate cells (HSC) are the main source for ECM production. MicroRNA29a (miR-29a) is a crucial antifibrotic miRNA that is repressed during fibrosis, resulting in up-regulation of collagen synthesis.
Methods; Intracellular and extracellular miRNA levels of primary and immortalized myofibroblastic HSC in response to profibrogenic stimulation by transforming growth factor β (TGFβ) or platelet-derived growth factor-BB (PDGF-BB) or upon inhibition of vesicular transport and autophagy processes were determined by quantitative polymerase chain reaction. Autophagy flux was studied by electron microscopy, flow cytometry, immunoblotting, and immunocytochemistry. Hepatic and serum miR-29a levels were quantified by using both liver tissue and serum samples from a cohort of chronic hepatitis C virus patients and a murine CCl4 induced liver fibrosis model.
Results: In our study, we show that TGFβ and PDGF-BB resulted in decrease of intracellular miR-29a and a pronounced increase of vesicular miR-29a release into the supernatant. Strikingly, miR-29a vesicular release was accompanied by enhanced autophagic activity and up-regulation of the autophagy marker protein LC3. Moreover, autophagy inhibition strongly prevented miR-29a secretion and repressed its targets’ expression such as Col1A1. Consistently, hepatic miR-29a loss and increased LC3 expression in myofibroblastic HSC were associated with increased serum miR-29a levels in CCl4-treated murine liver fibrosis and specimens of hepatitis C virus patients with chronic liver disease.
Conclusions: We provide evidence that activation-associated autophagy in HSC induces release of miR-29a, whereas inhibition of autophagy represses fibrogenic gene expression in part through attenuated miR-29a secretion.
Pathologies associated with tissue ischemia/reperfusion (I/R) in highly metabolizing organs such as the brain and heart are leading causes of death and disability in humans. Molecular mechanisms underlying mitochondrial dysfunction during acute injury in I/R are tissue-specific, but their details are not completely understood. A metabolic shift and accumulation of substrates of reverse electron transfer (RET) such as succinate are observed in tissue ischemia, making mitochondrial complex I of the respiratory chain (NADH:ubiquinone oxidoreductase) the most vulnerable enzyme to the following reperfusion. It has been shown that brain complex I is predisposed to losing its flavin mononucleotide (FMN) cofactor when maintained in the reduced state in conditions of RET both in vitro and in vivo. Here we investigated the process of redox-dependent dissociation of FMN from mitochondrial complex I in brain and heart mitochondria. In contrast to the brain enzyme, cardiac complex I does not lose FMN when reduced in RET conditions. We proposed that the different kinetics of FMN loss during RET is due to the presence of brain-specific long 50 kDa isoform of the NDUFV3 subunit of complex I, which is absent in the heart where only the canonical 10 kDa short isoform is found. Our simulation studies suggest that the long NDUFV3 isoform can reach toward the FMN binding pocket and affect the nucleotide affinity to the apoenzyme. For the first time, we demonstrated a potential functional role of tissue-specific isoforms of complex I, providing the distinct molecular mechanism of I/R-induced mitochondrial impairment in cardiac and cerebral tissues. By combining functional studies of intact complex I and molecular structure simulations, we defined the critical difference between the brain and heart enzyme and suggested insights into the redox-dependent inactivation mechanisms of complex I during I/R injury in both tissues.
Autism spectrum disorders (ASD) are highly heritable and are characterized by deficits in social communication and restricted and repetitive behaviors. Twin studies on phenotypic subdomains suggest a differing underlying genetic etiology. Studying genetic variation explaining phenotypic variance will help to identify specific underlying pathomechanisms. We investigated the effect of common variation on ASD subdomains in two cohorts including >2500 individuals. Based on the Autism Diagnostic Interview-Revised (ADI-R), we identified and confirmed six subdomains with a SNP-based genetic heritability h2SNP = 0.2–0.4. The subdomains nonverbal communication (NVC), social interaction (SI), and peer interaction (PI) shared genetic risk factors, while the subdomains of repetitive sensory-motor behavior (RB) and restricted interests (RI) were genetically independent of each other. The polygenic risk score (PRS) for ASD as categorical diagnosis explained 2.3–3.3% of the variance of SI, joint attention (JA), and PI, 4.5% for RI, 1.2% of RB, but only 0.7% of NVC. We report eight genome-wide significant hits—partially replicating previous findings—and 292 known and novel candidate genes. The underlying biological mechanisms were related to neuronal transmission and development. At the SNP and gene level, all subdomains showed overlap, with the exception of RB. However, no overlap was observed at the functional level. In summary, the ADI-R algorithm-derived subdomains related to social communication show a shared genetic etiology in contrast to restricted and repetitive behaviors. The ASD-specific PRS overlapped only partially, suggesting an additional role of specific common variation in shaping the phenotypic expression of ASD subdomains.
Objective: Nationwide data on the epidemiology, treatment characteristics, and long-term outcome of severe traumatic brain injury (TBI) in Germany is not yet existing. Neurosurgeons from the German Neurosurgery Society (DGNC) and traumatologists from the German Trauma Society (DGU), therefore, joined forces in 2016 to conceptualize a TBI module for the well-established Trauma Register of the DGU (TR-DGU). Here, we report how this “German National TBI registry (GNTR)” has been developed, implemented, and tested in a recently completed pilot period.
Methods: The conception and implementation process of the GNTR from August 2016 to February 2019 is described, and results of its 23-months long pilot period from February 2019 to December 2020 are presented. For the pilot period, TBI patients were prospectively enrolled at nine neurosurgical and traumatological hospitals across Germany. Inclusion criteria were treatment on the ICU ≥ 24h, or an ISS score ≥ 16. A variety of clinical, imaging, and laboratory parameters were collected, and the GOSE score was used to assess the outcome at discharge and 6- and 12 months follow-up.
Results: Details on the structure and dataset of the GNTR as well as milestones and pitfalls during its conception and implementation, are outlined. During the pilot period, a total of 264 TBI patients were enrolled. Their demographic characteristics, clinical, imaging, and radiological findings, and their early mortality and functional outcome are described. Furthermore, factors associated with an unfavorable outcome (GOSE 1-4) are assessed using uni- and multivariate regression analyses. Finally, problems and future directions of the GNTR are discussed.
Conclusion: The pilot period of the GNTR offers a first glance at the current epidemiology and treatment characteristics of TBI patients in Germany. More importantly, they show how a national TBI registry yielding high-quality prospective data can be developed, implemented, and tested within four years
The compulsive habit of cars
(2014)
The car dependence of people living in contemporary cities is a major concern for policy makers, who often find it difficult to persuade people into more sustainable transport modes. By contrast, recent insights from neuroscience have shown that a broad spectrum of behaviors can become habitual and, thus, resistant to change. Here, we outline the potential of collaboration between neuroscience and human geography aiming at a better understanding of habits that determine everyday commuting routines.
Introduction: The concurrent presence of both central nervous system (CNS) tumors and multiple sclerosis (MS) poses various diagnostic and therapeutic pitfalls and makes the clinical management of such patients challenging.
Methods: In this retrospective, single-center cohort study, we searched our clinical databases (2006–2019) for patients with concurrent CNS tumors and MS and described their disease courses. Age at diagnosis of the respective disease and probabilities for MS disease activity events (DAEs) with vs. without prior tumor-specific therapy were tested pairwise using t-test for dependent samples and exact binomial test.
Results: N = 16 patients with concurrent CNS tumors and MS were identified. MS diagnosis preceded the CNS oncological diagnosis by an average of 9 years (p = 0.004). More DAEs occurred in patients without prior chemotherapy (83.3%) than in patients with prior chemotherapy (16.7%; p = 0.008). This effect did not reach significance for patients with prior radiation therapy/radiosurgery (66.7% vs. 33.3%, p = 0.238). The average interval between DAEs and the last documented lymphopenia was 32.25 weeks.
Conclusions: This study describes the clinical and demographic features of patients with concurrent CNS tumors and MS and suggests several practical approaches to their clinical management. Our findings suggest that adding a disease-modifying MS therapy to the regimen of patients treated with chemotherapy is necessary only if the patient suffers from a highly active, aggressive course of MS. In view of the lack of prospective trials, individual risk assessments should remain the foundation of the decision on MS treatment in concurrent CNS tumor diseases.
Sphingosylphosphorylcholine (SPC) is a bioactive lipid that binds to G protein-coupled-receptors and activates various signaling cascades. Here, we show that in renal mesangial cells, SPC not only activates various protein kinase cascades but also activates Smad proteins, which are classical members of the transforming growth factor-β (TGFβ) signaling pathway. Consequently, SPC is able to mimic TGFβ-mediated cell responses, such as an anti-inflammatory and a profibrotic response. Interleukin-1β-stimulated prostaglandin E2 formation is dose-dependently suppressed by SPC, which is paralleled by reduced secretory phospholipase A2 (sPLA2) protein expression and activity. This effect is due to a reduction of sPLA2 mRNA expression caused by inhibited sPLA2 promoter activity. Furthermore, SPC upregulates the profibrotic connective tissue growth factor (CTGF) protein and mRNA expression. Blocking TGFβ signaling by a TGFβ receptor kinase inhibitor causes an inhibition of SPC-stimulated Smad activation and reverses both the negative effect of SPC on sPLA2 expression and the positive effect on CTGF expression. In summary, our data show that SPC, by mimicking TGFβ, leads to a suppression of proinflammatory mediator production and stimulates a profibrotic cell response that is often the end point of an anti-inflammatory reaction. Thus, targeting SPC receptors may represent a novel therapeutic strategy to cope with inflammatory diseases.
Sulforaphane (SFN) is a natural glucosinolate found in cruciferous vegetables that acts as a chemopreventive agent, but its mechanism of action is not clear. Due to antioxidative mechanisms being thought central in preventing cancer progression, SFN could play a role in oxidative processes. Since redox imbalance with increased levels of reactive oxygen species (ROS) is involved in the initiation and progression of bladder cancer, this mechanism might be involved when chemoresistance occurs. This review summarizes current understanding regarding the influence of SFN on ROS and ROS-related pathways and appraises a possible role of SFN in bladder cancer treatment.
In this comprehensive review, we will dissect the impact of research on proteoglycans focusing on recent developments involved in their synthesis, degradation, and interactions, while critically assessing their usefulness in various biological processes. The emerging roles of proteoglycans in global infections, specifically the SARS-CoV-2 pandemic, and their rising functions in regenerative medicine and biomaterial science have significantly affected our current view of proteoglycans and related compounds. The roles of proteoglycans in cancer biology and their potential use as a next-generation protein-based adjuvant therapy to combat cancer is also emerging as a constructive and potentially beneficial therapeutic strategy. We will discuss the role of proteoglycans in selected and emerging areas of proteoglycan science, such as neurodegenerative diseases, autophagy, angiogenesis, cancer, infections and their impact on mammalian diseases.
Background: To examine overall survival rates within a large cohort of German prostate cancer (PCa) patients and to compare these with life-expectancy (LE) predictions derived from German life tables. We hypothesized that the advantage of good general health in radical prostatectomy (RP) patients combined with favorable cancer outcomes might lead to even higher overall survival rates over 10 years compared to the LE of a general population.
Methods: A total of 6483 patients were treated with RP between 1992 and 2007 at the Martini-Klinik Prostate Cancer Center. Preoperative risk classification was performed according to D'Amico. Postoperative risk classification was performed according to the Cancer of the Prostate Risk Assessment score (CAPRA-S). A simulated cohort was created that resembled the exact age distribution of the RP population using Monte Carlo simulation which was based on data derived from official male German life tables (1992–2017). Markov chain was used to represent natural age progression of the simulated cohort. Kaplan–Meier plots were created to display the differences between 10-year observed overall survival (OS) and the simulated, predicted LE.
Results: For D'Amico low risk and intermediate risk, 10-year OS was 12.0% and 9.2% above predicted LE in the simulated cohort, respectively. For D'Amico high risk, OS was virtually the same as predicted LE (0.8% difference in favor of RP treated patients). For CAPRA-S low and intermediate risk, OS was 11.8% and 9.7% above predicted LE. For CAPRA-S high risk, OS was virtually the same as predicted LE (0.3% difference in favor of the simulated cohort).
Conclusions: Low- and intermediate risk PCa patients treated with RP can expect a very favorable overall survival, that even exceeds LE predictions. High risk patients' overall survival perfectly aligns with LE predictions.
Objectives: To test the effect of race/ethnicity on cancer-specific mortality after radical prostatectomy or external beam radiotherapy in localized prostate cancer patients. Methods: In the Surveillance, Epidemiology and End Results database 2004–2016, we identified intermediate-risk and high-risk white (n = 151 632), Asian (n = 11 189), Hispanic/Latino (n = 20 077) and African American (n = 32 550) localized prostate cancer patients, treated with external beam radiotherapy or radical prostatectomy. Race/ethnicity-stratified cancer-specific mortality analyses relied on competing risks regression, after propensity score matching for patient and cancer characteristics. Results: Compared with white patients, Asian intermediate- and high-risk external beam radiotherapy patients showed lower cancer-specific mortality (hazard ratio 0.58 and 0.70, respectively, both P ≤ 0.02). Additionally, Asian high-risk radical prostatectomy patients also showed lower cancer-specific mortality than white patients (hazard ratio 0.72, P = 0.04), but not Asian intermediate-risk radical prostatectomy patients (P = 0.08). Conversely, compared with white patients, African American intermediate-risk radical prostatectomy patients showed higher cancer-specific mortality (hazard ratio 1.36, P = 0.01), but not African American high-risk radical prostatectomy or intermediate- and high-risk external beam radiotherapy patients (all P ≥ 0.2). Finally, compared with white people, no cancer-specific mortality differences were recorded for Hispanic/Latino patients after external beam radiotherapy or radical prostatectomy, in both risk levels (P ≥ 0.2). Conclusions: Relative to white patients, an important cancer-specific mortality advantage applies to intermediate-risk and high-risk Asian prostate cancer patients treated with external beam radiotherapy, and to high-risk Asian patients treated with radical prostatectomy. These observations should be considered in pretreatment risk stratification and decision-making.
Objectives: To test the effect of race/ethnicity on cancer-specific mortality after radical prostatectomy or external beam radiotherapy in localized prostate cancer patients. Methods: In the Surveillance, Epidemiology and End Results database 2004–2016, we identified intermediate-risk and high-risk white (n = 151 632), Asian (n = 11 189), Hispanic/Latino (n = 20 077) and African American (n = 32 550) localized prostate cancer patients, treated with external beam radiotherapy or radical prostatectomy. Race/ethnicity-stratified cancer-specific mortality analyses relied on competing risks regression, after propensity score matching for patient and cancer characteristics. Results: Compared with white patients, Asian intermediate- and high-risk external beam radiotherapy patients showed lower cancer-specific mortality (hazard ratio 0.58 and 0.70, respectively, both P ≤ 0.02). Additionally, Asian high-risk radical prostatectomy patients also showed lower cancer-specific mortality than white patients (hazard ratio 0.72, P = 0.04), but not Asian intermediate-risk radical prostatectomy patients (P = 0.08). Conversely, compared with white patients, African American intermediate-risk radical prostatectomy patients showed higher cancer-specific mortality (hazard ratio 1.36, P = 0.01), but not African American high-risk radical prostatectomy or intermediate- and high-risk external beam radiotherapy patients (all P ≥ 0.2). Finally, compared with white people, no cancer-specific mortality differences were recorded for Hispanic/Latino patients after external beam radiotherapy or radical prostatectomy, in both risk levels (P ≥ 0.2). Conclusions: Relative to white patients, an important cancer-specific mortality advantage applies to intermediate-risk and high-risk Asian prostate cancer patients treated with external beam radiotherapy, and to high-risk Asian patients treated with radical prostatectomy. These observations should be considered in pretreatment risk stratification and decision-making.
Background: A trend towards inverse stage migration in prostate cancer (PCa) was reported. However, previous analyses did not take into account potential differences in sampling strategies (number of biopsy cores), which might have confounded these reports.
Material and Methods: Within our single-institutional database we identified PCa patients treated with radical prostatectomy (RP) between 2000 and 2020 (n = 21,646). We calculated the estimated annual percentage change (EAPC) for D'Amico risk groups, biopsy Gleason Grade Group (GGG), PSA and cT stage as well as postoperative RP GGG and pT stage relying on log linear regression methodology. Subsequently, we repeated the analyses after adjustment for number of cores obtained at biopsy.
Results: Absolute rates of D'Amico low risk decreased (−30.1%), while intermediate and high risk increased (+21.2% and +9.0%, respectively). Rates of GGG I decreased (−50.0%), while GGG II–V increased, with the largest increase in GGG II (+22.5%). This trend, albeit less pronounced, was also recorded after adjusted EAPC analyses (p < .05). Specifically, EAPC values for D'Amico low vs intermediate vs high risk were −1.07%, +0.37%, +0.45%, respectively, and EAPC values for GGG ranged between −0.71% (GGG I) and +0.80% (GGG IV). Finally, an increase in ≥cT2 (EAPC: +3.16%) was displayed (all p < .001). These trends were confirmed in EAPC calculations in RP GGG and pT stages (p < .001).
Conclusion: Our findings confirm the trend towards less frequent treatment of low risk PCa and more frequent treatment of high risk PCa, also after adjustment for number of biopsy cores.
Ataxia telangiectasia (A-T) is a devastating multi-system disorder characterized by progressive cerebellar ataxia and immunodeficiency. The neurological decline may be caused by multiple factors of which ongoing inflammation and oxidative stress may play a dominant role. The objective of the present investigation was to determine cerebrospinal fluid (CSF) proteins and possible low-grade inflammation and its relation to age and neurological deterioration. In the present study, we investigated 15 patients with A-T from 2 to 16 years. Our investigation included blood and CSF tests, clinical neurological examination, A-T score, and MRI findings. The albumin ratio (AR) was analyzed to determine the blood–brain-barrier function. In addition, inflammatory cytokines (IL-1α, IL-6, IL-8, IL-12 p40, IL-17A, IFN-γ, TNF-α) were measured by the multiplex cytometric bead array. We compared the results with those from an age-matched control group. Three of the A-T patients were analyzed separately (one after resection of a cerebral meningioma, one after radiation and chemotherapy due to leukemia, one after stem cell transplantation). Patient had significantly more moderate and severe side effects due to CSF puncture (vomiting, headache, need for anti-emetic drugs) compared with healthy controls. Total protein, albumin, and the AR increased with age indicating a disturbed blood barrier function in older children. There were no differences for cytokines in serum and CSF with the exception of IL-2, which was significantly higher in controls in serum. The AR is significantly altered in A-T patients, but low-grade inflammation is not detectable in serum and CSF.
The analysis of ethanol and of its congeners in blood plays an important role in forensic cases, especially when allegations are made that alcohol has been consumed after an accident. In alcoholic beverages, congener alcohols are by-products and are generated during fermentation. The assay of these compounds in serum samples and beverages has been previously performed using headspace-gas chromatography-flame ionization detection methods (HS-GC-FID). As an alternative, a robust headspace-gas chromatography-mass spectrometry (HS-GC-MS) procedure was developed and validated, which has the following advantages:
- Simultaneous determination of ethanol, congener alcohols and other
endogenous substances.
- Reduction of matrix interference by increasing selectivity and
specificity.
- Clear separation of the positional isomers 3-methyl-1-butanol and
2-methyl-1-butanol.
Highlights
• This current review covers studies that have identified long non-coding RNAs in aortic aneurysm development and progression.
• We separately discuss transcripts and mechanisms of importance to thoracic as well as abdominal aortic aneurysms.
• Functional data on lncRNAs being identified are highlighted.
• Some have been studied in human as well as experimental models of the disease pathology.
Abstract
Aortic aneurysm (AA) is a complex and dangerous vascular disease, featuring progressive and irreversible vessel dilatation. AA is typically detected either by screening, or identified incidentally through imaging studies. To date, no effective pharmacological therapies have been identified for clinical AA management, and either endovascular repair or open surgery remains the only option capable of preventing aneurysm rupture. In recent years, multiple research groups have endeavored to both identify noncoding RNAs and to clarify their function in vascular diseases, including aneurysmal pathologies. Notably, the molecular roles of noncoding RNAs in AA development appear to vary significantly between thoracic aortic aneurysms (TAAs) and abdominal aortic aneurysms (AAAs). Some microRNAs (miRNA - a non-coding RNA subspecies) appear to contribute to AA pathophysiology, with some showing major potential for use as biomarkers or as therapeutic targets. Studies of long noncoding RNAs (lncRNAs) are more limited, and their specific contributions to disease development and progression largely remain unexplored. This review aims to summarize and discuss the most current data on lncRNAs and their mediation of AA pathophysiology.
Despite major improvements of the therapy, many B-cell Non-Hodgkin’s lymphoma (B-NHL) entities still have a poor prognosis. New therapeutic options are urgently needed. Therefore this study sets out to investigate oncogenic signalling pathways in the two B-NHL entities mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) in order to define new potential therapeutic targets.
MCL cells overexpress the anti-apoptotic protein BCL-2, thereby they evade apoptosis. With venetoclax, the first-in-class BCL-2 specific inhibitor was approved and achieved good response rates in MCL. However, some cases display intrinsic or acquired resistance to venetoclax. In order to improve the therapy, this study aimed to identify genes which confer sensitivity or resistance towards venetoclax upon their respective knockout. To this end, a genome-wide CRISPR/Cas9-based loss-of-function screen was conducted in the MCL cell line Maver-1. The E3 ubiquitin
ligase MARCH5 was identified as one of the top hits conferring sensitivity
towards venetoclax upon its knockout. This finding was validated in a competitive growth assay including two more MCL cell lines, Jeko-1 and Mino. MARCH5 knockout also sensitised Jeko-1 cells towards venetoclax even though this cell line was insensitive towards venetoclax in its wild-type form. Using BH3 profiling, an increased dependency on BCL-2 of MARCH5-depleted cells confirmed this finding. The sensitisation was found to be based on induction of apoptosis upon MARCH5 knockout and to an even higher extent upon additional treatment of MARCH5-depleted cells with venetoclax. As already described for epithelial cancer entities, the BCL-2 family members MCL-1 and NOXA were upregulated in MCL cell lines upon MARCH5 knockout. This led to the hypothesis that MARCH5 is a potential
regulator of intrinsic apoptosis with NOXA as a key component. A competitive growth assay with MARCH5 and NOXA co-depleted cells revealed a partial reversion of the BCL-2 sensitisation compared to MARCH5 knockout alone. Furthermore, mass spectrometry-based methods were used to gain more insight into other cellular pathways and networks which might be regulated in a MARCH5-dependent manner. In an interactome analysis, proteins which regulate mitochondrial morphology, such as Drp-1 were identified as MARCH5 interactors. Besides this expected finding, interaction between MARCH5 and several members of the BCL-2 family as well as a potential connection between MARCH5 and vesicular trafficking was discovered. As expected, an ubiquitinome analysis of MARCH5-depleted cells revealed decreased levels of MCL-1 and NOXA ubiquitination. Additionally, a potential role of MARCH5 in the ubiquitination of several members of the cell cycle regulatory
pathway was discovered. Based on the broad spectrum of cellular pathways which seem to be regulated in a MARCH5-dependent manner, it was hypothesised that MARCH5 primarily regulates BCL-2 family members which in turn regulate intrinsic apoptosis on the one hand and additionally are involved in the regulation of various other pathways on the other hand.
In summary, this study provides insight into a MARCH5-dependent MCL1-1/NOXA axis in MCL cells and potential implications into related cellular processes.
In addition to the anti-apoptotic pathways described above, B-cell receptor (BCR) signalling is known to provide a pro-survival signal to both normal and malignant B-cells. Targeting the BCR signalling pathway therefore is a promising therapeutic target for B-cell malignancies. In order to gain more insight into the differential modes of BCR signalling of ABC- and GCB-DLBCL cells, genes/proteins which displayed differential essentiality in ABC- and GCB-DLBCL cells were aimed to be defined. Consequently, data sets from a CRISPR/Cas9-based loss-of-function screen
were re-analysed. SASH3 was identified as a gene which was essential for GCB- but not for ABC-DLBCL cells. Since this protein is known to be involved in T-cell receptor (TCR)-signalling, SASH3 was assumed to play a potential role in BCR signalling as well and was therefore investigated in more detail. A competitive growth assay confirmed that SASH3 knockout was toxic exclusively for GCB-DLBCL cell lines. An interactome analysis in ABC- and GCB-DLBCL cells revealed interaction between SASH3 and many components of the proximal BCR signalling pathway as well as several downstream signalling pathways such as the PI3K or the NF-ΚB pathway.
An integration of the interactome with data from the CRISPR/Cas9-based loss-offunction screen revealed differential essentiality of the SASH3-interacting proteins in ABC- and GCB-DLBCL cells. It was hypothesised that SASH3 might regulate PI3K signalling on which GCB- but not ABC-DLBCL cells are known to dependent. Discontinuation of the regulation of PI3K signalling could therefore be exclusively toxic to GCB-DLBCL cells.
Taken together, this study describes a subtype-specific dependency of GCB-DLBCL cells on SASH3. Furthermore, the SASH3 interactome has been investigated in B-cells for the first time, thereby highlighting a potential role in proximal BCR signalling and involvement in specific BCR-related downstream signalling pathways.
To clip or coil has been matter of debates for several years and is the domain of interdisciplinary decision making. However, the microsurgical outcome has still been elusive concerning wide neck aneurysms (WNA). A retrospective single center study was performed with all patients with ruptured WNA (rWNA) and unruptured WNA (uWNA) admitted to author´s institute between 2007–2017. Microsurgical outcome was evaluated according to Raymond-Roy occlusion grade and follow-up angiography was performed to analyze the stability of neck/aneurysm remnants and retreatment poverty. Of 805 aneurysms, 139 were rWNA (17.3%) and 148 uWNA (18.4%). Complete occlusion was achieved in 102 of 139 rWNA (73.4%) and 112 of 148 uWNA (75.6%). Neck remnants were observed in 36 patients with rWNA (25.9%) and 30 patients with uWNA (20.3%), 1 (0.7%) and 6 (4.1%) patients had aneurysmal remnant, respectively. Overall complication rate was 11.5%. At follow-up (939/1504 months), all remnants were stable except for one, which was further conservatively treated with marginal retreatment rate under 1%. Even the risk of de-novo aneurysm was higher than the risk for remnant growth (2.6% vs 0% in rWNA; 8.7% vs 5.3% in uWNA) without significant difference. Microsurgical clipping is effective for complete occlusion of r/uWNA with low complication. Furthermore, the risk of remnant growth is marginal even lower than the risk of de-novo rate low retreatment rate.
Background: Dysphagia is a common and severe symptom of traumatic brain injury (TBI) affecting up to 78% of patients. It is associated with pneumonia, increased morbidity and mortality. Although subdural hematoma (SDH) accounts for over 50% of TBI, the occurrence of dysphagia in this subtype has not been investigated. This study investigates the overall frequency, clinical predictors of dysphagia and functional outcome of patients with SDH associated dysphagia.
Methods: All patients presenting in author ́s institution between 2007 and 2020 with SDH were included in the study. Patients with SDH and clinical suspicion for dysphagia received a clinical swallowing assessment by a speech and language pathologist (SLP). Furthermore the severity of dysphagia was rated according to swallowing disorder scale.Functional outcome was evaluated by Glasgow outcome scale (GOS).
Results: Of 545 patients with SDH, 71 patients had dysphagia (13%). The prevalence of dysphagia was significantly lower in the surgical arm compared to the conservative arm (11.8% vs 21.8%; OR 0.23; p=0.02). Independent predictors for dysphagia were GCS <13 at admission (p<0.001; OR 4.17), cardiovascular disease (p=0.002; OR 2.29) and pneumonia (p=0.002; OR 2.88) whereas operation was a protective factor (p<0.001; OR 0.2). All patients with dysphagia improved significantly under SLP treatment from initial diagnosis to hospital discharge (p<0.01). However, patients with most severe grade of dysphagia showed no significant improvement during the clinical course. Patients with dysphagia had significantly worse outcome (GOS 1-3) compared to those without dysphagia (48.8% vs 26.4%; p<0.001).
Conclusion: Dysphagia is a frequent symptom in SDH and the early identification of dysphagia is crucial regarding initiation of treatment and functional outcome. Surgery is effective in preventing dysphagia and should be considered in high-risked patients.
Introduction: Dysphagia is a common and severe symptom of traumatic brain injury (TBI) affecting up to 78% of patients. It is associated with pneumonia, increased morbidity, and mortality. Although subdural hematoma (SDH) accounts for over 50% of TBI, the occurrence of dysphagia in this subtype has not been investigated yet.
Methods: All patients with SDH admitted to the author's institution between the years 2007 and 2020 were included in the study. Patients with SDH and clinical suspicion for dysphagia received a clinical swallowing assessment by a speech and language pathologist (SLP). Furthermore, the severity of dysphagia was rated according to swallowing disorder scale. Functional outcome was evaluated by the Glasgow outcome scale (GOS).
Results: Out of 545 patients with SDH, 71 patients had dysphagia (13%). The prevalence of dysphagia was significantly lower in the surgical arm compared to the conservative arm (11.8 vs. 21.8%; OR 0.23; p = 0.02). Independent predictors for dysphagia were GCS < 13 at admission (OR 4.17; p < 0.001), cardiovascular disease (OR 2.29; p = 0.002), and pneumonia (OR 2.88; p = 0.002), whereas the operation was a protective factor (OR 0.2; p < 0.001). In a subgroup analysis, right-sided SDH was an additional predictor for dysphagia (OR 2.7; p < 0.001). Overall, patients with dysphagia improved significantly under the SLP treatment from the initial diagnosis to hospital discharge (p < 0.01). However, a subgroup of patients with the most severe grade of dysphagia showed no significant improvement. Patients with dysphagia had significantly worse outcomes (GOS 1–3) compared to those without dysphagia (48.8 vs. 26.4%; p < 0.001).
Conclusion: Dysphagia is a frequent symptom in SDH, and the early identification of dysphagia is crucial regarding the initiation of treatment and functional outcome. Surgery is effective in preventing dysphagia and should be considered in high-risked patients.
Background: Epileptic seizures are common clinical features in patients with acute subdural hematoma (aSDH); however, diagnostic feasibility and therapeutic monitoring remain limited. Surface electroencephalography (EEG) is the major diagnostic tool for the detection of seizures but it might be not sensitive enough to detect all subclinical or nonconvulsive seizures or status epilepticus. Therefore, we have planned a clinical trial to evaluate a novel treatment modality by perioperatively implanting subdural EEG electrodes to diagnose seizures; we will then treat the seizures under therapeutic monitoring and analyze the clinical benefit.
Methods: In a prospective nonrandomized trial, we aim to include 110 patients with aSDH. Only patients undergoing surgical removal of aSDH will be included; one arm will be treated according to the guidelines of the Brain Trauma Foundation, while the other arm will additionally receive a subdural grid electrode. The study's primary outcome is the comparison of incidence of seizures and time-to-seizure between the interventional and control arms. Invasive therapeutic monitoring will guide treatment with antiseizure drugs (ASDs). The secondary outcome will be the functional outcome for both groups as assessed via the Glasgow Outcome Scale and modified Rankin Scale both at discharge and during 6 months of follow-up. The tertiary outcome will be the evaluation of chronic epilepsy within 2-4 years of follow-up.
Discussion: The implantation of a subdural EEG grid electrode in patients with aSDH is expected to be effective in diagnosing seizures in a timely manner, facilitating treatment with ASDs and monitoring of treatment success. Moreover, the occurrence of epileptiform discharges prior to the manifestation of seizure patterns could be evaluated in order to identify high-risk patients who might benefit from prophylactic treatment with ASDs.
Trial registration: ClinicalTrials.gov identifier no. NCT04211233.
Purpose: Acute-on-chronic subdural hematoma (acSDH) describes acute bleeding into a chronic subdural hematoma (SDH), after surgery or second trauma. Because seizures are a well-known complication of SDH, associated with substantial morbidity and mortality, we aimed to analyze the incidence of acute symptomatic seizures (ASz), including status epilepticus, and determine the functional outcomes in this specific cohort of patients.
Methods: A retrospective analysis was performed, including patients with acSDH who were admitted to our department between 2010 and 2019. The incidence and timely onset of ASz and status epilepticus were evaluated. Functional outcomes at discharge and at 3–6 month follow-up were analyzed based on the modified Rankin scale.
Results: Of 506 patients with chronic SDH, 29 patients (5.7%) were diagnosed with acSDH. The overall incidence of ASz and status epilepticus were 72.4% and 10.3%, respectively. Favorable outcomes were identified in 11 patients (52.4%) in the ASz group compared with 6 patients (75%) in the non-ASz group. The mortality rate was higher in the ASz group compared with that in the control group (29% vs 0%). At follow-up, favorable outcomes were similar to those observed at discharge (52.4% in the ASz group and 71.4% in the control group). The mortality rate was still higher in the ASz group, at 32% compared with 14% for the control group.
Conclusion: AcSDH has a high risk for ASz, including status epilepticus, and is associated with unfavorable outcomes and high mortality. Thus, prophylactic treatment with antiepileptic drugs should be considered among this specific cohort of patients.
Background: Research on chronic subdural hematoma (cSDH) management has primarily focused on potential recurrence after surgical evacuation. Herein, we present a novel postoperative/non-invasive treatment that includes a supervised Valsalva maneuver (SVM), which may serve to reduce SDH recurrence. Accordingly, the aims of the study were to investigate the effects of SVM on SDH recurrence rates and functional outcomes.
Methods: A prospective study was conducted from December 2016 until December 2019 at the Goethe University Hospital Frankfurt. Of the 204 adult patients with surgically treated cSDH who had subdural drains placed, 94 patients were assigned to the SVM group and 82 patients were assigned to the control group. The SVM was performed by having patients blow into a self-made SVM device at least two times/h for 12 h/day. The primary end-point was SDH recurrence rate, while secondary outcomes were morbidity and functional outcomes at 3 months of follow-up.
Results: SDH recurrence was observed in 16 of 94 patients (17%) in the SVM group, which was a significant reduction as compared with the control group, which had 24 of 82 patients (29.3%; p = 0.05) develop recurrent SDHs. Further, the infection rate (e.g., pneumonia) was significantly lower in the SVM group (1.1%) than in the control group (13.4%; p < 0.001; odds ratio [OR] 0.1). At the 3-month follow-up, 85 of 94 patients (90.4%) achieved favorable outcomes in the SVM group compared with 62 of 82 patients (75.6%) in the control group (p = 0.008; OR 3.0). Independent predictors for favorable outcome at follow-up were age (OR 0.9) and infection (OR 0.2).
Conclusion: SVM appears to be safe and effective in the post-operative management of cSDHs, reducing both recurrence rates and infections after surgical evacuation, thereby resulting in favorable outcomes at follow-up.
Post-exercise hypotension (PEH) is the phenomenon of lowered blood pressure after a single bout of exercise. Only a fraction of people develops PEH but its occurrence correlates well with long-term effects of sports on blood pressure. Therefore, PEH has been suggested as a suitable predictor for the effectivity of exercise as therapy in hypertension. Local vascular bioactive lipids might play a potential role in this context. We performed a cross-over clinical pilot study with 18 healthy volunteers to investigate the occurrence of PEH after a single short-term endurance exercise. Furthermore, we investigated the plasma lipid profile with focus on arachidonic acid (AA)-derived metabolites as potential biomarkers of PEH. A single bout of ergometer cycling induced a significant PEH in healthy volunteers with the expected high inter-individual variability. Targeted lipid spectrum analysis revealed significant upregulation of several lipids in the direct post-exercise phase. Among these changes, only 15- hydroxyeicosatetranoic acid (HETE) correlated significantly with the extent of PEH but in an AA-independent manner, suggesting that 15-HETE might act as specific PEH-marker. Our data indicate that specific lipid modulation might facilitate the identification of patients who will benefit from exercise activity in hypertension therapy. However, larger trials including hypertonic patients are necessary to verify the clinical value of this hypothesis.
Glioblastoma multiforme accounts for more than 80% of all malignant gliomas in adults and a minor fraction of new annual cases occurs in children. In the last decades, research shed light onto the molecular patterns underlying human malignancies which resulted in a better understanding of the disease and finally an improved long term survival for cancer patients. However, malignancies of the central nervous system and especially glioblastomas are still related to poor outcomes with median survivals of less than 6 months despite extensive surgery, chemotherapy and radiation. Hence, a better understanding of the molecular mechanism driving and sustaining cancerous mutations in glioblastomas is crucial for the development of targeted therapies. Apoptosis, a form of programmed cell death, is an important feature of eukaryotic cells and crucial for the maintenance of multicellular homeostasis. Because apoptosis is a highly complex and tightly regulated signaling pathway, resisting apoptotic stimuli and avoiding cell death is a hallmark of the cancerous transformation of cells. Hence, targeting molecular structures to reestablish apoptotic signaling in tumor cells is a promising approach for the treatment of malignancies. Smac mimetics are a group of small molecular protein inhibitors that structurally derive from an intracellular protein termed Smac and selectively block Inhibitor of apoptosis (IAP) proteins, which are often aberrantly expressed in cancer. Several studies confirmed the antitumoral effects of Smac mimetics in different human malignancies, including glioblastoma, and give rationales for the development of potent Smac mimetics and Smac mimetic-based combination protocols. This study investigates the antitumoral activity of the bivalent Smac mimetic BV6 in combination with Interferon α. Latter is a well characterized cytokine with an essential role in immunity, cell differentiation and apoptosis. This study further aims to address the molecular mechanisms underlying the antitumoral activity of the combination treatment by using well established molecular cell death assays, flow cytometry, western blot analysis, genetic approaches and selective pharmacological inhibition. Since different Smac mimetics and Smac mimetic-based combination therapies are currently under clinical evaluations, findings of this study may have broad implications for the application of Smac mimetics as clinical cancer therapeutics.
Mutations in the Von Hippel–Lindau (VHL) gene are the driving force in many forms of clear cell renal cell carcinoma (ccRCC) and promote hypoxia-inducible factor (HIF)-dependent tumor proliferation, metastasis and angiogenesis. Despite the progress that has already been made, ccRCC generally remain resistant to conventional therapies and ccRCC patients suffer from metastasis and acquired resistance, highlighting the need for novel therapeutic options. Cysteinyl leukotriene receptor 1 (CysLTR1) antagonists, like zafirlukast, are administered in bronchial asthma to control eicosanoid signaling. Intriguingly, long-term use of zafirlukast decreases cancer risk and leukotriene receptor antagonists inhibit tumor growth, but the mechanisms still remain unexplored. Therefore, we aim to understand the mechanisms of zafirlukast-mediated cell death in ccRCC cells. We show that zafirlukast induces VHL-dependent and TNFα-independent non-apoptotic and non-necroptotic cell death in ccRCC cells. Cell death triggered by zafirlukast could be rescued with antioxidants and the PARP-1 inhibitor Olaparib, and additionally relies on HIF-2α. Finally, MG-132-mediated proteasome inhibition sensitized VHL wild-type cells to zafirlukast-induced cell death and inhibition of HIF-2α rescued zafirlukast- and MG-132-triggered cell death. Together, these results highlight the importance of VHL, HIF and proteasomal degradation in zafirlukast-induced oxidative cell death with potentially novel therapeutic implications for ccRCC.
Objectives: The aim of this study was to evaluate the development and status quo of the quality of high throughput in vitro diagnostic testing for tetanus and diphtheria antitoxin antibody (ATX) concentrations based on external quality assessment (EQA) data.
Methods: We analyzed manufacturer-specific data of 22 EQA surveys—each for the detection of tetanus and diphtheria ATX—to check the diagnostic strength of the corresponding in vitro diagnostic systems.
Results: While the results were mostly well aligned, individual surveys showed widely dispersed ATX concentrations. The medians of manufacturer collectives deviated from the overall median by up to 8.9-fold in the case of diphtheria ATX and by up to 3.5-fold in the case of tetanus ATX. Such a distribution in the results is particularly critical in the cut-off range for immunity and may lead to an incorrect assessment of vaccination status.
Conclusion: These results were surprising as there are International Standards for both ATX; however, the results may be linked to the high ATX concentration of the reference material, which deviates considerably from clinically significant concentrations. To increase the accuracy and diagnostic strength of both assays, we recommend a recalibration of the test systems and verification of their traceability to the International Standards.
Lactate dehydrogenase from pig heart is inactivated by the NAD+ -analog P1-N6-(4-azidophenylethyl)adenosine-P2-[4-(3-azidopyridinio)butyl]diphosphate (6) upon irradiation with UV light of wavelengths in the range from 300 to 380 nm. The decrease in enzyme activity can be prevented by the addition of NAD+ and oxalate. The modified enzyme shows a reduced binding capacity for its coenzyme as compared to native lactate dehydrogenase. The amount of incorporated coenzyme is deduced from the ribose content of inactivated enzyme. Tryptic digestion of the modified protein and separation of the peptides by HPLC yields 5 ribose-containing fractions. One of them, fraction 6 6 , is split by treatment with nucleotide pyrophosphatase into two subfractions, 63 and 58. Only subfraction 63 contains ribose. Whereas peptide 58 shows a UV absorption spectrum similar to that of 4-(3-aminopyridinio)-butyl phosphate (3). Amino acid analyses of the peptides indicate that the inactivator forms covalent bonds with different parts of the protein: Peptide 63 is characterized by a great portion of hydrophobic amino acids whereas peptide 58 shows a high degree of hydrophilicity.
Sulfhydryl Groups, Methylmercury Containing Inactivator, Coenzyme Analogue Nicotinamide-(S-methylmercury-thioinosine) dinucleotide was formed by reaction of nicotin amide-(6-thiopurine) dinucleotide with methylmercury chloride. The compound exhibits coenzyme properties in the test with LDH (Km=1.5 × 10-4 м , Vmax=12500) and LADH (Km=1.7 × 10-4 м, Vmax=27) and inactivates YADH and GAPDH. From incubations with LDH and LADH the mercury containing coenzyme could be regained by column chromatography. The compound seems to be qualified for the X-ray structure analysis of the coenzyme-enzyme complex for some dehyrogenases based on the proportion of the heavy metal.
Many proteins have been found to operate in a complex with various biomolecules such as proteins, nucleic acids, carbohydrates, or lipids. Protein complexes can be transient, stable or dynamic and their association is controlled under variable cellular conditions. Complexome profiling is a recently developed mass spectrometry-based method that combines mild separation techniques, native gel electrophoresis, and density gradient centrifugation with quantitative mass spectrometry to generate inventories of protein assemblies within a cell or subcellular fraction. This review summarizes applications of complexome profiling with respect to assembly ranging from single subunits to large macromolecular complexes, as well as their stability, and remodeling in health and disease.
Clear native electrophoresis and blue native electrophoresis are microscale techniques for the isolation of membrane protein complexes. The Coomassie Blue G-250 dye, used in blue native electrophoresis, interferes with in-gel fluorescence detection and in-gel catalytic activity assays. This problem can be overcome by omitting the dye in clear native electrophoresis. However, clear native electrophoresis suffers from enhanced protein aggregation and broadening of protein bands during electrophoresis and therefore has been used rarely. To preserve the advantages of both electrophoresis techniques we substituted Coomassie dye in the cathode buffer of blue native electrophoresis by non-colored mixtures of anionic and neutral detergents. Like Coomassie dye, these mixed micelles imposed a charge shift on the membrane proteins to enhance their anodic migration and improved membrane protein solubility during electrophoresis. This improved clear native electrophoresis offers a high resolution of membrane protein complexes comparable to that of blue native electrophoresis. We demonstrate the superiority of high resolution clear native electrophoresis for in-gel catalytic activity assays of mitochondrial complexes I–V. We present the first in-gel histochemical staining protocol for respiratory complex III. Moreover we demonstrate the special advantages of high resolution clear native electrophoresis for in-gel detection of fluorescent labeled proteins labeled by reactive fluorescent dyes and tagged by fluorescent proteins. The advantages of high resolution clear native electrophoresis make this technique superior for functional proteomics analyses.
Congenital diaphragmatic hernia (CDH) is a major congenital malformation with high mortality. Outcome data on larger unselected patient groups in Germany are unavailable as there is no registry for CDH. Therefore, routine data from the largest German health insurance fund were analyzed for the years 2009–2013. Main outcome measures were incidence, survival and length of hospital stay. Follow-up was 12 months. 285 patients were included. The incidence of CDH was 2.73 per 10,000 live births. Overall mortality was 30.2%. A total of 72.1% of the fatalities occurred before surgery. Highest mortality (64%) was noted in patients who were admitted to specialized care later as the first day of life. Patients receiving surgical repair had a better prognosis (mortality: 10.8%). A total of 67 patients (23.5%) were treated with ECMO with a mortality of 41.8%. The median cumulative hospital stay among one-year survivors was 40 days and differed between ECMO- and non-ECMO-treated patients (91 vs. 32.5 days, p < 0.001). This is the largest German cohort study of CDH patients with a one-year follow-up. The ECMO subgroup showed a higher mortality. Another important finding is that delayed treatment in specialized care increases mortality. Prospective clinical registries are needed to elucidate the treatment outcomes in detail.
Varicella zoster virus (VZV) belongs to one of the eight herpes viruses known to infect humans. While primary VZV infection (chickenpox) is generally a disease of childhood, herpes zoster occurs primarily in elderly persons (>50 years). Herpes zoster, also called shingles, is a neurocutaneous disease resulting from reactivation of latent VZV infection within dorsal root ganglia. Severe complications may occur in elderly persons and immunocompromised of any age, including severe complication of the eye, ear, skin and internal organs, and the peripheral and central nervous systems. A progressive decline of VZV-specific cell-mediated immunity and age are associated with an increased incidence and severity of herpes zoster and postherpetic neuralgia (PHN). PHN is the most common complication of herpes zoster causing chronic, debilitating pain. In cases with characteristic signs and symptoms (presence of prodromal pain, eruptions, grouped vesicles, segmental pain), the diagnosis is almost distinctive enough and no laboratory investigations are required. However, for patients lacking no characteristic pathology, a rapid laboratory diagnosis may be helpful to begin antiviral therapy as soon as possible. Antiviral therapy should be initiated immediately within 72 h after rash onset, particularly in older patients. The main aim of treatment is to control and reduce acute zoster pain, shorten virus replication, avoid dissemination of skin lesions and prevent PHN and other severe complications. The aim of the present review is to outline advantages and disadvantages of different herpes zoster laboratory methods (microscopy, direct immunofluorescence assay, detection of viral DNA, virus isolation and serological methods). A live attenuated VZV vaccine has been developed to prevent herpes zoster and PHN in individuals >60 years of age (Shingles Prevention Study). This review summarises the epidemiology, pathogenesis, clinical aspects, complications, therapy and prevention of varicella zoster.
Background: Candida spp. are a frequent cause of nosocomial bloodstream infections worldwide.
Objective: To evaluate the use patterns and outcomes associated with intravenous (IV) fluconazole therapy in intensive care units in Spain and Germany.
Patients and methods: The research reported here was a prospective multicenter longitudinal observational study in adult intensive care unit patients receiving IV fluconazole. Demographic, microbiologic, therapy success, length of hospital stay, adverse event, and all-cause mortality data were collected at 14 sites in Spain and five in Germany, from February 2004 to November 2005.
Results: Patients (n = 303) received prophylaxis (n = 29), empiric therapy (n = 140), preemptive therapy (n = 85), or definitive therapy (n = 49). A total of 298 patients (98.4%) were treated with IV fluconazole as first-line therapy. The treating physicians judged therapy successful in 66% of prophylactic, 55% of empiric, 45% of preemptive, and 43% of definitive group patients. In the subgroup of 152 patients with proven and specified Candida infection only, 32% suffered from Candida specified as potentially resistant to IV fluconazole. The overall mortality rate was 42%.
Conclusion: Our study informs treatment decision makers that approximately 32% of the patients with microbiological results available suffered from Candida specified as potentially resistant to IV fluconazole, highlighting the importance of appropriate therapy.
Aims: In primary central nervous system tumours, epithelial-to-mesenchymal transition (EMT) gene expression is associated with increased malignancy. However, it has also been shown that EMT factors in gliomas are almost exclusively expressed by glioma vessel-associated pericytes (GA-Peris). In this study, we aimed to identify the mechanism of EMT in GA-Peris and its impact on angiogenic processes.
Methods; In glioma patients, vascular density and the expression of the pericytic markers platelet derived growth factor receptor (PDGFR)-β and smooth muscle actin (αSMA) were examined in relation to the expression of the EMT transcription factor SLUG and were correlated with survival of patients with glioblastoma (GBM). Functional mechanisms of SLUG regulation and the effects on primary human brain vascular pericytes (HBVP) were studied in vitro by measuring proliferation, cell motility and growth characteristics.
Results: The number of PDGFR-β- and αSMA-positive pericytes did not change with increased malignancy nor showed an association with the survival of GBM patients. However, SLUG-expressing pericytes displayed considerable morphological changes in GBM-associated vessels, and TGF-β induced SLUG upregulation led to enhanced proliferation, motility and altered growth patterns in HBVP. Downregulation of SLUG or addition of a TGF-β antagonising antibody abolished these effects.
Conclusions: We provide evidence that in GA-Peris, elevated SLUG expression is mediated by TGF-β, a cytokine secreted by most glioma cells, indicating that the latter actively modulate neovascularisation not only by modulating endothelial cells, but also by influencing pericytes. This process might be responsible for the formation of an unstructured tumour vasculature as well as for the breakdown of the blood–brain barrier in GBM.
The effects of exercise interventions on unspecific chronic low back pain (CLBP) have been investigated in many studies, but the results are inconclusive regarding exercise types, efficiency, and sustainability. This may be because the influence of psychosocial factors on exercise induced adaptation regarding CLBP is neglected. Therefore, this study assessed psychosocial characteristics, which moderate and mediate the effects of sensorimotor exercise on LBP. A single-blind 3-arm multicenter randomized controlled trial was conducted for 12-weeks. Three exercise groups, sensorimotor exercise (SMT), sensorimotor and behavioral training (SMT-BT), and regular routines (CG) were randomly assigned to 662 volunteers. Primary outcomes (pain intensity and disability) and psychosocial characteristics were assessed at baseline (M1) and follow-up (3/6/12/24 weeks, M2-M5). Multiple regression models were used to analyze whether psychosocial characteristics are moderators of the relationship between exercise and pain, meaning that psychosocial factors and exercise interact. Causal mediation analysis were conducted to analyze, whether psychosocial characteristics mediate the exercise effect on pain. A total of 453 participants with intermittent pain (mean age = 39.5 ± 12.2 years, f = 62%) completed the training. It was shown, that depressive symptomatology (at M4, M5), vital exhaustion (at M4), and perceived social support (at M5) are significant moderators of the relationship between exercise and the reduction of pain intensity. Further depressive mood (at M4), social-satisfaction (at M4), and anxiety (at M5 SMT) significantly moderate the exercise effect on pain disability. The amount of moderation was of clinical relevance. In contrast, there were no psychosocial variables which mediated exercise effects on pain. In conclusion it was shown, that psychosocial variables can be moderators in the relationship between sensorimotor exercise induced adaptation on CLBP which may explain conflicting results in the past regarding the merit of exercise interventions in CLBP. Results suggest further an early identification of psychosocial risk factors by diagnostic tools, which may essential support the planning of personalized exercise therapy.
Background: Biological psychiatry aims to understand mental disorders in terms of altered neurobiological pathways. However, for one of the most prevalent and disabling mental disorders, Major Depressive Disorder (MDD), patients only marginally differ from healthy individuals on the group-level. Whether Precision Psychiatry can solve this discrepancy and provide specific, reliable biomarkers remains unclear as current Machine Learning (ML) studies suffer from shortcomings pertaining to methods and data, which lead to substantial over-as well as underestimation of true model accuracy.
Methods: Addressing these issues, we quantify classification accuracy on a single-subject level in N=1,801 patients with MDD and healthy controls employing an extensive multivariate approach across a comprehensive range of neuroimaging modalities in a well-curated cohort, including structural and functional Magnetic Resonance Imaging, Diffusion Tensor Imaging as well as a polygenic risk score for depression.
Findings Training and testing a total of 2.4 million ML models, we find accuracies for diagnostic classification between 48.1% and 62.0%. Multimodal data integration of all neuroimaging modalities does not improve model performance. Similarly, training ML models on individuals stratified based on age, sex, or remission status does not lead to better classification. Even under simulated conditions of perfect reliability, performance does not substantially improve. Importantly, model error analysis identifies symptom severity as one potential target for MDD subgroup identification.
Interpretation: Although multivariate neuroimaging markers increase predictive power compared to univariate analyses, single-subject classification – even under conditions of extensive, best-practice Machine Learning optimization in a large, harmonized sample of patients diagnosed using state-of-the-art clinical assessments – does not reach clinically relevant performance. Based on this evidence, we sketch a course of action for Precision Psychiatry and future MDD biomarker research.
Long non-coding RNAs (lncRNAs) orchestrate various biological processes and regulate the development of cardiovascular diseases. Their potential therapeutic benefit to tackle disease progression has recently been extensively explored. Our study investigates the role of lncRNA Nudix Hydrolase 6 (NUDT6) and its antisense target fibroblast growth factor 2 (FGF2) in two vascular pathologies: abdominal aortic aneurysms (AAA) and carotid artery disease. Using tissue samples from both diseases, we detected a substantial increase of NUDT6, whereas FGF2 was downregulated. Targeting Nudt6 in vivo with antisense oligonucleotides in three murine and one porcine animal model of carotid artery disease and AAA limited disease progression. Restoration of FGF2 upon Nudt6 knockdown improved vessel wall morphology and fibrous cap stability. Overexpression of NUDT6 in vitro impaired smooth muscle cell (SMC) migration, while limiting their proliferation and augmenting apoptosis. By employing RNA pulldown followed by mass spectrometry as well as RNA immunoprecipitation, we identified Cysteine and Glycine Rich Protein 1 (CSRP1) as another direct NUDT6 interaction partner, regulating cell motility and SMC differentiation. Overall, the present study identifies NUDT6 as a well-conserved antisense transcript of FGF2. NUDT6 silencing triggers SMC survival and migration and could serve as a novel RNA-based therapeutic strategy in vascular diseases.
Background: Intraoperative blood salvage (IBS) is regarded as an alternative to allogeneic blood transfusion excluding the risks associated with allogeneic blood. Currently, IBS is generally avoided in tumor surgeries due to concern for potential metastasis caused by residual tumor cells in the erythrocyte concentrate.
Methods: The feasibility, efficacy and safety aspects of the new developed Catuvab procedure using the bispecific trifunctional antibody Catumaxomab was investigated in an ex-vivo pilot study in order to remove residual EpCAM positive tumor cells from the autologous erythrocyte concentrates (EC) from various cancer patients, generated by a IBS device.
Results: Tumor cells in intraoperative blood were detected in 10 of 16 patient samples in the range of 69–2.6 × 105 but no residual malignant cells in the final erythrocyte concentrates after Catuvab procedure. IL-6 and IL-8 as pro-inflammatory cytokines released during surgery, were lowered in mean 28-fold and 52-fold during the Catuvab procedure, respectively, whereas Catumaxomab antibody was detected in 8 of 16 of the final EC products at a considerable decreased and uncritical residual amount (37 ng in mean).
Conclusion: The preliminary study results indicate efficacy and feasibility of the new medical device Catuvab allowing potentially the reinfusion of autologous erythrocyte concentrates (EC) produced by IBS device during oncological high blood loss surgery. An open-label, multicenter clinical study on the removal of EpCAM-positive tumor cells from blood collected during tumor surgery using the Catuvab device is initiated to validate these encouraging results.
Background Vasoplegic syndrome is frequently observed during cardiac surgery and resembles a complication of high mortality and morbidity. There is a clinical need for therapy and prevention of vasoplegic syndrome during complex cardiac surgical procedures. Therefore, we investigated different strategies in a porcine model of vasoplegia.
Methods We evaluated new medical therapies and prophylaxis to avoid vasoplegic syndrome in a porcine model. After induction of anesthesia, cardiopulmonary bypass was established through median sternotomy and central cannulation. Prolonged aortic cross-clamping (120 min) simulated a complex surgical procedure. The influence of sevoflurane-guided anesthesia (sevoflurane group) and the administration of glibenclamide (glibenclamide group) were compared to a control group, which received standard anesthesia using propofol. Online hemodynamic assessment was performed using PiCCO® measurements. In addition, blood and tissue samples were taken to evaluate hemodynamic effects and the degree of inflammatory response.
Results Glibenclamide was able to break through early vasoplegic syndrome by raising the blood pressure and systemic vascular resistance as well as less need of norepinephrine doses. Sevoflurane reduced the occurrence of the vasoplegic syndrome in the mean of stable blood pressure and less need of norepinephrine doses.
Conclusion Glibenclamide could serve as a potent drug to reduce effects of vasoplegic syndrome. Sevoflurane anesthesia during cardiopulmonary bypass shows less occurrence of vasoplegic syndrome and therefore could be used to prevent it in high-risk patients.
Clinical Perspective; what is new?
* to our knowledge, this is the first randomized in vivo study evaluating the hemodynamic effects of glibenclamide after the onset of vasoplegic syndrome
* furthermore according to literature research, there is no study showing the effect of sevoflurane-guided anesthesia on the occurrence of a vasoplegic syndrome
Clinical Perspective; clinical implications?
to achieve better outcomes after complex cardiac surgery there is a need for optimized drug therapy and prevention of the vasoplegic syndrome
Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells
(2021)
The RAS/MEK/ERK genetic axis is commonly altered in rhabdomyosarcoma (RMS), indicating high activity of downstream effector ERK1/2 kinase. Previously, we have demonstrated that inhibition of the RAS/MEK/ERK signaling pathway in RMS is insufficient to induce cell death due to residual pro-survival MCL-1 activity. Here, we show that the combination of ERK1/2 inhibitor Ulixertinib and MCL-1 inhibitor S63845 is highly synergistic and induces apoptotic cell death in RMS in vitro and in vivo. Importantly, Ulixertinib/S63845 co-treatment suppresses long-term survival of RMS cells, induces rapid caspase activation and caspase-dependent apoptosis. Mechanistically, Ulixertinib-mediated upregulation of BIM and BMF in combination with MCL-1 inhibition by S63845 shifts the balance of BCL-2 proteins towards a pro-apoptotic state resulting in apoptosis induction. A genetic silencing approach reveals that BIM, BMF, BAK and BAX are all required for Ulixertinib/S63845-induced apoptosis. Overexpression of BCL-2 rescues cell death triggered by Ulixertinib/S63845 co-treatment, confirming that combined inhibition of ERK1/2 and MCL-1 effectively induces cell death of RMS cells via the intrinsic mitochondrial apoptotic pathway. Thus, this study is the first to demonstrate the cytotoxic potency of co-inhibition of ERK1/2 and MCL-1 for RMS treatment.
Background: Routine human papillomavirus (HPV) testing is performed in cervival cancer and is required for classification of some head and neck cancers. In penile cancer a statement on HPV association of the carcinoma is required. In most cases p16 immunohistochemistry as a surrogate marker is applied in this setting. Since differing clinical outcomes for HPV positive and HPV negative tumors are described we await HPV testing to be requested more frequently by clinicians, also in the context of HPV vaccination, where other HPV subtypes are expected to emerge.
Method: Therefore, a cohort of archived, formalin-fixed paraffin embedded (FFPE) penile neoplasias was stained for p16 and thereafter tested for HPV infection status via PCR based methods. Additionally to Sanger sequencing, we chose LCD-Array technique (HPV 3.5 LCD-Array Kit, Chipron; LCD-Array) for the detection of HPV in our probes expecting a less time consuming and sensitive HPV test for our probes.
Results: We found that LCD-Array is a sensitive and feasible method for HPV testing in routine diagnostics applicable to FFPE material in our cohort. Our cohort of penile carcinomas and carcinomas in situ was associated with HPV infection in 61% of cases. We detected no significant association between HPV infection status and histomorphological tumor characteristics as well as overall survival.
Conclusions: We showed usability of molecular HPV testing on a cohort of archived penile carcinomas. To the best of our knowledge, this is the first study investigating LCD-Array technique on a cohort of penile neoplasias.
The activation of the transcription factor NF-E2-related factor 2 (Nrf2) maintains cellular homeostasis in response to oxidative stress by the regulation of multiple cytoprotective genes. Without stressors, the activity of Nrf2 is inhibited by its interaction with the Keap1 (kelch-like ECH-associated protein 1). Here, we describe (3S)-1-[4-[(2,3,5,6-tetramethylphenyl) sulfonylamino]-1-naphthyl]pyrrolidine-3-carboxylic acid (RA839), a small molecule that binds noncovalently to the Nrf2-interacting kelch domain of Keap1 with a Kd of ∼6 μm, as demonstrated by x-ray co-crystallization and isothermal titration calorimetry. Whole genome DNA arrays showed that at 10 μm RA839 significantly regulated 105 probe sets in bone marrow-derived macrophages. Canonical pathway mapping of these probe sets revealed an activation of pathways linked with Nrf2 signaling. These pathways were also activated after the activation of Nrf2 by the silencing of Keap1 expression. RA839 regulated only two genes in Nrf2 knock-out macrophages. Similar to the activation of Nrf2 by either silencing of Keap1 expression or by the reactive compound 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me), RA839 prevented the induction of both inducible nitric-oxide synthase expression and nitric oxide release in response to lipopolysaccharides in macrophages. In mice, RA839 acutely induced Nrf2 target gene expression in liver. RA839 is a selective inhibitor of the Keap1/Nrf2 interaction and a useful tool compound to study the biology of Nrf2.
In murine models, the expression of inducible nitric oxide synthase (iNOS) in myocardial infarction (MI) has been reported to be the result of tissue injury and inflammation. In the present study, mRNA expression of iNOS, hypoxia-inducible factor-1α (HIF-1α), and vascular endothelial growth factor (VEGF) was investigated in postmortem human infarction hearts. Since HIF-1α is the inducible subunit of the transcription factor HIF-1, which regulates transcription of iNOS and VEGF, the interrelation between the three genes was observed, to examine the molecular processes during the emergence of MI. iNOS and VEGF mRNAs were found to be significantly upregulated in the affected regions of MI hearts in comparison to healthy controls. Upregulation of HIF-1α was also present but not significant. Correlation analysis of the three genes indicated a stronger and significant correlation between HIF-1α and iNOS mRNAs than between HIF-1α and VEGF. The results of the study revealed differences in the expression patterns of HIF-1 downstream targets. The stronger transcription of iNOS by HIF-1 in the affected regions of MI hearts may represent a pathological process, since no correlation of iNOS and HIF-1α mRNA was found in non-affected areas of MI hearts. Oxidative stress is considered to cause molecular changes in MI, leading to increased iNOS expression. Therefore, it may also represent a forensic marker for detection of early changes in heart tissue.
IL-38 is the latest discovered cytokine of the IL-1 family and has been added to the IL-36 subfamily. Since its discovery in 2001, increasing evidence suggests predominantly anti-inflammatory properties of IL-38, which are most likely exerted through three potential receptors, the IL-1 Receptor 1 (IL-1R1), IL-36 Receptor (IL-36R) and the IL-1 Receptor Accessory Protein Like 1 (IL-1RAPL1). However, to this date detailed knowledge of IL-38 functioning remains to be examined. Importantly, how IL-38 is processed, secreted from cells and the exact mechanisms of target receptor binding and intracellular signaling are not fully understood. Further, IL-38 has been associated with regulatory functions in autoimmune diseases like systemic lupus erythematosus (SLE) and psoriasis. At the same time however, connections between B cells as indispensable part of immunity and IL-38 remain rare.
In this study we examined the influence of IL-38 in peripheral human blood B cells differentiating into antibody secreting cells using a three-step in vitro differentiation process. We first show that all potential IL-38 binding receptors are present on peripheral blood B cells on a gene expression level and remain detectable throughout B cell differentiation. Next, while B cells treated with exogenous IL-38 depict no differences in early B cell activation markers, the process of B cell differentiation revealed significant alterations in B cell phenotype created by IL-38 treatment. Predominantly on day 7 of the differentiation process, IL-38 treated B cells showed significantly reduced CD38 expression which depicts an important step in development towards plasma cells. We hypothesize that IL-38 acts antagonistically on the IL-1R1 pathway reducing Nuclear factor kappa B (NFκB) expression and consequently decreasing CD38 expression. Further IL-38 reduced early antibody production while increasing IgM secretion at the end stages of differentiation. Next, we repeated the differentiation assays under the influence of additional IL-21 stimulation to further enhance plasma cell development. In these experiments, the impact of IL-38 on B cell differentiation and immunoglobulin production were reduced, indicating a comparatively moderate relevance of IL-38 for B cell differentiation. We then examined how proliferation and cell death were impacted by exogenous IL-38 during B cell differentiation. IL-38 treatment alone significantly reduced B cell survival which was further augmented by IL-21 stimulation. We conclude that IL-38 and IL-21 act synergistically in promoting B cell apoptosis, also depicting an anti-inflammatory property of IL-38. Finally, using a siRNA we successfully performed an IL-38 knockdown experiment of human blood B cells reducing IL-38 expression to 44% measured on day 4 of B cell differentiation. In these experiments we observed reversed tendencies of CD38 expression compared to exogenous IL-38 treatment. Here, IL-38 knockdown cells showed increased CD38 expression indicating endogenous regulatory properties of IL-38 in B cell differentiation.
Our project, for the first time proves direct effects of IL-38 on human B cells. The results support previous research of IL-38 to act anti-inflammatory as it seems to modulate B cell differentiation, survival, and immunoglobulin production in a down-regulatory manner. These findings pave way for more detailed research on the connection between B cell homoeostasis and IL-38 function.
Simple Summary: Infections are an important cause of morbidity and mortality in childhood cancer treatment. The aim of our retrospective study was to assess the infectious burden in pediatric sarcoma patients during neoadjuvant chemotherapy administered according to the EWING 2008, CWS SoTiSaR and EURAMOS clinical trial or registry. Our analyses indicate a substantial infectious morbidity in this group of patients, with 58.8% experiencing at least one episode of febrile neutropenia (FN) and 20.6% at least one microbiologically documented infection (MDI). We also identified parameters that impact on the occurrence of FN and MDIs, including treatment protocol, patient age, and mucositis. These findings may contribute to a better risk stratification for prevention and management of FN and infections as well as for maintaining quality of life, cost control, and optimum outcomes of anticancer treatment.
Abstract: The purpose of this retrospective, single-center cohort study was to assess the infectious burden in pediatric sarcoma patients during neoadjuvant chemotherapy. The review included all patients with a new diagnosis of Ewing sarcoma, osteosarcoma or soft tissue sarcoma between September 2009 and December 2018 who were enrolled in the EWING 2008, CWS SoTiSaR and EURAMOS clinical trial or registry. Primary endpoints were the occurrence of febrile neutropenia (FN) and microbiologically documented infection (MDI). Parameters with a potential impact on FN and MDI were also analyzed. A total of 170 sarcoma patients (median age: 13 years, range: 0–21; 96 m/74 f) received 948 chemotherapy courses (median: 6; range: 2–8). Of these patients, 58.8% had ≥1 FN episode and 20.6% ≥ 1 MDI. FN occurred in 272/948 courses (28.7%) with fever of unknown origin (FUO) in 231 courses and 45 MDI and 19 clinically documented infections (CDI) occurring in a total of 57 courses. Patients enrolled in EWING 2008 had significantly more FN (p < 0.001), infections (p = 0.02) and MDI (p = 0.035). No infection-related deaths were observed. Younger age, tumor type and localization, and higher median and maximum mucositis grades were significantly associated with higher numbers of FN (p < 0.001), and younger age (p = 0.024) and higher median mucositis grade (p = 0.017) with MDI. The study shows substantial infectious morbidity in sarcoma patients during neoadjuvant chemotherapy treatment and opportunities to improve prevention and management.
Pseudomonas aeruginosa is a human pathogen that causes health-care associated blood stream infections (BSI). Although P. aeruginosa BSI are associated with high mortality rates, the clinical relevance of pathogen-derived prognostic biomarker to identify patients at risk for unfavorable outcome remains largely unexplored. We found novel pathogen-derived prognostic biomarker candidates by applying a multi-omics approach on a multicenter sepsis patient cohort. Multi-level Cox regression was used to investigate the relation between patient characteristics and pathogen features (2298 accessory genes, 1078 core protein levels, 107 parsimony-informative variations in reported virulence factors) with 30-day mortality. Our analysis revealed that presence of the helP gene encoding a putative DEAD-box helicase was independently associated with a fatal outcome (hazard ratio 2.01, p = 0.05). helP is located within a region related to the pathogenicity island PAPI-1 in close proximity to a pil gene cluster, which has been associated with horizontal gene transfer. Besides helP, elevated protein levels of the bacterial flagellum protein FliL (hazard ratio 3.44, p < 0.001) and of a bacterioferritin-like protein (hazard ratio 1.74, p = 0.003) increased the risk of death, while high protein levels of a putative aminotransferase were associated with an improved outcome (hazard ratio 0.12, p < 0.001). The prognostic potential of biomarker candidates and clinical factors was confirmed with different machine learning approaches using training and hold-out datasets. The helP genotype appeared the most attractive biomarker for clinical risk stratification due to its relevant predictive power and ease of detection.
Several lines of evidence suggest the ligand-sensing transcription factor Nurr1 as a promising target to treat neurodegenerative diseases. Nurr1 modulators to validate and exploit this therapeutic potential are rare, however. To identify novel Nurr1 agonist chemotypes, we have employed the Nurr1 activator amodiaquine as template for microscale analogue library synthesis. The first set of analogues was based on the 7-chloroquiolin-4-amine core fragment of amodiaquine and revealed superior N-substituents compared to diethylaminomethylphenol contained in the template. A second library of analogues was subsequently prepared to replace the chloroquinolineamine scaffold. The two sets of analogues enabled a full scaffold hop from amodiaquine to a novel Nurr1 agonist sharing no structural features with the lead but comprising superior potency on Nurr1. Additionally, pharmacophore modeling based on the entire set of active and inactive analogues suggested key features for Nurr1 agonists.
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Objective: This study was undertaken to calculate epilepsy-related direct, indirect, and total costs in adult patients with active epilepsy (ongoing unprovoked seizures) in Germany and to analyze cost components and dynamics compared to previous studies from 2003, 2008, and 2013. This analysis was part of the Epi2020 study.
Methods: Direct and indirect costs related to epilepsy were calculated with a multicenter survey using an established and validated questionnaire with a bottom-up design and human capital approach over a 3-month period in late 2020. Epilepsy-specific costs in the German health care sector from 2003, 2008, and 2013 were corrected for inflation to allow for a valid comparison.
Results: Data on the disease-specific costs for 253 patients in 2020 were analyzed. The mean total costs were calculated at €5551 (±€5805, median = €2611, range = €274–€21 667) per 3 months, comprising mean direct costs of €1861 (±€1905, median = €1276, range = €327–€13 158) and mean indirect costs of €3690 (±€5298, median = €0, range = €0–€11 925). The main direct cost components were hospitalization (42.4%), antiseizure medication (42.2%), and outpatient care (6.2%). Productivity losses due to early retirement (53.6%), part-time work or unemployment (30.8%), and seizure-related off-days (15.6%) were the main reasons for indirect costs. However, compared to 2013, there was no significant increase of direct costs (−10.0%), and indirect costs significantly increased (p < .028, +35.1%), resulting in a significant increase in total epilepsy-related costs (p < .047, +20.2%). Compared to the 2013 study population, a significant increase of cost of illness could be observed (p = .047).
Significance: The present study shows that disease-related costs in adult patients with active epilepsy increased from 2013 to 2020. As direct costs have remained constant, this increase is attributable to an increase in indirect costs. These findings highlight the impact of productivity loss caused by early retirement, unemployment, working time reduction, and seizure-related days off.
Background: Refractory status epilepticus (RSE) represents a serious medical condition requiring early and targeted therapy. Given the increasing number of elderly or multimorbid patients with a limitation of life-sustaining therapy (LOT) or within a palliative care setting (PCS), guidelines-oriented therapy escalation options for RSE have to be omitted frequently. Objectives: This systematic review sought to summarize the evidence for fourth-line antiseizure drugs (ASDs) and other minimally or non-invasive therapeutic options beyond guideline recommendations in patients with RSE to elaborate on possible treatment options for patients undergoing LOT or in a PCS. Methods: A systematic review of the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, focusing on fourth-line ASDs or other minimally or non-invasive therapeutic options was performed in February and June 2020 using the MEDLINE, EMBASE and Cochrane databases. The search terminology was constructed using the name of the specific ASD or therapy option and the term ‘status epilepticus’ with the use of Boolean operators, e.g. “(brivaracetam) AND (status epilepticus)”. The respective Medical Subject Headings (MeSH) and Emtree terms were used, if available. Results: There is currently no level 1, grade A evidence for the use of ASDs in RSE. The best evidence was found for the use of lacosamide and topiramate (level 3, grade C), followed by brivaracetam, perampanel (each level 4, grade D) and stiripentol, oxcarbazepine and zonisamide (each level 5, grade D). Regarding non-medicinal options, there is little evidence for the use of the ketogenic diet (level 4, grade D) and magnesium sulfate (level 5, grade D) in RSE. The broad use of immunomodulatory or immunosuppressive treatment options in the absence of a presumed autoimmune etiology cannot be recommended; however, if an autoimmune etiology is assumed, steroid pulse, intravenous immunoglobulins and plasma exchange/plasmapheresis should be considered (level 4, grade D). Even if several studies suggested that the use of neurosteroids (level 5, grade D) is beneficial in RSE, the current data situation indicates that there is formal evidence against it. Conclusions: RSE in patients undergoing LOT or in a PCS represents a challenge for modern clinicians and epileptologists. The evidence for the use of ASDs in RSE beyond that in current guidelines is low, but several effective and well-tolerated options are available that should be considered in this patient population. More so than in any other population, advance care planning, advance directives, and medical ethical aspects have to be considered carefully before and during therapy.
The article Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life‑Sustaining Therapies: A Systematic Review, written by Laurent M. Willems, Sebastian Bauer, Kolja Jahnke, Martin Voss, Felix Rosenow, Adam Strzelczyk, was originally published Online First without Open Access. After publication in volume 34, issue 8, pages 801–826 the author decided to opt for Open Choice and to make the article an Open Access publication. Post-publication open access was funded by Projekt DEAL. Therefore, the copyright of the article has been changed to © The Author(s) 2021 and the article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. The original article has been corrected.
Tuberous sclerosis complex (TSC) is a rare genetic disease that is, besides cutaneous and visceral organ manifestations, typically associated with a severe, usually drug refractory epilepsy at a very early stage of the disease. Due to its direct effect on the mTOR signaling pathway dysregulated by TSC and its synergistic effects on other organ manifestations, the rapamycin derivative everolimus (EVE) is increasingly being used. The aim of this systematic review is to evaluate the efficacy, safety and tolerability of EVE in patients with TSC-associated, refractory epilepsy.
Objective: This study was undertaken to quantify epilepsy-related costs of illness (COI) in Germany and identify cost-driving factors.
Methods: COI were calculated among adults with epilepsy of different etiologies and severities. Multiple regression analysis was applied to determine any epilepsy-related and sociodemographic factors that serve as cost-driving factors.
Results: In total, 486 patients were included, with a mean age of 40.5 ± 15.5 years (range = 18–83 years, 58.2% women). Mean 3-month COI were estimated at €4911, €2782, and €2598 for focal, genetic generalized, and unclassified epilepsy, respectively. The mean COI for patients with drug-refractory epilepsy (DRE; €7850) were higher than those for patients with non-DRE (€4720), patients with occasional seizures (€3596), or patients with seizures in remission for >1 year (€2409). Identified cost-driving factors for total COI included relevant disability (unstandardized regression coefficient b = €2218), poorer education (b = €2114), living alone (b = €2612), DRE (b = €1831), and frequent seizures (b = €2385). Younger age groups of 18–24 years (b = −€2945) and 25–34 years (b = −€1418) were found to have lower overall expenditures. A relevant disability (b = €441), DRE (b = €1253), frequent seizures (b = €735), and the need for specialized daycare (b = €749) were associated with higher direct COI, and poorer education (b = €1969), living alone (b = €2612), the presence of a relevant disability (b = €1809), DRE (b = €1831), and frequent seizures (b = €2385) were associated with higher indirect COI.
Significance: This analysis provides up-to-date COI data for use in further health economics analyses, highlighting the high economic impacts associated with disease severity, disability, and disease-related loss of productivity among adult patients with epilepsy. The identified cost drivers could be used as therapeutic and socioeconomic targets for future cost-containment strategies.
Objectives: Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for stroke prevention in patients with atrial fibrillation (AF). For various reasons, it is important to consider patients’ preferences regarding type of medication, particularly in view of the established relationship between preferences towards treatment, associated burden of treatment, and treatment adherence. This review aimed to systematically analyse the scientific literature assessing the preferences of AF patients with regard to long-term oral anticoagulant (OAC) treatment.
Methods: We searched the MEDLINE, Scopus and EMBASE databases (from 1980 to 2015), added records from reference lists of publications found, and conducted a systematic review based on all identified publications. Outcomes of interest included any quantitative information regarding the opinions or preferences of AF patients towards OAC treatment, ideally specified according to different clinical or convenience attributes describing different OAC treatment options.
Results: Overall, 27 publications describing the results of studies conducted in 12 different countries were included in our review. Among these, 16 studies analysed patient preferences towards OACs in general. These studies predominantly assessed which benefits (mainly lower stroke risk) AF patients would require to tolerate harms (mainly higher bleeding risk) associated with an OAC. Most studies showed that patients were willing to accept higher bleeding risks if a certain threshold in stroke risk reduction could be reached. Nevertheless, most of the publications also showed that the preferences of AF patients towards OACs may differ from the perspective of clinical guidelines or the perspective of physicians. The remaining 11 studies included in our review assessed the preferences of AF patients towards specific OAC medication options, namely NOACs versus VKAs. Our review showed that AF patients prefer easy-to-administer treatments, such as treatments that are applied once daily without any food/drug interactions and without the need for bridging and frequent blood controls.
Conclusion: Stroke risk reduction and a moderate increase in the risk of bleeding are the most important attributes for an AF patient when deciding whether they are for or against OAC treatment. If different anticoagulation options have similar clinical characteristics, convenience attributes matter to patients. In this review, AF patients favour attribute levels that describe NOAC treatment.
The deep fascia is intimately linked to skeletal muscle and may be involved in delayed onset muscle soreness (DOMS). The present study therefore explored the effect of eccentric exercise on fascia stiffness and its relation with DOMS. Healthy active male adults (n = 19, 27 ± 4 years) performed 6 x 10 maximal eccentric knee flexions using an isokinetic dynamometer. Before (baseline) as well as immediately (T0), 1 hour (T1), and each day up to 72 hours (T24 to T72) afterwards, shear wave elastography was used to measure the mechanical stiffness of the biceps femoris muscle and the overlying fascia. As a surrogate of DOMS, pain upon palpation was captured by means of a 100mm visual analogue scale. While muscle stiffness remained unchanged (p > 0.05), deep fascia stiffness increased from baseline to T24 (median: 18 kPa to 21.12 kPa, p = 0.017) and T72 (median: 18 kPa to 21.3 kPa, p = 0.001) post-exercise. Linear regression showed an association of stiffness changes at T24 and pressure pain at T72 (r2 = 0.22, p < 0.05). Maximal eccentric exercise leads to a stiffening of the fascia, which, in turn, is related to the magnitude of future DOMS. Upcoming research should therefore gauge the effectiveness of interventions modifying the mechanical properties of the connective tissue in order to accelerate recovery.
Many countries have restricted public life during the SARS-CoV2 pandemic. As related measures limited the access to sports facilities, this dissertation aimed (1) to examine changes in physical activity (PA) and well-being in affected countries, and (2) to determine the effectiveness of a digital home exercise program in this context.
Part 1 (PA/well-being) of the dissertation was a digital survey administered in 14 countries. Participants reported a 41 - 42% reduction of PA (NPAQ-SF) during restrictions (n=13,503 valid responses). Compliance with international PA guidelines decreased by nearly 19%. Mental well-being declined substantially (n=14,975 responses; 68.1 to 51.9 points on the WHO5 index) and the proportion of individuals at risk of depression tripled (14.2% to 45.2%). Physical well-being (SF-36 Pain) decreased slightly (85.8% to 81.3%). About two thirds (68.1%) of the respondents reported being interested in digital home exercise.
For Part 2 (digital home exercise) of the dissertation, an international multicenter randomized, controlled trial was performed allocating healthy adults (n=763; 33±12 years) to an intervention (IG) or control (CG) group. In contrast to the CG, the IG was offered live-streamed home exercise for four weeks. Subsequently, both groups had access to pre-recorded workouts for another four weeks. Outcomes were measured weekly using validated questionnaires. Mixed-models data analyses revealed an up to 1.65-fold (95% CI: 1.4-1.94; week 1) increase of PA relative to the CG. Moreover, small improvements in exercise motivation (SKK scale), psychological well-being (WHO-5 index), sleep quality (MOS Sleep Scale), and anxiety symptoms (GAD-7 Scale) were observed for IG.
The results of this dissertation suggest that public life restrictions associated with the pandemic had significant adverse effects on movement behavior and well-being. Digital home exercise can help to maintain and/or increase health- beneficial PA and well-being and may hence represent a supportive element of viral containment efforts.
Background: In recent months, Omicron variants of SARS-CoV-2 have become dominant in many regions of the world, and case numbers with Omicron subvariants BA.1 and BA.2 continue to increase. Due to numerous mutations in the spike protein, the efficacy of currently available vaccines, which are based on Wuhan-Hu 1 isolate of SARS-CoV-2, is reduced, leading to breakthrough infections. Efficacy of monoclonal antibody therapy is also likely impaired.
Methods: In our in vitro study using A549-AT cells constitutively expressing ACE2 and TMPRSS2, we determined and compared the neutralizing capacity of vaccine-elicited sera, convalescent sera and monoclonal antibodies against authentic SARS-CoV-2 Omicron BA.1 and BA.2 compared with Delta.
Findings: Almost no neutralisation of Omicron BA.1 and BA.2 was observed using sera from individuals vaccinated with two doses 6 months earlier, regardless of the type of vaccine taken. Shortly after the booster dose, most sera from triple BNT162b2-vaccinated individuals were able to neutralise both Omicron variants. In line with waning antibody levels three months after the booster, only weak residual neutralisation was observed for BA.1 (26%, n = 34, 0 median NT50) and BA.2 (44%, n = 34, 0 median NT50). In addition, BA.1 but not BA.2 was resistant to the neutralising monoclonal antibodies casirivimab/imdevimab, while BA.2 exhibited almost a complete evasion from the neutralisation induced by sotrovimab.
Interpretation: Both SARS-CoV-2 Omicron subvariants BA.1 and BA.2 escape antibody-mediated neutralisation elicited by vaccination, previous infection with SARS-CoV-2, and monoclonal antibodies. Waning immunity renders the majority of tested sera obtained three months after booster vaccination negative in BA.1 and BA.2 neutralisation. Omicron subvariant specific resistance to the monoclonal antibodies casirivimab/imdevimab and sotrovimab emphasizes the importance of genotype-surveillance and guided application.
Funding: This study was supported in part by the Goethe-Corona-Fund of the Goethe University Frankfurt (M.W.) and the Federal Ministry of Education and Research (COVIDready; grant 02WRS1621C (M.W.).
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
(2021)
Due to numerous mutations in the spike protein, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) raises serious concerns since it may significantly limit the antibody-mediated neutralization and increase the risk of reinfections. While a rapid increase in the number of cases is being reported worldwide, until now there has been uncertainty about the efficacy of vaccinations and monoclonal antibodies. Our in vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19. Since SARS-CoV-2 Omicron was resistant to casirivimab and imdevimab, genotyping of SARS-CoV-2 may be needed before initiating mAb treatment. Variant-specific vaccines and mAb agents may be required to treat COVID-19 due to Omicron and other emerging variants of concern.
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
(2021)
Due to numerous mutations in the spike protein, the SARS-CoV-2 variant of concern Omicron (B.1.1.529) raises serious concerns since it may significantly limit the antibody-mediated neutralization and increase the risk of reinfections. While a rapid increase in the number of cases is being reported worldwide, until now there has been uncertainty about the efficacy of vaccinations and monoclonal antibodies. Our in vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19. Since SARS-CoV-2 Omicron was resistant to casirivimab and imdevimab, genotyping of SARS-CoV-2 may be needed before initiating mAb treatment. Variant-specific vaccines and mAb agents may be required to treat COVID-19 due to Omicron and other emerging variants of concern.
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.
We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R.
We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 5.71 and 3.64, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.6-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab.
In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which however, might be circumvented by a combination therapy with casirivimab together.
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together.
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.
We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R.
We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.5-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab.
In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which however, might be circumvented by a combination therapy with casirivimab together.